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Abstract 
Trachoma is the leading infectious cause of blindness worldwide and is initiated by 
repeated infection of the conjunctiva with Chlamydia trachomatis (Ct). In some 
individuals this causes chronic inflammation and fibrosis that progresses in the 
absence of Ct. The work presented in this thesis sought to determine the role and 
contribution of miRNA and epithelial-mesenchymal transition (EMT) in various stages 
of trachomatous disease. Epithelial cells did not differentially express miRNA at 48 
hours post infection with virulent plasmid-competent and avirulent plasmid-free ocular 
strains of Ct. Expression of inflammatory cytokines and growth factors were increased 
in response to virulent Ct infection but the induction of EMT was not detected in 
response to either strain. In a set of 161 samples from children living in a trachoma 
hyper-endemic region in Guinea-Bissau, miR-155 was upregulated in children with 
active trachoma and current Ct infection and miR-184 was downregulated in children 
with active trachoma with and without Ct infection. In a set of 194 samples from adults 
in The Gambia, miR-1285 and miR-147b were upregulated in inflammatory 
trachomatous scarring. Differential expression of these miR indicates the regulation of 
inflammation, wound healing and cell proliferation pathways. Immunohistochemistry 
was used to study conjunctival biopsies from Tanzanian adults with trachomatous 
trichiasis and found increased epithelial expression of the pro-inflammatory mediator 
and antimicrobial peptide S100A7 and connective tissue growth factor. Pro-
inflammatory cytokine IL-1β expression was increased in the subepithelium relative to 
controls. Trichiasis cases had increased disruption of collagen deposition patterns and 
increased sub-clinical inflammatory cell infiltrates, but no differences in epithelial 
atrophy and myofibroblasts were detected relative to controls. There was no evidence 
for the occurrence of EMT in biopsy tissue from trachomatous trichiasis cases. These 
data suggest that EMT does not have a major role in conjunctival fibrosis and highlight 
the importance of inflammation in trachomatous pathology. 
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1.1 Introduction to trachoma  
 
Trachoma is initiated by infection of the tarsal conjunctiva with the intracellular 
bacterium Chlamydia trachomatis (Ct). Sightsavers International estimates that every 
15 minutes a person looses sight as a result of trachoma [1]. As such, trachoma 
remains the world’s leading infectious cause of blindness despite significant efforts to 
control and eliminate the disease [2]. Trachoma is currently considered endemic in 51 
countries worldwide and only seven formerly endemic countries have reached target 
elimination thresholds [2]. Forty million people are currently estimated to have active 
trachoma and eight million people suffer with un-operated trichiasis [3]. The Alliance for 
Global Elimination of Blinding Trachoma has set the goal of 2020 for the elimination of 
trachoma. The aim is to control trachoma through the implementation of Surgery for 
trichiasis, Antibiotics to treat infection, Facial cleanliness and Environmental 
improvements to reduce transmission (SAFE). Currently 31 trachoma-endemic 
countries implement SAFE, which is effective in controlling trachoma if well conducted. 
Azithromycin is the antibiotic of choice used in mass drug administration (MDA) 
programmes for trachoma control. There are additional beneficial effects of 
azithromycin MDA, including reduced all-cause mortality [4] and potential to reduce 
clinical disease through its anti-inflammatory properties [5]. There remains a need to 
pursue vaccine development however as there are circumstances when SAFE is 
poorly effective and there is uncertainty about its universal application. The lack of 
randomized controlled trials examining the effectiveness of the F and E components for 
the interruption of transmission, alongside the historical lack of molecular laboratory 
tools able to identify transmission events raises questions on the basic understanding 
of their effectiveness. Additional concerns with the A component include the long-term 
use of antibiotics in populations where MDA has failed to control disease [6] and 
introduction of resistance in other bacterial species [7]. It is also not currently 
understood whether effective mass treatment leads to arrested immunity and it is 
unclear what impact the elimination of ocular chlamydial exposure in childhood might 
exert later in adolescent and adult urogenital disease. Chlamydiae can reside in the 
gastrointestinal tract in the absence of clinical disease and this has led to the 
suggestion that azithromycin treatment failures (at least in urogenital disease) may be 
because gastrointestinal Chlamydiae are refractory to azithromycin treatment and can 
act as a source for auto-inoculation [8,9]. Although implementation of MDA is effective 
in reducing the prevalence of Ct infection [10], re-infection is common and may be re-
introduced by migrants [11]. Furthermore there is evidence that scarring trachoma 
progresses in the absence of Ct infection [12], therefore it is likely that a large number 
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of individuals will continue to progress towards trichiasis even once Ct infection is 
controlled at the population level. Epilation provides a temporary relief from minor 
trichiasis and surgery to rotate the tarsal conjunctiva is currently the main intervention 
for major trichiasis, however recurrence rates from trichiasis surgery can reach 60% by 
3 years [13]. In order to prevent the progressive fibrosis leading to trichiasis, a better 
understanding of the causative mechanism is required. A vaccine offering effective 
long-term protection against disease in both ocular and urogenital chlamydial disease 
remains desirable.  
 
There are a number of classification systems for the clinical signs of trachoma. Under 
the WHO simplified grading system, the presence of five or more follicles on the 
conjunctival surface is classified as trachomatous inflammation follicular (TF). Ct 
infection is independently associated with TF (OR = 11.2 (95% CI 6.9–18.1) [14]), 
although this value varies between populations depending on disease sign prevalence 
and becomes disassociated from TF once prevalence is low. Repeated Ct infection in 
endemic communities can trigger chronic conjunctival inflammation (trachomatous 
inflammation intense, TI) in some individuals, causing conjunctival fibrosis 
(trachomatous scarring, TS). Ct infection is rarely found in adults with scarring [12], 
suggesting that early life Ct infection is an important priming event that may establish a 
stable pro-fibrotic environment. Progressive fibrosis may lead to entropion, inward 
turning or mis-directed lashes (trachomatous trichiasis, TT) all of which abrade the 
corneal surface. This abrasive damage may lead to corneal opacity (CO) and 
blindness. Figure 1.1 shows reflective in vivo confocal microscopy scans, histology 
sections and photographs of the tarsal conjunctiva that illustrate the changes in tissue 
architecture that occur in the different stages of trachomatous disease.   
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Figure 1.1. Images from a normal healthy eye (A-D) and from individuals with 
follicular trachoma (E-H), trachomatous scarring (I-L), trichiasis and progressive 
scarring (M-P). A, E, I and M are photographs of the tarsal conjunctiva showing 
normal appearance (A), papillary inflammation and follicles (E), bands of trachomatous 
scarring (I) and extreme trichiasis and corneal opacity (M). B, C, F, G, H, J, K and L are 
in vivo confocal microscopy images of the tarsal conjunctiva at various depths (the bar 
represents 50μm). A moderate number of inflammatory nuclei are present in the sub-
epithelium of a healthy eye (B), whereas a higher number are present in trachomatous 
inflammation (F). Follicles can be seen in (G) and (H). The connective tissue of the 
healthy conjunctiva is amorphous (C), whereas successive grades of trachomatous 
scarring are seen as a heterogeneous clumpy appearance (J), defined tissue bands 
that make up <50% of the scan area (K) and defined bands that make up >50% of the 
scan area (L). D and N-P are histological images of tissue scarring using polarized light 
(original magnification x100). In the healthy conjunctiva, collagen fibers are parallel 
(arrows) with the surface epithelium (D), whereas progressive disorganization of this 
appearance is observed in scarring (N-P). Images are kindly provided with permission 
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from Matthew Burton and Victor Hu and are adapted from Hu et al., 2011 [15] and Hu 
et al., 2013 [16].  
 
The human trachoma vaccine trials that took place in the 1960s concluded that some 
short-term strain-specific protection from infection was induced, amidst concerns that 
pathology was exacerbated in some cases, supported by data from monkey models 
[17]. The data from these large placebo-controlled trials has been recently 
reinterpreted in the context of current grading systems and our current knowledge of 
disease pathogenesis. Only trial III in The Gambia recorded evidence of conjunctival 
scarring. Two doses of prophylactic vaccination made from two live strains in mineral 
oil were given three weeks apart to children aged 0-4 years old. There was no 
protection from active trachoma, however the vaccinated group had a reduced 
prevalence of scarring disease two years later [18]. When all three Gambian trials are 
reviewed in the context of what is now known about disease pathogenesis, vaccine-
induced exacerbation of disease may not be a significant concern, raising hopes that 
current vaccine formulations may be successful [17,19]. Understanding the 
immunology and pathology of trachomatous disease is therefore essential for the 
development of a vaccine that invokes a protective, and not a pathogenic, host 
response.  
 
1.2 Anatomy of the tarsal conjunctiva in trachoma 
 
The conjunctiva is a mucous membrane that lines the insides of the eyelids and the 
white of the eyeball (the sclera). The palpebral (tarsal) conjunctiva lines the inner 
eyelid, the bulbar conjunctiva covers the sclera and the fornix conjunctiva forms a 
junction between the tarsal and bulbar sections. The conjunctival epithelium is formed 
of a non-keratinized layer of columnar and squamous stratified epithelial cells 2-5 cells 
thick, which is interspersed with goblet cells [20]. Goblet cells are highly differentiated 
epithelial cells and their primary role is to produce mucins, which, in addition to the 
membrane-associated mucins produced by apical epithelial cells, prevent desiccation 
of the ocular surface and trap commensal and pathogenic bacteria [21]. Other innate 
immune functions of the conjunctival epithelium include tight junctions between cells 
that prevent pathogen entry, release of antimicrobial peptides and expression of 
pattern recognition receptors (PRRs). PRRs are found on the cell membrane or in the 
cytosol and can respond to pathogen associated molecular patterns (PAMPs) or 
damage associated molecular patterns (DAMPs). PRRs include Toll-like Receptors 
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(TLRs), NOD-like receptors (NLRs), C-type Lectin receptors (CLRs) and RIG-I-like 
receptors (RLRs).  
 
Beneath the epithelium lies the stroma, or connective tissue, which is separated from 
the epithelium by the basement membrane. The stroma is made up of fibroblasts and 
contains blood vessels, nerves and sebaceous glands (glands which secrete sebum to 
lubricate the skin). The superficial stroma contains lymphoid tissue, which is not 
present in children <3 months of age [22]. As a result, neonates cannot make 
conjunctival follicles and instead respond with papillary inflammation [23]. Beneath the 
stroma lies the tarsal plate, which is made up of dense connective tissue (mainly 
collagen type I) and gives the eyelid its structure.   
 
Upon recognition of a pathogen via a PRR, epithelial cells secrete cytokines and 
chemokines that recruit and activate innate immune cells, which subsequently 
activates the adaptive immune system. Follicles are generated in the subepithelial 
tissue, consisting of germinal centers (immature proliferating lymphocytes) surrounded 
by mature lymphocytes and plasma cells. Follicles can be seen by eye as small white 
dots. Papillary inflammation is the formation of numerous tiny projections of tissue 
around central vascular cores. When papillary inflammation is severe the conjunctiva 
appears swollen, red and deep vessels are obscured [24]. Repeated rounds of 
inflammation in trachoma are thought to drive scarring in the tarsal plate, though the 
mechanism is unknown (discussed further below) Accumulation of scarring in the tarsal 
plate causes it to contract, causing entropion (infolding of the eyelid) and trichiasis 
(ingrowth of the eyelashes).  
 
1.3 Wound healing 
 
Infection and inflammation can cause tissue damage. The body responds to tissue 
damage through the process of wound healing, which has four distinct phases. These 
are hemostasis (clot formation), inflammation, proliferation and remodeling. In the 
inflammatory phase, immune cells including recruited macrophages and resident 
fibroblasts release pro-inflammatory cytokines, growth factors and matrix 
metalloproteinases (MMPs). As well as countering infection, these factors stimulate 
keratinocyte and fibroblast proliferation and extracellular-matrix (ECM) deposition. 
Activated fibroblasts known as myofibroblasts migrate into the wound space, deposit 
ECM and contract the wound to form a scar. These myofibroblasts originate both from 
local activated fibroblasts and from bone marrow-derived fibroblast-like cells that are 
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recruited to the wound. It is also thought that some myofibroblasts originate from local 
epithelial cells via epithelial-mesenchymal transition [25]. The wound is re-epithelialized 
and finally remodeled, whereby collagen type III (deposited during the proliferation 
phase) is replaced and realigned with collagen type I and unwanted cells are removed 
by apoptosis.  
 
Aberrant inflammation can greatly affect the normal course of wound healing. Embryos 
heal wounds without scar formation before the third trimester and the wound is 
associated with a lower level of inflammation [26]. Likewise adult oral wounds have a 
lower inflammatory component and scarring is less severe [27]. In an environment of 
chronic inflammation an aberrant wound healing response is triggered, leading to 
progressive fibrosis and organ damage. In the conjunctiva, chronic inflammation 
associated with trachoma and other diseases such as Stephen-Johnson syndrome, 
linear Immunoglobulin A disease (LAD), ocular cicatricial pemphigoid (OCP) or chronic 
atopic keratoconjunctivitis can lead to progressive scarring and eventually loss of organ 
function [12,28–30].   
 
1.4 Chlamydia trachomatis  
 
Ct is a gram-negative-like intracellular bacterium with a biphasic developmental cycle 
that infects host epithelial cells (Figure 1.2). Chlamydial strains are separated into three 
biovars that preferentially (though not exclusively) infect distinct sites in the human 
body: trachoma, urogenital and LGV (lymphogranuloma venereum). Serovars A-C 
infect the conjunctival epithelium, causing trachoma. Serovars D-K infect the epithelial 
lining of the genital tract and cause urethritis. Serovars L1-3 can also infect the genital 
tract and rectum but are more invasive, surviving in macrophages and spreading to 
local lymph nodes, causing a disease known as LGV and proctitis in men who have 
sex with men. Although serovars A-C and D-K are thought not to disseminate and to 
remain in the epithelium, there is growing evidence that the gastrointestinal tract could 
be a reservoir of urogenital Ct infection and could result in autoinoculation [8,31]. Ct 
has also been detected in the joints, blood and other tissues of humans [32–34].  
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Figure 1.2. Ct developmental cycle. EB: elementary body, RB: reticulate body, AB: 
aberrant body, N: nucleus. Elementary bodies (EBs) are the smaller, infectious form. 
EBs attach to the host cell membrane and are endocytosed (1), forming an intracellular 
vacuole known as an inclusion body (2). Multiple inclusion bodies in a cell fuse into one 
(3). Phago-lysosomal fusion is blocked, providing an intracellular niche for the bacteria 
[35]. EBs undergo differentiation into larger reticulate bodies (RBs) (4). Stress, such as 
penicillin or interferon gamma (IFNγ), can induce RBs to enter a reversible state of 
persistence (ABs) (5). RBs multiply by binary fission inside the inclusion (6), then 
differentiate back into EBs (7), whereupon they are released by cell lysis or extrusion to 
continue the infection cycle [36] (8). Ct can also prevent host cell cytokinesis, leading 
to the formation of multinucleated cells [37–39] (9). The timepoint (in hours) at which 
each stage of the developmental cycle occurs after initial EB attachment and entry is 
shown. 
 
The host cell receptors involved in Ct attachment and entry have not been fully defined. 
The epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR) 
and platelet-derived growth factor receptor-β (PDGFRβ) are thought to be involved in 
chlamydial attachment [40–43] and activation of EGFR was required for Ct 
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development [43]. Tyrosine phosphorylated proteins accumulate at the entry site 
[44,45] and actin polymerization forms a scaffold around the nascent inclusion [46]. Ct 
possesses a number of virulence factors that enable it to form a protective intracellular 
niche in which to complete the developmental cycle and to avoid the host immune 
response, discussed further in the following section (section 1.5). RBs divide by binary 
fission inside the inclusion, doubling their numbers every 2-3 hours. They are thought 
to go through 6-10 rounds of replication before differentiating back into EBs, yielding 
64-1024 EBs from a single infecting EB [47–49]. The Ct inclusion is then thought to be 
released by extrusion or lysis of the host cell [36] (Figure 1). These two processes 
were found to occur at near equivalent frequencies [36]. There is evidence to suggest 
that cells can repair their membrane following release of Ct, remaining viable and a 
suitable host in which residual EBs can complete another developmental cycle [50]. 
Location of the Ct inclusion on the cells equator can block cytokinesis, leading to 
formation of multinucleated cells, which is thought to confer a growth advantage to Ct 
via an increase in golgi content (an important source of lipids for Ct) [37–39]. If the host 
cell divides successfully however it is thought that only one daughter cell inherits the 
inclusion. If there are two inclusions in the dividing cell, both daughters may inherit one 
each or one daughter may inherit both [39]. 
 
Stressors such as IFNγ, penicillin and nutrient starvation can induce a state of 
persistence in chlamydial development in vitro. Upon induction of persistence, RBs 
transition into aberrant forms (ABs; Figure 1) which are usually larger and do not 
divide. ABs are non-cultivable and have altered metabolism, antigen, transcriptional 
and non-coding RNA profiles [51–54], however they remain viable. Genome replication 
continues but cytokinesis of the AB does not occur. Upon removal of the stress stimuli, 
RBs are thought to bud off the AB and continue the normal developmental cycle [55]. 
Chlamydial persistence is well described in vitro (reviewed in [56]), however until 
recently [57] there has been little evidence to suggest that persistence occurs in 
humans in vivo at urogenital or ocular anatomical sites.  
 
The developmental cycle of Ct takes longer in ocular serovars in comparison to 
urogenital serovars (D-K and L2) [58]. Urogenital serovars converted from RBs back to 
EBs within 20-24 hours and completed the developmental cycle by 30-48 hours post 
infection of cell lines in vitro. In ocular serovars EB conversion began around 30-36 
hours and the developmental cycle completed by 48-68 hours post infection [58]. 
Genomic replication was also slower in serovar A (A/HAR-13) compared to D (D/UW-
3/Cx) and L2 (L2/434/Bu). Considerable variation occurs within serovars between 
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strains however; serovar A strain A2497 has been reported to grow faster than 
L2/434/Bu (Richard Haywood; personal communications). 
 
1.5 Chlamydia trachomatis virulence factors 
 
Defining the identity and function of chlamydial virulence factors has previously been 
restricted due to the obligate intracellular growth requirement of the pathogen. 
However, significant advances have been made in recent years and our understanding 
of chlamydial virulence mechanisms has grown rapidly [59–64]. Virulence factors 
identified through whole genome sequencing analysis and in vitro and animal studies 
include the polymorphic outer membrane protein family (Pmp’s) [65–68], the type three 
secretion system (T3SS) and effectors [69–71], genes involved in tryptophan [72–74] 
and glycogen [59,75] biosynthesis, members of the incA [76,77] and phospholipase D 
[78,79] families, genes from the heat shock protein family [80,81], the chlamydial 
cytotoxin [82] and plasmid-encoded genes implicated in the regulation of chromosomal 
virulence factors [83–85]. These virulence factors are described in detail elsewhere 
[86], however the chlamydial cytotoxin and the plasmid are discussed further below.  
 
The chlamydial cytotoxin is located in the plasticity zone (PZ), a site of extensive 
genomic variation between the chlamydial serovars [87,88]. The function of the toxin is 
thought to involve GTPase inactivation and guanylate binding protein neutralization 
resulting in IFNγ resistance [82,89,90]. IFNγ stimulation of cells in vitro and in vivo 
induces transcription of genes that co-operate to eliminate intracellular bacteria, 
suggesting that inhibition of this mechanism may contribute to the pathogenesis of 
chlamydial disease [90]. The genomic organisation of the cytotoxin varies such that 
oculogenital strains have a single gene with a large deletion, lymphogranuloma 
venereum (LGV) strains lack the gene entirely, whilst the closely related C. muridarum 
(Cm) has three intact copies [91,92]. This most likely reflects the IFNγ evasion 
mechanism employed by Cm in the mouse compared with that employed by urogenital 
strains in humans [125, 112]. Since ocular strains lack a functional trp operon, required 
for synthesis of the essential amino acid tryptophan, and only have a partial toxin, how 
they evade IFNγ is not fully understood. Ocular chlamydial infection of mice does not 
reproduce the clinical features of disease seen in humans, whereas ocular chlamydial 
infection of Guinea-Pigs and non-human primates (NHPs) more closely models active 
trachoma in humans [93,94]. The differences between model species and chlamydial 
strains regarding chlamydial virulence [91,92], infection course [95,96] and immune 
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response [97] highlight the importance of using appropriate model experimental 
systems. 
 
The chlamydial plasmid has been shown to function as a virulence factor in urogenital 
murine and ocular NHP models [85,93]. Phenotypic differences vary between plasmid-
cured and wild-type strains with respect to infectivity, glycogen accumulation, induction 
of inflammation and activation of toll-like receptor pathways [75,98]. Plasmid deletion 
mutagenesis studies showed that deletion of the plasmid-encoded pgp4 gene results in 
an in vitro phenotype identical to that of a plasmid-free strain [83]. Bacterial 
transcriptome analysis found a decrease in transcript levels of a subset of 
chromosomal genes in a naturally occurring plasmid-free strain of Ct, demonstrating 
that the plasmid is a transcriptional regulator of virulence-associated genes [84]. The 
failure of plasmid-free Ct to produce and store glycogen might confer a survival 
disadvantage in nutrient limited settings, such as at mucosal surfaces [84]. 
Maintenance of the plasmid at the relatively low copy number of 5-6 plasmids per 
genome [99] carries inherent risk of plasmid-loss during cell partition [100], but 
naturally occurring plasmid-free strains are rare [101–103]. This suggests that 5-6 
plasmid copies may maximize infectivity or intracellular survival whilst provoking 
minimal host immune response. Recent host transcriptome studies suggest that the 
plasmid may stimulate host cell expression of PD-L1, which induces programmed cell 
death in immune effector cells, suggesting a possible mechanism for plasmid virulence 
[104,105]. The plasmid is clearly strongly selected for during successful infection or 
transmission [98] and studies have shown that a plasmid-cured Ct strain is less virulent 
in ocular infection of macaques, does not cause pathology and can function as a live 
attenuated vaccine [139]. The absence of pathology in animal models infected with 
plasmid-free Ct suggests that parallel study of the host response to plasmid-competent 
and plasmid-free Ct will bring us closer to understanding the immunopathology of 
trachoma.   
 
1.6 Immunopathology of trachoma  
 
Despite extensive research, the mechanistic link between chronic inflammation and 
progressive scarring remains elusive [12]. The scarring observed in both trachoma and 
urogenital disease is thought to be a result of the host response to infection rather than 
a direct effect of the bacteria. Defining the features of protective versus pathogenic 
immunological responses in chlamydial disease (reviewed in [106]) is crucial to 
understanding disease and for efficacious vaccine design. 
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Currently, two models have been put forward to explain the immunopathogenesis of 
chlamydial disease: the immunological and cellular paradigms. The traditional 
immunological paradigm implicates the adaptive immune system. Initial studies on 
chlamydial infection found that repeated infection exacerbated inflammation and that 
inflammatory pathology continued in the absence of Ct. At first, a delayed type 
hypersensitivity (DTH) reaction triggered by a chlamydial antigen was hypothesized. 
The chlamydial heat shock protein 60 (HSP60) was considered a candidate antigen to 
trigger DTH, but was not found to exacerbate pathology when tested in a guinea-pig 
model [107]. Antibodies to HSP60 predicted a 2-3 fold higher risk of Ct pelvic 
inflammatory disease (PID) in humans and higher levels of antibodies specific to 
HSP60 were found in women with the most severe forms of urogenital disease [108]. 
Likewise antibodies to HSP60 were associated with tubal factor infertility (TFI) and 
inflammatory trachoma [109,110], however it remains unclear whether these antibodies 
cause pathology or are a result of a greater number or more severe episodes of 
infection. More recent screening of sera from trichiasis patients and controls detected 
differential patterns of antibody recognition for a number of Ct antigens, however 
HSP60 responses were not significantly different [111].  
 
Previous research demonstrated that individuals with scarring trachoma had Th2 
patterns of cytokine expression [112], whereas those with strong Th1 responses 
efficiently cleared infection [113]. This opposed the DTH theory and suggested that a 
Th2 response was either ineffectual at clearing infection or led to enhanced pathology 
and that CD4+ Th1 IFNγ responses were a key element of protective immunity in 
trachoma. Both CD8+ and CD4+ T cell infiltrates are associated with the conjunctival 
follicles that are characteristic of TF however CD4+ T cells are thought to outnumber 
CD8+ [114]. NK cells have more recently been identified as a major early source of 
IFNγ in response to Ct [115]. Despite the primary function of CD8+ T cells in defense 
against intracellular pathogens, data from murine models previously found a limited 
role for CD8+ T cells in anti-Ct immunity [116]. Recent evidence in the macaque model 
of trachoma challenges this theory and suggests that depletion of CD8+ T cells can 
abrogate protective immunity [117]. Characterization of the roles of each of these cell 
types in chronic scarring trachoma has proved difficult to address however, largely due 
to the long-term natural history of scarring disease. 
 
Stephens suggested an alternative model of disease [118] in which epithelial cells at 
the infection site play a central role as mediators of the innate immune response. 
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Epithelial cells infected with Ct secrete a number of proinflammatory cytokines and 
growth factors, such as IL-8, GRO, IL-1, IL-6 and granulocyte-macrophage colony-
stimulating factor (GM-CSF). The secretion of these cytokines is delayed compared to 
the kinetics of secretion upon infection with other invasive bacteria and persists 
throughout the 2-4 day developmental cycle of Ct. The secretion of IL-1 by infected 
cells was shown to up-regulate pro-inflammatory cytokine production by neighboring 
uninfected cells, promoting a strong inflammatory response [119]. Lymphocytes of the 
adaptive immune system are attracted to the infection site by the chemotactic gradient 
and subsequent infections include memory populations that amplify the response. Ct 
infected cells also secreted the pro-fibrotic cytokine IL-11, a member of the IL-6 family 
[120,121]. Recent evidence from a primary-like polarized epithelial cell model showed 
that IL-11 was secreted preferentially from the basolateral membrane and IL1ra from 
the apical membrane in Ct-infected cells [122]. The T cell chemokines RANTES and 
IP10 were also down-regulated in productively Ct-infected cells, suggesting that Ct 
attempts to avoid stimulation of the immune response in order to maintain its 
intracellular niche, potentially leading to longer infections and chronic pathology [122]. 
Recent genome-wide scale array studies from clinical samples support Stephens’ 
hypothesis. Expression profiling of children in The Gambia with active trachoma versus 
healthy controls revealed a strong up-regulation of the innate immune response [123]. 
Along with the expected infiltration of neutrophils, lymphocytes and the inflammatory 
cytokine pathways consistent with histopathology [124], the natural killer (NK) cell 
response was also enhanced. A transcriptome study conducted in Ethiopian adults with 
either trachomatous trichiasis (TT) or TT with inflammation (TTI) versus healthy 
controls found that despite less than 1% Ct infection prevalence, markers of ongoing 
sub-clinical inflammation and tissue remodeling were evident in the TT group and were 
more pronounced in the TTI group [125]. These markers were consistent with an 
activated and pro-inflammatory epithelium. There was a lack of evidence for a pro-
fibrotic Th2 response and a very limited Th1 response. Subsequent targeted 
quantitative-PCR studies have re-emphasized the role of the innate immune response 
in trachoma in both children and adults [126,127]. These studies found antimicrobial 
peptides psoriasin (S100A7), DEFb4A and SAA1, inflammatory cytokines IL-17, IL-1β 
and TNF, inflammatory chemokines (CCL18 and CXCL5), MMPs and CTGF were up-
regulated in trachomatous disease. Increased IL-17 expression was highlighted as 
characteristic of active trachoma and is thought to coordinate the pro-inflammatory 
response [126].  
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Overall these studies suggest that clearance of Ct infection requires an appropriate 
acute Th1 response with IFNγ and CD8+ T cells. They also support the case for the 
central role of epithelial cells in ongoing trachomatous inflammation and pathogenesis 
that leads to TT. This would imply that neither the cellular nor the immunological 
paradigm can fully explain disease, but that active cross talk between cellular (innate 
epithelial cell responses) and immunological (adaptive immunity) systems is required. 
A failure to generate an effective Th1 response to clear Ct infection (leading to chronic 
infection and inflammation), combined with an overactive innate epithelial inflammatory 
response throughout an individuals life might be risk factors for scarring progression. 
 
1.7 Small RNAs and chlamydial disease 
 
One possible explanation for the chronic inflammation and continued presence of 
active disease signs in populations once ocular Ct infection has been controlled is 
epigenetic change of the host cell state. “Epigenetics” describes changes in gene 
expression that are heritable through cell division, without alteration to the DNA 
sequence itself. These changes can be applied directly to DNA (CpG methylation), the 
proteins DNA is packaged around (chromatin modifications such as histone 
methylation or acetylation) and to the transcribed message (micro RNA mediated 
silencing).  
 
Only 20% of transcription across the human genome is associated with protein-coding 
genes [128] and it has become clear that many of the non protein-coding RNA species 
that are transcribed have important regulatory roles. These non-coding RNA species 
include micro RNA (miRNA), short interfering RNA (siRNA), piwi-interacting RNA 
(piRNA), small nucleolar RNAs (snoRNA), other small RNA and long non-coding RNA 
(lncRNA (>200 nucleotides)).  
 
MiRNA (miR) are short (18-22 nucleotide) single stranded sequences of RNA that post-
transcriptionally regulate gene expression. MiRNA encoding sequences make up only 
around 2% of the human genome, but are estimated to regulate >60% of protein-
coding genes [129]. Single or small numbers of miR can be master regulators of entire 
biological pathways and thus their abnormal expression can lead to disease. MiR 
regulate gene expression through binding to complementary messenger RNA (mRNA) 
sequences in the cytosol in association with Argonaute proteins, forming a RNA-
induced silencing complex (RISC), leading to inhibition or degradation of the target 
mRNA [130]. The “seed sequence” of the miR, nucelotides 2-7 from the five prime end, 
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guides target selection [131]. Half of known miR are found in polycistronic units and are 
expressed in parallel, often sharing structure and function [132,133]. Due to flexibility in 
binding complementarity an individual miR can target hundreds of different genes, and 
a gene might be targeted by many different miR [133], forming a complex network of 
regulation. Abnormal expression of miR may occur by the same factors regulating 
expression of any gene, including epigenetic control of pre-miR transcription or SNP’s 
in the miR coding sequence. MiR expression can also be regulated at the post-
transcriptional level (as pre-miR or mature miR), by RNA-binding proteins or by circular 
RNAs that can act as ‘sponges’ [134–137]. Due to the far-reaching and complex roles 
of miR, a small change in expression can have a profound effect on tissue 
homeostasis. 
MiR are an important part of the host response to bacteria, both pathogenic and 
commensal. Inflammation must be tightly regulated; excess can lead to organ damage 
whereas insufficient inflammation may facilitate the dissemination of infection. Several 
miR are well characterized as having important roles in the immune response against 
bacteria (reviewed in [138–140]). MiR-146 and miR-155 are up-regulated in immune 
cells following infection with a range of bacteria, including Helicobacter pylori, 
Salmonella enterica, Listeria monocytogenes, Francisella tularensis and 
Mycobacterium species. Both miR-155 and miR-146 function in negative feedback 
loops to prevent excessive inflammation by silencing targets in the TLR4 signalling 
pathway. MiR-155 also maintains TNF expression and is essential for an appropriate 
adaptive immune response. The miR response to Ct infection in humans has not 
previously been investigated, however, others have examined the expression of miR 
during urogenital infection of mice with Ct or Cm. Distinct patterns of miR expression 
were elicited by two strains of Cm that varied in virulence in the murine genital tract 
[141]. MiR-223-3p and miR-18a-5p were induced in mice by both strains at 24 hours 
post-infection. Interestingly, miR-155 expression was increased in response to 
avirulent Cm, but not in response to the virulent strain of Cm. The failure to up-regulate 
miR-155 in the virulent infection model could indicate an absence of the negative 
feedback loop that is required to prevent excessive inflammation, leading to the 
increased pathology that was observed. Gupta and colleagues investigated miR 
expression following Cm infection in the murine genital model at a later time point. At 6 
days post bacterial challenge, miR-125b-5p, -135a, -16, -214, -30c, 30-e, -182, 183 
and -23b were down-regulated in the lower genital tract and miR-146 and -451 were 
up-regulated [142]. These changes were not maintained at 12 days post infection. 
Knockdown of -125b-5p, -30c and -182 led to a failure to control Cm infection and in 
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CD4-/- mice, levels of miR-125b-5p, -182, -183 and -135 were up-regulated relative to 
wild type infected mice. MiR-125b maintains the naivety of T cells and is down-
regulated upon their differentiation and maturation [143]. MiR-125b also targets TNF 
and is thought to maintain the inactivity of macrophages in the absence of bacterial 
TLR stimulation [138]. MiR-125b down-regulation may therefore be required for an 
appropriate immune response. Igietseme and colleagues have shown that upon 
urogenital infection of mice with a virulent LGV Ct strain (L2), murine miR-21, -103, -
107, let-7i and -92b were down-regulated in the oviducts, though the time-point at 
which these changes in expression are observed is unclear [144].  
Overexpression of miR-146a in psoriatic skin lesions has been linked to a SNP in the 
miR-146 gene in a large cohort of Chinese patients [145]. Wang and colleagues looked 
at the association of polymorphisms in miR-146a and the NRLP3 inflammasome in 
association with susceptibility and severity of urogenital Ct infection in two cohorts of 
Dutch and Finnish women [146]. A SNP in NLRP3 was found to associate with lower 
abdominal pain in Ct positive women, however, no link with miR-146a was found.  
 
Transcriptome arrays comparing gene expression at various stages of trachomatous 
disease have found many thousands of genes are differentially regulated [123,125]. 
Given that single or small numbers of miR can regulate entire biological pathways, the 
study of miR in trachoma offers a chance to reduce some of this complexity to identify 
the key pathways that are dysregulated. As a preliminary step, a data mining approach 
(MSigDB) was used to identify miR that were enriched for predicted targets within lists 
of differentially regulated genes from four trachoma transcriptomes. The results are 
shown in Table 1.1. Of interest are the miR with known roles in the regulation of EMT, 
which is discussed further below. A number of miR that have been identified as 
differentially expressed in Ct and Cm infection are enriched for targets in these 
datasets, particularly in the comparison of active disease with Ct infection against 
controls, which is closest biologically to these murine models. Many of the miR were 
predicted to have roles regulating cell proliferation and apoptosis. This could be 
reflective of Ct preventing host cell apoptosis to maintain the intracellular niche or T cell 
and fibroblast proliferation contributing to inflammation and fibrosis, however, a 
drawback of using data mining techniques is the relative abundance of cancer-related 
miR associations and pathways that dominate the literature.  
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Table 1.1. MiR predicted to regulate differentially expressed transcripts from four array 
datasets.  
 
 
 
The study of miR can thus advance our understanding of the key biological pathways 
involved in health and disease processes and how they are controlled. In addition, due 
to their relatively small numbers and profound effects, miR can also be used as 
diagnostic tools, biomarkers and therapeutic targets. Expression levels of just a few 
 
MsigDb predicted miR based on differentially regulated mRNA transcripts  
(FC>1.5 Adj.P<0.01) from 4 trachoma transcriptomes 
miR Functional 
categories 
Active disease with Ct 
infection  
(GSE20436) 
Active disease 
(GSE20430) 
Trachomatou
s Scarring 
disease with 
inflammation 
(GSE24383) 
Trachomatous  
trichiasis with 
inflammation 
(GSE23705) 
Inflammation / 
Infection LET-7 family [144]   MIR-511 LET-7 family [144] 
  MIR-125A/B [142] 
 
  MIR-19A/B 
  MIR-19A/B 
 
  MIR-224 
        MIR-29A/B/C 
EMT/fibrosis MIR-200B/C, MIR-429     MIR-200B/C, MIR-429 
  MIR-506 
 
  MIR-29A/B/C 
    
 
  MIR-506 
        MIR-520D 
Cell cycle/ 
Cancer LET-7 family [144] MIR-518A-2 MIR-128A/B LET-7 family [144] 
  MIR-124A MIR-186 
MIR-21 
[141,144] MIR-19A/B 
  MIR-125A/B [142] MIR-130A/B, MIR-301 MIR-26A/B MIR-22 
  MIR-15 family 
 
MIR-519A/B/C MIR-224 
  
MIR-17-5P, MIR-20A/B, 
MIR-106A/B, MIR-519D 
 
  
MIR-25, MIR-32, MIR-
92, MIR-363, MIR-367 
[144] 
  MIR-19A/B 
 
  MIR-516-3P 
  MIR-218 
 
  MIR-519A/B/C 
  MIR-23A/B [142] 
 
  MIR-520D 
  MIR-30A/B/C/D/E-5P [142] 
 
    
  MIR-519A/B/C 
 
    
  MIR-524 
 
    
  MIR-9       
Other MIR-130A/B, MIR-301 
 
MIR-153 MIR-27A/B 
        MIR-516-5P 
Phenotype comparisons are as follows: Normal healthy (N) children age 1-9 versus those with 
active trachoma (TF) and Ct infection (GSE20436); children age 1-9 with TF (with or without Ct 
infection) versus N (GSE20430); N adults versus adults with trachomatous scarring and clinical 
inflammation (TSI) (GSE24383); and N adults versus adults with trichiasis and clinical 
inflammation (TTI) (GSE23705). Enriched miR are grouped into functional categories based 
well characterized roles in the literature. References show published studies that identify miR 
in bold as differentially expressed in chlamydial infection. 
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miR in tissue, blood or plasma have been suggested as biomarkers for early larynx 
carcinoma [147], breast cancer [148], drug-resistant epilepsy [149] and Alzheimer’s 
disease [150]. Furthermore miRNA levels can be manipulated in vivo for therapeutic 
purposes [151]. Silencing of miR-155 in mice, which is upregulated upon LPS 
stimulation, by systemic administration of an anti-miR (a complementary sequence to 
bind and inhibit miR-155) led to a downregulation of granulocyte colony stimulating 
factor in murine splenocyte cells, thus conferring targeted silencing of miR-155 with the 
potential to reduce acute or chronic inflammatory disease [152]. A systemic anti-miR-
122 drug was safe and effective following Phase 2a human clinical trials for the 
treatment of Hepatitis C virus, due to the requirement of human miR-122 for viral 
replication [153]. The study of miR expression in human chlamydial disease, which has 
not yet been reported, will advance our understanding of the key biological pathways 
under control in various stages of the disease process. It might also enable us to find a 
small number of miR that could identify individuals at increased risk of future scarring 
sequelae, and could enable the development of therapeutic interventions in these 
individuals. Alternatively, an early miRNA correlate of protection from scarring 
sequelae could be used to assess vaccine efficacy. 
 
1.8 Epithelial-mesenchymal transition and chlamydial disease 
 
EMT is a reversible process by which epithelial cells differentiate into mesenchymal 
cells. Currently 3 types of EMT are recognised. In type-I EMT, epithelial cells 
differentiate into mesenchymal cells to migrate around the growing embryo during fetal 
development. These mesenchymal cells can then transform back into epithelia through 
the reverse process of mesenchymal-epithelial transition (MET) to establish new 
distant sites of epithelial tissue. Type-II EMT is associated with inflammation-induced 
tissue fibrosis and type-III EMT occurs in cancer when epithelial tumors metastasize. It 
is thought that the 3 types of EMT have similar stimuli, signaling cascades and 
regulation [154,155]. Endothelial cells also differentiate into mesenchymal cells when 
subjected to the same stimuli (EndMT) and can contribute to cardiac fibrosis [156].  
 
Type-II EMT (EMT-2) occurs in response to inflammation and can lead to loss of organ 
function through pathological fibrosis. Inflammatory cytokines, growth factors and 
MMPs activate a chain of transcription factors that cause a down-regulation of 
epithelial characteristics in cells and gain of mesenchymal properties. The basement 
membrane is degraded by MMPs, allowing differentiating cells to migrate into the 
interstitial tissue [157]. New mesenchymal cells can then acquire a myofibroblast 
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phenotype [158], secreting collagen 1 and expressing -smooth muscle actin and 
therefore contributing to extracellular matrix deposition and ‘wound’ contraction. EMT-2 
is known to contribute to the pathology of many fibrotic diseases, including kidney 
fibrosis [158], idiopathic pulmonary fibrosis [159], cardiac and liver fibrosis [156,160]. In 
a murine model of liver fibrosis up to 45% of fibroblasts were found to have originated 
from hepatocytes [156,160]. Evidence of EMT has been shown in both acute wound 
healing and in chronic fibrotic (hypertrophic) scars where there is also evidence of 
unresolved inflammation [161]. EMT-2 ceases when inflammatory stimuli stop; 
therefore it appears that EMT-2 only becomes pathological in an environment of 
chronic inflammation. Having said that, EMT cells can be resistant to apoptosis 
(reviewed in [162]), possibly arising from the need for resilient cells to seed new sites 
of epithelial tissue in embryonic development. In addition to resisting apoptosis, EMT 
cells can acquire stem-cell-like properties allowing self-renewal [163–165], a property 
which is known to play a role in various cancers and which could contribute to the 
chronic fibrosis that is observed in trachoma. EMT-activating transcription factor ZEB1 
represses expression of the stemness-inhibiting miR-200 family, therefore releasing 
expression of stem cell factors and leading to EMT and self-renewal. The in silico 
analysis presented in Table 1 suggests that the miR-200 family may be associated with 
trachoma.  
 
Primary hepatocytes infected with Hepatitis C virus in vitro have been shown to up-
regulate biomarkers of EMT [166]. LPS-treated intrahepatic biliary epithelial cells up-
regulate TGF1 in vitro and stimulate EMT through the TGF1/SMAD2/3 pathway 
[167]. EMT-2 has also been observed during Herpes virus infection in vitro and in vivo 
and following E. coli infection in vitro [168,169]. Helicobacter pylori virulence factors 
VacA and CagA disrupt epithelial cell tight junctions and polarity [170–172] and up-
regulation of EMT transcription factors and biomarkers in gastric cell lines requires both 
the cag pathogenicity island and NFkB activation [173,174]. EMT can thus be 
stimulated indirectly through inflammatory signals or directly by pathogens. Ct infected 
epithelial cells in ex vivo fallopian tube tissue show phenotypic changes characteristic 
of EMT, such as decreased polarity and cell adhesion [175]. The WNT pathway was 
up-regulated and -catenin was recruited to the chlamydial inclusion. Loss of epithelial 
cell-cell adhesion, N-cadherin/-catenin complex formation and recruitment of -
catenin to the chlamydial inclusion has also been observed in vitro [176]. Nectin-1, an 
integral molecule of epithelial cell tight junctions and adherens junctions was down-
regulated at the post-transcriptional level by 85% in Ct infected HeLa cells, which was 
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dependent on live infection [177]. Disruptions to key components of the WNT and 
Notch signaling pathways, inter-cellular junctions and adhesion and cytoskeletal 
remodeling have been identified by RNA-sequencing as early as one hour post-
infection of HeLa cells with serovar E Ct [178]. Transcriptomic profiling of TT and 
subsequent gene-set enrichment analysis has also shown significant enrichment in 
members of the WNT pathway [125,179]. These data therefore support a role for WNT 
signaling in both active infection and later stages of chlamydial disease. Given that 
WNT signaling stimulates EMT in vitro [180] and the Akt/-catenin pathway mediates 
EMT activation following HCV and H. pylori infection [166,172], it is tempting to 
speculate that Ct induces EMT-2 in the conjunctival epithelium, either directly or via Ct-
induced inflammation.  
 
EMT-2 (hereafter referred to as EMT) might therefore present a mechanism by which 
trachomatous inflammation leads to fibrosis in the tarsal plate. Knowledge of this 
mechanism might enable targeted interventions or rational vaccine design.  
 
1.9 Overall summary  
 
A large number of individuals remain at risk of progressing to scarring trachoma and 
trichiasis. There is therefore a need to understand the immunopathogenesis of the 
disease in order to develop therapeutic treatments to halt scarring progression or to 
develop a protective vaccine. It is also hoped that research on the 
immunopathogenesis of trachoma might be transferable to urogenital chlamydial 
disease, for which is it more difficult to obtain clear clinical phenotypes to correlate with 
laboratory findings. Preliminary evidence suggests that EMT might have a role in the 
inflammation-induced fibrosis of chlamydial disease, and miR could be master 
regulators of the inflammatory and fibrotic pathways that lead to progressive 
trachomatous scarring. The chlamydial plasmid has a role in pathogen virulence and 
the resulting host immunopathology, and as such might effect EMT induction or miR 
regulation. The Ct plasmid is therefore a tool with which to investigate the role of these 
factors in chlamydial disease.  
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2.1 Purpose 
 
Repeated chlamydial infection of the conjunctiva throughout childhood appears to 
prime or imprint the conjunctiva, causing some individuals in endemic communities to 
become chronically inflamed and develop fibrosis that persists throughout their lives, 
even in the absence of detectable Ct infection. This fibrosis leads to trichiasis, pain and 
blindness. The mechanisms that drive chronic immunopathology and the reasons why 
only a proportion of Ct-exposed individuals go on to develop scarring trachoma are not 
currently understood.  
 
Inflammatory episodes are a major risk factor for scarring progression. Inflammation 
can induce EMT, whereby epithelial cells differentiate into pro-fibrotic mesenchymal 
cells and contribute to tissue fibrosis in the underlying stroma. MiR are small single-
stranded RNA species that regulate gene expression post-transcriptionally and single 
or small numbers of miR can hold tight control over inflammatory and pro-fibrotic 
pathways. Ocular infections with plasmid-free Ct strains result in reduced inflammatory 
pathology in animal models and thus might lead to attenuated EMT induction and 
differential miR responses. The roles of EMT and miR in human ocular chlamydial 
disease, their contribution to trachomatous scarring and the effect of the Ct plasmid on 
EMT and miR responses have not yet been investigated. 
 
The purpose of this thesis was to investigate a) whether differential expression of miR 
is associated with the pathological changes in the conjunctiva that occur in response to 
and continue in the absence of Ct, b) whether EMT occurs in response to inflammation 
in the conjunctiva and contributes to the fibrotic pathology of trachoma and c) what 
effect the presence of the Ct plasmid has on EMT induction and miR expression.  
 
2.2 Hypotheses 
 
1. Single or small numbers of miR that control inflammatory and fibrotic pathways 
are differentially expressed in the conjunctiva during active and scarring 
trachoma.  
2. Infection of epithelial cell lines with plasmid-free and plasmid-competent Ct 
strains induces differential expression of miR. 
3. Ct infection and inflammation induce EMT in conjunctival epithelial cells and this 
process contributes to trachomatous scarring in vivo. 
4. A plasmid-free ocular strain of Ct is attenuated in the induction of pathological 
miR, inflammation and EMT responses. 
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2.3 Aims 
 
1. To examine the expression of miR in the conjunctiva of individuals with scarring 
trachoma in the presence of clinical inflammation and from individuals with 
active trachoma (trachomatous inflammation – follicular and/or trachomatous 
inflammation – intense) in the presence of Ct infection relative to normal healthy 
controls. 
2. To examine the expression of miR in plasmid-free and plasmid-competent Ct 
infected relative to uninfected epithelial cell lines. 
3. To examine the induction of inflammation and EMT in epithelial cells in vitro in 
response to infection with plasmid-free and plasmid-competent Ct strains. 
4. To investigate the presence and localisation of pro-inflammatory mediators, 
growth factors and EMT biomarkers in tissue from individuals with trichiasis at 
the protein level. 
 
2.4 Specific Objectives 
 
1. To identify miR associated with scarring trachoma in the presence and absence 
of clinically significant inflammation using qPCR. 
2. To establish infection models in clinically relevant epithelial cell lines in vitro 
with ocular plasmid-free and plasmid-competent Ct strains. 
3. To examine miR expression in epithelial cells in response to plasmid-free and 
plasmid-competent Ct strains using small RNA sequencing by synthesis (SBS) 
technology and quantitative real-time PCR (qPCR). 
4. To identify miRNA associated with active trachoma in the presence and 
absence of current Ct infection using SBS and qPCR.  
5. To determine whether miRNA can be used as classifiers of disease in active 
and scarring trachoma. 
6. To examine induction of inflammation and EMT in epithelial cells in response to 
plasmid-free and plasmid-competent Ct strains using qPCR, microscopy and a 
scratch wound model. 
7. To investigate the expression of pro-inflammatory mediators, growth factors and 
biomarkers of EMT in tissue from individuals with trichiasis using 
immunohistochemistry (IHC).   
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4.1 Use of HCjE cells and HEp-2 cells for modelling the epithelial response to Ct 
infection  
HEp-2 and HeLa cells are human epithelial cell lines that are commonly used for Ct 
infection models. HEp-2 cells were originally derived from an epidermoid carcinoma of 
the larynx, however due to the presence of HeLa cell chromosome markers they are 
suspected to be contaminated by HeLa cells. The HEp-2 cells used in this study were a 
kind gift from collaborators at the University of Southampton and the original source is 
unknown. The American Tissue Type Collection (ATCC) HEp-2 cell line CCL-23 is 
positive for keratin by immunoperoxidase staining and contains human papilloma viral 
DNA sequences and HeLa marker chromosomes. HeLa cells were derived from a 
glandular adenocarcinoma of the cervix [1].  
 
Although used widely in studies, there are data to suggest that HeLa cells (and 
therefore HEp-2 cells) may not be an appropriate cell line in which to study the host 
response to Ct infection. RNA and DNA sequencing of a HeLa Kyoto cell line 
discovered evidence of a chromosomal rearrangement event (chromothripsis) and 
alarming levels of aneuploidy and differential gene expression in cell cycle and DNA 
repair pathways [2]. Ct modulates the host cell cycle in order to optimize bacterial 
replication and survival [3,4], which could be affected by the abnormal expression of 
cell cycle genes with unknown consequences. What is more, there are mixed reports 
concerning the expression of TLRs and downstream members of TLR signalling 
pathways in HeLa cells, which are crucial in pathogen recognition. Wyllie et al., found 
that ATCC HeLa cells (exact strain not reported) did not express TLR1, TLR2 or MD-2 
(a cofactor required for TLR4 function) mRNA [5]. Kurt-Jones et al., also examined 
gene expression in ATCC HeLa cells (exact strain not reported) and found that TLR2 
and TLR8 were not expressed and that HeLa were unresponsive to TLR2 stimuli, 
although cytokines were secreted in response to TNFα [6]. In contrast, another study 
reported that all 10 TLRs were expressed in HeLa cells, also using gene expression 
analysis (ATCC#: CCL-2) [7]. Plasmid-free strains of Ct fail to activate TLR2 and as a 
result do not induce pathology in the murine genital tract [8]. A lack of specific TLR 
machinery in HeLa cells would lead to an aberrant innate cellular response to infection, 
with the potential to mislead researchers.  
 
Studies using more physiologically appropriate cell lines and polarized epithelial cell 
models have shown that Ct entry, productivity, response to antimicrobial drugs and 
host responses differ in comparison to Ct infection of non-polarized epithelial cell 
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monolayers [9–12]. Infectivity of a serovar E strain of Ct was higher in endometrial 
HEC-1B cells relative to HeLa and McCoy cells when cells were grown in monolayer 
(flask) cultures [9]. When cells were cultured three-dimensionally on collagen-coated 
microcarrier beads the Ct developmental cycle completed faster in all three cell lines 
relative to monolayer cultures, however in HEC-1B cells Ct entry was faster, genome 
replication was greater and progeny from were slightly more infectious relative to HeLa 
and McCoy cells [9]. In contrast, the more virulent strain L2 that disseminates in vivo 
and causes LGV showed equal attachment, entry and growth productivity in polarized 
HeLa and HEC-1B and non-polarized HeLa cells [13]. This perhaps reflects the 
virulence of L2 and might suggest that growth of less virulent ocular (serovars A-C) and 
urogenital (serovars D-K) strains of Ct is more susceptible to changes in the local 
environment. A recent study using a primary-like immortalized endocervical epithelial 
cell model found that polarized cells localized expression of certain inflammatory 
mediators to the apical or basal surface in response to infection with a serovar D strain 
of Ct [12]. These data indicate that growth of ocular Ct strains may be more successful 
and the host response more complex when using cellular models that better mimic the 
in vivo environment. 
For investigation of the ocular response to Ct infection it was therefore desirable to use 
an epithelial cell line of conjunctival origin. Three conjunctival epithelial cell lines have 
been reported in the literature: HCjE, IOBA-NHC [14] and Wong-Kilbourne derivative of 
Chang conjunctiva (ChWK), however ChWK cells are suspected to be contaminated by 
HeLa cells [15,16]. Primary cells were not used in this PhD project due to the reported 
difficulty in obtaining and growing pure primary epithelial cells from conjunctival tissue. 
 
The HCjE cell line was established by James G. Rheinwald and colleagues in 2002 
[17]. Primary conjunctival keratinocytes from an 82-year-old clinically normal man were 
grown from explanted or minced tissue. These cells were determined to be genetically 
normal and were co-cultivated through 1-4 serial passages with feeder cells 
(mitomycin-treated Swiss 3T3J2 cells). Following this they were cultured in keratinocyte 
serum-free medium supplemented with bovine pituitary extract, epidermal growth factor 
(EGF) and calcium chloride [17]. HCjE cells were engineered to express hTERT (to 
prevent telomere shortening), a p-16 insensitive mutant of cdk4 (to abolish p-16 
control) and a dominant negative mutant of p53 (to abolish p53 function). All three of 
these mutations were necessary to achieve immortality of this cell line. The 
differentiation characteristics of this cell line were subsequently investigated by Gipson 
and colleagues in 2003 [18]. The keratin and mucin expression repertoire of HCjE cells 
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was shown to be similar to that of native epithelial cells and cells stratified when grown 
on plastic, type I collagen and when implanted into severe combined immunodeficient 
(SCID) mice [18]. Stratified apical cells flattened and produced membrane-associated 
mucins, however basal cell polarity was not detected and HCjE cells failed to fully 
differentiate into polarized epithelium. Despite a subpopulation of HCjE cells 
expressing small amounts of the goblet-cell specific mucin, MUC5AC, goblet cells that 
had differentiated from HCjE cells could not be detected [18].  
 
One study has compared the growth of an ocular serovar A strain of Ct, A/HAR-13, in 
HeLa and HCjE cells [19]. Cells were grown on cell culture plastic (24 well plates), were 
not polarized or stratified and were infected with Ct inoculum in sucrose phosphate 
glutamate and were rocked at 37°C for 2 hours to facilitate infection. A/HAR-13 grew 
faster in HCjE cells than in HeLa cells, whereas urogenital Ct serovars grew faster in 
HeLa cells. The authors concluded that this reflected the tissue tropism of Ct serovars.  
 
This project sought to use the HCjE cell line to investigate the conjunctival epithelial 
cell response to Ct infection. The HCjE cells used were a kind gift from the laboratory 
of Professor Ilene Gipson (Harvard University). The specific objectives were to 
establish Ct infection models in HEp-2 cells and to perform experiments in the more 
physiologically appropriate HCjE cell line. This chapter reports the growth kinetics of Ct 
in these two cell lines and the methods used to investigate Ct infectivity in HCjE cells.  
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4.2. Methods 
 
In vitro culture and Ct infection of human epithelial cell lines  
 
Human epithelial type 2 (HEp-2) cells were cultured in MEM (Gibco, Life Technologies) 
supplemented with 1% gentamicin (Gibco), 10% FBS (Gibco), and 1% L-glutamine 
(Gibco). For in vitro experiments, cells were seeded in 12 well plates at 3x105 cells per 
well in MEM. An immortalized human conjunctival epithelial cell line (HCjE) was 
cultured in Keratinocyte serum-free medium (K-sfm) with L-Glutamine (Gibco) 
supplemented with 25g/ml bovine pituitary extract (Gibco), 0.2ng/ml epidermal growth 
factor (Gibco), 0.4mM CaCl2 (Sigma) and 5% gentamicin and incubated at 37°C with 
5% atmospheric CO2. For experiments, HCjE cells were seeded in 12 well plates at 
3x105 cells per well. Initial infection experiments cultured HCjE cells in K-sfm 
throughout. For later HCjE cell infection experiments, cells were seeded in 1:1 K-sfm 
[with supplements]: Dulbecco’s Modified Eagle Medium: Nutrient Mixture F12 
(DMEM/F12) [with 10% FBS, 1% gentamicin and 1% L-glutamine] (Gibco) and were 
switched to DMEM/F12 [with supplements] upon infection 24 hours later. Cell lines 
were tested for Mycoplasma contamination upon receipt and regularly thereafter using 
the LookOut® Mycoplasma PCR Detection kit (Sigma-Aldrich) following the 
manufacturers instructions. Methods to test cell line identity such as human lymphocyte 
antigen (HLA) testing, karyotyping, isoenzyme or short tandem repeat (STR) analyses 
were not performed.  
 
HEp-2 and HCjE cells were infected with serovar A Ct strains: A2497 (described in 
[20]), its plasmid cured counterpart (A2497P-) [21] and A/HAR-13 [20] and LGV strain 
L2/434/Bu [22]. Cells were infected 24 hours after seeding at a multiplicity of infection 
(MOI) of 0.5 or 1 and with or without the addition of cycloheximide where described. 
Cycloheximide (Sigma) was used at a final concentration of 1g/ml. Ct cultures and 
mock-infected cells were centrifuged at 1800 r.p.m. for 1 hr to facilitate infection and 
were incubated at 37°C in 5% CO2. Cells were not washed after the addition of Ct 
inoculum or centrifugation. DEAE-Dextran (Sigma) was used instead of centrifugation 
where described. Twenty-four hours after seeding, media was removed from wells and 
replaced with Hanks Balanced Salt Solution (HBSS) (Gibco) containing 30mg/L DEAE-
Dextran. Wells were left to stand at room temperature for 20 minutes. HBSS and 
DEAE-Dextran were removed, cells were washed in HBSS and Ct inoculum in media 
was added. After one hour of incubation at 37°C the inoculum was removed, cells were 
washed in HBSS and media was added. Two or six replicates were carried out for each 
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experiment where described. At the indicated timepoints post-infection (hpi), media 
was removed and cells were washed in 1X PBS (Sigma). Productive infection was 
measured by ddPCR and through visualization of inclusions using confocal and phase 
microscopy.  
 
Nucleic acid extraction  
 
Three hundred microliters of lysis buffer (Norgen Biotek) was added to each well and 
cells were harvested by scraping. Total RNA and DNA were extracted using the 
Norgen RNA and DNA purification kit according to the manufacturers instructions.  
 
Ct infection load by droplet digital PCR  
 
Droplet-digital PCR was carried out to quantitate Ct infection, as described previously 
(Chapter 4; [23,24]). An initial assay detecting Ct omcB and human RPP30 
endogenous control was carried out on all samples to determine Ct load. Another 
assay detecting Ct omcB and Ct plasmid DNA was performed to check for cross 
contamination of plasmid competent Ct in plasmid-free Ct cultures. Ct omcB and 
human RPP30 primer and probe sequences are described elsewhere (Chapter 4). The 
Ct plasmid primer and probe sequences were forward: 5’ 
CAGCTTGTAGTCCTGCTTGAGAGA 3’, reverse: 5’ 
CAAGAGTACATCGGTCAACGAAGA 3’, probe: [HEX] 
CCCCACCATTTTTCCGGAGCGA [BHQ1]. Thermal cycling conditions were as follows: 
95C hold for 10 minutes, followed by 40 cycles of 95C for 10 seconds and 60C for 
20 seconds with a final hold of 98C for 12 minutes. ddPCR was performed on a Bio-
Rad QX100 Instrument and data were collected using Quantalife software (Bio-Rad). 
Copy number was calculated in R using previously published scripts [23].  
 
Confocal microscopy  
 
Cell monolayers were seeded on glass coverslips and at 48 hpi media was removed 
and cells were washed in 1X PBS. Two hundred l ice cold 100% methanol was added 
to each well for 10 minutes. Cells were washed in 1X PBS and incubated in 200 l 1% 
w/v BSA/PBS for 30 minutes at room temperature to block non-specific fluorescence. 
Cells were incubated for 30 minutes in the dark with 100 l of a 1% v/v solution of anti-
Chlamydia trachomatis MOMP antibody (FITC) (ab30951; Abcam) in 1% w/v 
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BSA/PBS. Cells were washed 3x in 1X PBS for 5 minutes each wash. DAPI dilactate 
(1g/ml (Sigma)) was added for 5 minutes. Cells were washed 3x in 1X PBS. Slides 
were mounted with coverslips and viewed on a Zeiss LSM510 confocal microscope at 
40X magnification. Images were captured using the tile function in Volocity, V5.5.1 
(PerkinElmer).   
 
Qiagen RT2 Profiler antibacterial response PCR arrays 
 
RNA was reverse transcribed using MiScript RTII kits with the HiFlex buffer (Qiagen) to 
synthesise a cDNA library. Qiagen RT2 profiler antibacterial response qPCR array 
cards were carried out using RT2 SYBR Green ROX qPCR master mix (Qiagen) 
following the manufacturers instructions. PCR was performed on a 7500HT 96-well 
Standard block PCR instrument (Applied Biosystems, ThermoFisher Scientific, Life 
Technologies).   
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4.3 Ct growth in HEp-2 and HCjE cells  
 
4.3.1 Growth of ocular serovars in HEp-2 cells 
 
HEp-2 cells grew quickly, were small and round and had the pavement-like morphology 
characteristic of epithelial cells. Inclusions could be seen by phase microscopy 
between 48-72 hours post infection with Ct. Cells were free of Mycoplasma on all 
occasions tested.  
 
The Ct chromosomal copy number (omcB) of A2497, A2497P- and A/HAR-13 
decreased between 0 and 12 hours post infection (hpi) in HEp-2 cells. By 24 hpi, 
A2497 OmcB copies began to increase, whereas A2497P- took slightly longer and an 
increase was seen at 48 hpi. Levels of A2497 and A2497P- were comparable by 48 
hpi. A/HAR-13 growth was not as successful in comparison to A2497 and A2497P-. 
Although A/HAR-13 copy numbers increased by 48 hpi, the total number of OmcB 
copies was still lower than that of the starting inoculum (Figure 4.1). This difference 
was clearly evident by microscopy of chlamydial inclusions in HEp-2 cell monolayers 
(Figure 4.2). A2497 and A2497P- achieved comparable numbers of inclusions, 
whereas far fewer inclusions could be seen in A/HAR-13 infected cells. A2497P- 
formed the “bulls-eye” inclusions characteristic of plasmid-free Ct [25–27], with 
inclusions appearing donut-like and hollow in the middle. These can be seen in more 
detail in the insert of Figure 4.2B. In contrast A2497 inclusions were solid throughout. 
A2497 and A2497P- inclusions were angular and enlarged to fill the cell cytoplasm, 
whereas A/HAR-13 inclusions were small and round. No plasmid DNA was detected in 
the DNA of A2497P- infected cells (data not shown).  
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Figure 4.1. Genome copy number (omcB) of A/HAR-13, A2497P- and A2497 strains of 
Ct in HEp-2 cells at the indicated timepoints post-infection. Cells were infected at an 
MOI of 1. Genome copy number is shown on a log(10) scale. Timepoints post-infection 
are shown on a non-linear scale. Two replicates of each timepoint/infection were 
carried out. Boxes show the range between the two values (one from each replicate). 
Red: A/HAR-13, Blue: A2497P-, Yellow: A2497.  
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Figure 4.2. HEp-2 cell monolayers infected with Ct strains A2497 (A), A2497P- (B), 
A/HAR-13 (C) and mock-infected cells (D) at 48 hpi. “Bulls-eye” inclusions can be seen 
for A2497P- infected cells in the insert of (B). Cell nuclei were stained with DAPI (blue) 
and Ct inclusions were stained with anti-C. trachomatis MOMP antibody (FITC 
(green)). Cells were infected at an MOI of 1 and viewed at 40X magnification. 
Representative photomicrographs were taken from one of two replicates for each 
condition. Inserts show a section of each field at a greater magnification. Scale bars 
represent 100μm.  
 
4.3.2 Growth of ocular serovars in HCjE cells 
 
HCjE cells were slow growing and were larger than HEp-2 cells. Cells were flattened 
and difficult to see clearly using phase microscopy, particularly once confluency was 
 79 
achieved, however the pavement-like morphology could be seen. Cells were free of 
Mycoplasma on all occasions tested.  
 
HCjE cells were infected with the same inoculum and volume that was used to infect 
HEp-2 cells in section 4.3.1. In contrast to HEp-2 cells, all Ct strains failed to grow 
productively in HCjE cells (Figure 4.3). The genome copy number of A2497 and 
A2497P- decreased consistently over time, even up to 144 hpi. A/HAR-13 genome 
copy number decreased at a faster rate than A2497 and A2497P- (similar to HEp-2 
cells), however it increased slightly between 72 and 144 hpi. The lack of productive 
infection was evident through microscopy; very few inclusions could be identified and 
they were small and round, similar to A/HAR-13 growth in HEp-2 cells (Figure 4.4). No 
plasmid DNA was detected in A2497P- infected cell DNA (data not shown).  
 
 
 
Figure 4.3. Genome copy number (omcB) of A/HAR-13, A2497P- and A2497 strains of 
Ct in HCjE cells at the indicated timepoints post-infection. Genome copy number is 
shown on a log(10) scale. Timepoints post-infection are shown on a non-linear scale.  
Cells were infected at an MOI of 1. Boxplots show the median (thick black horizontal 
line), the interquartile range (solid coloured box) and the minimum and maximum 
values (dotted line or empty circles) of the six replicates for each timepoint/infection. 
Red: A/HAR-13, Blue: A2497P-, Yellow: A2497. 
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Figure 4.4. HCjE cell monolayers infected with Ct strains A2497 (A), A2497P- (B), 
A/HAR-13 (C) and mock-infected cells (D) at 48 hpi. Cell nuclei were stained with DAPI 
(blue) and Ct inclusions were stained with anti-C. trachomatis MOMP antibody (FITC 
(green)). Cells were infected with an MOI of 1 and viewed at 40X magnification. 
Representative photomicrographs were taken from one of two replicates for each 
condition. The arrow indicates a Ct inclusion, shown at greater magnification in the 
insert. Scale bars represent 100μm. 
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4.4 Optimization of Ct growth in HCjE cells 
 
4.4.1 Infection medium and facilitation 
 
The addition of serum to HCjE cells is thought to slow cell replication and promote 
differentiation. HCjE cells can be switched to DMEM/F12 media containing FCS in 
order to promote differentiation and stratification [18]. The calcium and tryptophan 
levels in the media of K-sfm (in which HCjE cells were grown and infected in section 
4.3.2), MEM (in which HEp-2 cells were grown) and DMEM/F12 were compared (Table 
4.1). The calcium concentration of K-sfm was lower than that of MEM and DMEM/F12, 
whereas tryptophan levels were comparable. In case of low calcium or the 
differentiation state of HCjE cells hindering chlamydial growth, the infectivity of Ct in 
HCjE cells grown in DMEM/F12 was investigated. 
 
Table 4.1. Nutrient levels in media used for HEp-2 and HCjE cells 
 Calcium (mg/L) Tryptophan (mg/L) 
K-sfm  80  8.98 
MEM 200  10 
DMEM/F12 116.6 9.02 
Footnote: total nutrient levels are shown after addition of supplements.  
 
Centrifugation was used to facilitate chlamydial infection in the experiments described 
above. DEAE-Dextran is an alternative method that polarizes cell membranes and is 
thought to facilitate uptake of EBs by cells. HCjE (seeded and infected in K-sfm) and 
HEp-2 cells were infected with A2497, A2497P- and A/HAR-13 (three wells of each 
condition) and were centrifuged for one hour at 1800 rpm, as was used in all previous 
infections (Section 4.3). Another three wells of each Ct strain in each cell line were 
treated with DEAE-Dextran prior to infection. HCjE cells were seeded in 1:1 K-
sfm:DMEM/F12 and switched to DMEM/F12 upon infection 24 hours later. Cells were 
stained at 48 hpi and inclusions were viewed using confocal microscopy. Images were 
taken using the tile function, recording 9 images of adjacent fields that were then 
stitched together. One such tiled image was taken per well so that three images were 
taken per cell line/infection. The number of cells and the number of inclusions in each 
image were counted using ImageJ. Infectivity was calculated [(number of infected 
cells/total number of cells)*100) for each of the three images and the average is shown 
in Table 4.2.  
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Table 4.2. Average infectivity achieved by ocular Ct strains at 48 hpi in HEp-2 and 
HCjE cells. 
 
HEp-2 cells HCjE cells 
Ct strain Centrifuge Dextran 
Centrifuge        
(K-sfm) 
Dextran 
(DMEM/F12) 
A2497p+ 22.40% 22.20% 6% 4.30% 
A2497p- 1.30% 1.90% 0.80% 0.60% 
A/HAR-13 0.20% 0.20% 0.40% 0.50% 
 
The infectivity of Ct in HCjE cells grown in DMEM/F12 and infected using DEAE-
Dextran was no different to the infectivity achieved using centrifugation and K-sfm 
media. There was also no difference in infectivity achieved by DEAE-Dextran versus 
centrifugation in HEp-2 cells. The inocula used in this experiment were derived from 
different Ct harvests to the experiments described above and the differences in 
infectivity between A2497 and A2497P- are likely due to inaccurate quantification of 
inclusion forming units (IFU) in the inoculum, rather than differential infectivity. Identical 
volumes of inoculum for each Ct strain were added to each cell line. The power to 
detect differences in infection success in HCjE cells was limited by calculating 
infectivity as very few inclusions could be identified using centrifugation or DEAE-
Dextran. Quantifying genome copy number by ddPCR at various timepoints post 
infection might have revealed more subtle differences owing to different media and 
infection facilitators. Another limitation of this experiment was that the effects of 
DMEM/F12 and DEAE-Dextran cannot be differentiated and they may have cancelled 
each other out. They would have best been performed as independent conditions, with 
the addition of centrifugation and DEAE-Dextran (combined). 
 
4.4.2 Growth of an LGV strain of Ct in HCjE and HEp-2 cells 
 
Virulent LGV strain L2 was grown in HEp-2 and HCjE cells in order to compare growth 
kinetics and infectivity to that of ocular strains. L2 does not require infection facilitation 
due to its virulence. HCjE cells were seeded in 1:1 K-sfm:DMEM/F12 and infected in 
DMEM/F12. Genome copy number of L2 dropped between 0 and 24 hpi, however it 
increased again by 48 hpi and steadily increased over time in both cell lines (Figure 
4.5). Genome copy number decreased to much lower levels in HCjE cells compared to 
HEp-2 cells. Despite amplification of L2 genome copy number in HCjE cells, the load at 
72 and 144 hpi remained lower than that of the starting inoculum. Large inclusions of 
L2 were clearly seen through phase microscopy of HCjE cells, however there were far 
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fewer than in HEp-2 cells (Figure 4.6). Inclusion morphology was equivalent in both cell 
lines. 
 
 
 
Figure 4.5. Genome copy number (omcB) of Ct strain L2 in HCjE and HEp-2 cells at 
the indicated timepoints post-infection. Genome copy number is shown on a log(10) 
scale. Timepoints (hours post-infection (hpi)) are shown on a non-linear scale. Cells 
were infected at an MOI of 0.5. Two replicates of each timepoint/infection were 
performed. Boxes show the range between the two values (one from each replicate). 
Red: HEp-2 cells, Black: HCjE cells.  
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Figure 4.6. HCjE and HEp-2 cell monolayers infected with Ct strain L2 at 48 hpi. (A) 
and (C) are L2 infected HEp-2 cells, (B) and (D) are L2 infected HCjE cells. (A) and (B) 
were taken at 5X magnification, (C) and (D) were taken at 20X magnification. Cells 
were infected at an MOI of 0.5. Representative photomicrographs were taken from one 
of three replicates for each cell line. 
 
4.4.3 Ct growth in the presence of cycloheximide  
 
In order to address whether the production of innate antimicrobial mediators by HCjE 
cells inhibited Ct growth, HEp-2 and HCjE cells were infected with A2497, A2497P- 
and A/HAR-13 in the presence and absence of cycloheximide and the genome copy 
number was quantified at 48 hpi. The mean OmcB load of A2497P- and A2497 in HEp-
2 cells increased in the presence of cycloheximide (Figure 4.7), however the genome 
copy number of A/HAR-13 did not. The high variation in genome copy number of Ct 
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infected cycloheximide-treated HEp-2 cells was partly due to an abnormal amount of 
cell death in 2/6 biological replicates, for reasons unknown, therefore the overall yield 
was lower. Ct growth in HCjE cells was not improved in the presence of cycloheximide; 
in fact it was reduced (Figure 4.7). Unfortunately genome copy number was not 
measured over time; therefore it was not clear whether there was any growth of Ct in 
HCjE cells or whether it steadily declined over time as in section 4.3.2.  
 
 
 
Figure 4.7. Genome copy number (omcB) of ocular Ct strains in HEp-2 and HCjE cells 
at 48 hpi in the presence (C+) and absence (C-) of cycloheximide. Genome copy 
number is shown on a log(10) scale. Cells were infected at an MOI of 1. Six replicates 
of each timepoint/infection were performed. Red: A/HAR-13, Blue: A2497P-, Yellow: 
A2497. 
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4.5 Profiling the PRR and associated signaling pathways repertoire in HEp-2 
cells. 
 
Although HCjE cells were a preferable choice of cell line for conducting in vitro 
investigations of the host epithelial response to ocular Ct infection, productive infection 
of Ct in HCjE cells was not achieved. Their slow growth was also a limiting factor in the 
number of optimization experiments that could be performed given the number of 
experimental repeats, conditions and timepoints required. Many researchers use HEp-
2 and HeLa cells to study the host response to both urogenital and ocular Ct infection 
[26,28–30]. This is likely due to the ease and speed of growing these cells in large 
numbers and the productive infection of Ct that can be achieved. This also perhaps 
reflects the relative difficulty in establishing Ct infection in other cell lines. Limited 
resources were available for further optimization of Ct growth in HCjE cells or to source 
another conjunctival cell line/primary cells; therefore in order to complete aims 2 and 3 
(Chapter 2) of this PhD project, the suitability of the HEp-2 cell line for in vitro 
experiments was evaluated.  
 
Due to controversy in the literature, the PRR profile of HEp-2 cells was investigated in 
order ensure they could respond appropriately to Ct infection. As a proof of principle, 
two Qiagen RT2 antibacterial response qPCR arrays were performed using cDNA from 
uninfected HEp-2 cells (at 0h) and HEp-2 cells 6 hours post infection with A2497. Each 
qPCR card contains 5 housekeeping genes and 84 genes that are involved in the 
antibacterial response. The geometric mean of the 5 housekeeping genes was taken 
and subtracted from each target separately for each card to give a delta cycle 
threshold value (dCT). The fold change of gene expression in A2497 infected HEp-2 
cells was compared to gene expression in uninfected cells using the delta delta Ct 
method [31]. All 84 antibacterial response genes had cycle thresholds ≤35 in 
uninfected HEp-2 cells, except NLRP3, which had a cycle threshold value of 36.7. 
Thirty-seven genes were downregulated in A2497 infected cells (6 hpi) and 18 genes 
were upregulated (FC ≥1.5) (Table 4.3). TLRs 1, 2, 4, 5, 6, 9 and co-factors LY96 (MD-
2) and CD14 were expressed by HEp-2 cells (TLR1, 4, 5, 6 and CD14 had a FC <1.5 
and are not shown in Table 4.3). Among the most upregulated genes were C reactive 
protein (CRP), NOD-like receptor proteins 1 and 3 (NLRP1/3), TLR2, inflammatory 
cytokines TNF and IL8 and CARD9 (a regulator of NOD signaling and cell apoptosis). 
Among the most downregulated genes were the antimicrobial peptide PRTN3, MD-2 
(TLR4 cofactor), MEFV (pyrin; regulates inflammation), CARD6 (apoptosis related) and 
IFNB1 (antiviral and pro-inflammatory). Several genes in the NOD-like receptor, TLR 
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signaling, inflammatory response and antimicrobial pathways were downregulated. 
Statistical testing was not performed as only one card (one repeat) was performed for 
uninfected HEp-2 cells (-VE 0h) and A2497 infected HEp-2 cells (A2497 6h).  
 
 
Table 4.3. Expression of antibacterial response genes with ≥1.5 fold change in A2497 
infected HEp-2 cells at 6 hpi (A2497 6 h) relative to uninfected HEp-2 cells (-VE 0h). 
 
Gene Symbol dCT* -VE 0h dCT* A2497 6h Fold Change 
NOD-Like receptor signalling 
  MEFV 12.378 14.98 0.16 
SUGT1 0.658 2.41 0.30 
HSP90AA1 -1.882 -0.37 0.35 
PSTPIP1 13.448 14.84 0.38 
NLRC4 7.168 8.31 0.45 
NOD2 12.388 13.42 0.49 
XIAP 6.798 6.01 1.73 
BIRC3 5.748 4.92 1.78 
NLRP1 16.958 15.27 3.22 
NLRP3 18.128 14.51 12.28 
Signaling Downstream of Antibacterial Responses 
MAP2K1 5.558 6.54 0.51 
CHUK (IKKα) 5.108 5.7 0.66 
JUN 10.348 9.69 1.58 
RELA 6.298 5.64 1.58 
MAPK3 8.398 7.59 1.75 
Antimicrobial peptides 
  PRTN3 16.178 20.88 0.04 
MPO 12.968 14.62 0.32 
CTSG 14.038 15.62 0.33 
BPI 12.278 13.81 0.35 
LTF 12.848 14.3 0.37 
LYZ 14.958 16.07 0.46 
CAMP 12.238 12.94 0.61 
SLPI 6.278 5.61 1.59 
Apoptosis 
   CARD6 7.858 10.02 0.22 
RIPK2 4.138 5.49 0.39 
MAPK8 (JNK1) 5.348 6.25 0.54 
PYCARD 11.878 12.56 0.62 
AKT1 7.428 6.8 1.55 
CASP1 12.618 11.75 1.83 
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CARD9 15.648 13.25 5.27 
Inflammatory response 
  IFNB1 13.428 15.77 0.20 
CCL5 6.388 8.37 0.25 
IL12B 11.898 13.71 0.28 
APCS 11.648 13.37 0.30 
IL12A 7.368 8.95 0.33 
SLC11A1 9.748 10.96 0.43 
LBP 11.768 12.85 0.47 
RAC1 0.808 1.69 0.54 
CCL3 13.908 14.56 0.64 
IL8 9.668 8.25 2.67 
TNF 15.208 12.61 6.05 
CRP 16.728 12.74 15.87 
TLR signalling 
   LY96 (MD-2) 12.998 15.48 0.18 
TLR9 15.198 16.63 0.37 
PIK3CA 4.158 5.58 0.37 
MAP3K7 3.138 4.33 0.44 
IRAK3 9.898 10.93 0.49 
IRF5 10.728 11.61 0.54 
TRAF6 5.878 6.5 0.65 
MYD88 6.178 6.8 0.65 
TIRAP 11.688 11.01 1.60 
TOLLIP 10.118 9.32 1.74 
IRAK1 7.978 6.92 2.08 
TLR2 15.368 14.24 2.19 
Other bacterial PRRs 
   DMBT1 13.118 13.97 0.55 
*dCT = delta cycle threshold value, normalized to the mean of 5 housekeeping genes 
(ACTB, B2M, GAPDH, HPRT1, RPLP0) 
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4.6 Discussion  
 
Productive growth was achieved of A2497, A2497P- and L2 Ct strains in HEp-2 cells. 
A/HAR-13 growth in HEp-2 cells was less successful and by 48 hpi the genome copy 
number was still slightly lower than that of the starting inoculum. Unfortunately genome 
copy number in HEp-2 cells was not measured beyond 48 hpi however it might be 
expected to increase further. Genome copy number decreased at early timepoints post 
infection and increased between 24 and 48 hpi. The HEp-2 cells used in these 
experiments possessed the normal repertoire of PRRs and responded to Ct infection 
by upregulating inflammatory (IL-8, TNF, CRP) and pathogen-response genes 
(NLRP1/3, CARD9, TLR2). More genes were downregulated than upregulated in 
A2497 infected cells at 6 hpi. This might reflect interference by Ct with host response 
pathways or negative feedback by the host cell to prevent excessive stimulation and 
inflammation. No significant differences in gene expression were detected until 24 hpi 
in A2497 infected HeLa cells using a transriptome microarray however [26], suggesting 
that with more biological repeats and statistical testing these differences may not be 
significant. These data suggest that HEp-2 cells can initiate a normal and appropriate 
innate immune response to Ct infection.   
 
Productive growth of Ct was not achieved in HCjE cells and this was a limitation to this 
project. The genome copy number of ocular strains decreased steadily over time. 
A/HAR-13 genome copy numbers decreased lower than A2497 and A2497P-, however 
in contrast to A2497 and A2497P- there was a slight increase between 72 and 144 hpi. 
The virulent Ct strain L2 proliferated in both cell lines from 24 hpi, however the initial 
fall in genome copy number was much larger in HCjE cells and did not recover enough 
to match the genome copy number in the starting inoculum, even at 144 hpi. Nutrient-
rich HCjE differentiation medium, DEAE-Dextran and cycloheximide did not improve Ct 
growth in HCjE cells.  
 
Cycloheximide inhibits protein synthesis in eukaryotic organisms. Addition of 
cycloheximide to Ct cultures at a concentration that suppresses, but does not 
completely inhibit host protein synthesis, increases chlamydial yield [32,33]. This is 
thought to allow Ct to harness host machinery and nutrients to enhance its own growth. 
As expected, addition of cycloheximide increased yield of ocular strains in HEp-2 cells 
but surprisingly this was not the case in HCjE cells. HEp-2 cells grow quickly and are 
not inhibited by contact once confluence is achieved, therefore inhibiting growth by 
adding cycloheximide presumably provides a large pool of nutrients for Ct. In contrast, 
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HCjE cells grow slowly and are inhibited once confluent. The addition of differentiation 
medium (DMEM/F12) further inhibits growth and promotes stratification. It is therefore 
reasonable to speculate that adding cycloheximide to HCjE cells does not significantly 
increase the pool of nutrients available to Ct, so there is no growth advantage. This has 
previously been observed for C. pneumonia (Cpn) growth in polarized epithelial cell 
models where cycloheximide had a negligible impact [34].  
 
The production of innate antimicrobial mediators by HCjE cells, such as have been 
described for other immortalized primary epithelial cell lines [35], might have interfered 
with chlamydial growth. In this case the addition of cycloheximide might have 
prevented production of these antimicrobials and permitted Ct growth, but this was not 
the case. Cycloheximide was added at the point of infection however so constitutively 
expressed antimicrobials may have been present and sufficient to prevent infection. 
Cycloheximide could be added prior to the addition of Ct inoculum (over an extended 
timecourse due to the unknown longevity of potential antimicrobial mediators in culture 
medium) to investigate this further. 
 
It was previously reported that the ocular Ct strain A/HAR-13 grew faster in HCjE cells 
than in HeLa cells, owing to ecological niche adaptation, although the IFU achieved at 
the final timepoint (48hpi) was the same in both cell lines [19]. L2 grew faster in HeLa 
and achieved higher final IFUs in HeLa compared to HCjE [19]. In my hands, A/HAR-
13 grew very poorly in both HCjE and HEp-2 cells and growth was even less 
successful in HCjE cells. This observation is supported by data from Kari et al., who 
found that A2497 produced ~10 fold more recoverable IFU than A/HAR-13 when grown 
in HeLa cells [20]. The Ct strains A2497, A2497P- and A/HAR-13 used in this study 
were kind gifts from Laszlo Kari (Rocky Mountains Laboratories, NIH, USA). HCjE cells 
were isolated in 2003, therefore the A/HAR-13/HCjE cell infection experiments 
published by Miyairi et al., [19] in 2006 were performed soon after establishment of the 
cell line and the Ct strains were likely from different stocks. It is possible that genetic 
changes relating to infection susceptibility of HCjE cells and infectivity of A/HAR-13 
accumulated through multiple passages in different laboratories over time, which could 
explain some of the differences in growth and infectivity [36–40]. Unfortunately 
karyotyping or other tests to ensure the HCjE cell line was correct were not performed, 
therefore the possibility that the HCjE cells used in these experiments were not 
genetically normal cannot be ruled out. Human lymphocyte antigen (HLA) testing, 
karyotyping, isoenzyme, short tandem repeat (STR) analyses or other such methods 
should be performed before any further work with this cell line takes place. 
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Interestingly, A/HAR-13 showed a slight increase in genome copy number in HCjE 
cells between 72 and 144 hpi. This could indicate a more successful method of natural 
reinfection of host cells following the first infection cycle. Alternatively it could be due to 
HCjE cells having differentiated into a more infection-susceptible phenotype over time 
in culture. This observation was strain specific however as it did not occur in A2497 or 
A2497P- infected HCjE cells.   
 
Genome copy number of ocular strains in HCjE cells declined steadily over time, 
whereas L2 showed evidence of genome amplification in HCjE cells. L2 had a 
comparable growth curve in both cell lines, however the initial drop in genome copy 
number was much steeper in HCjE cells. Given that HCjE cells did not appear to 
actively inhibit Ct growth, as no improvement was observed upon addition of 
cycloheximide, this might suggest that the problem lies in entry into the host cell. L2 is 
more virulent and disseminates to the lymph nodes in vivo, whereas ocular strains 
remain in the conjunctival epithelium. Perhaps the enhanced virulence of L2 allowed 
more effective entry into host cells and once inside successful growth was achieved. It 
is possible that a cell surface receptor required for chlamydial attachment and entry 
was absent from HCjE cells, or that the mucins produced by HCjE cells, particularly on 
the apical surface [18], were more effective at preventing Ct penetration and 
attachment. The entry of Ct into host cells could be examined by electron microscopy 
or cryo-electron tomography as described previously [10,41] in order to investigate this 
further.  
 
The rocking method of Ct infection facilitation was used by Miyairi et al., to achieve 
productive infection of A/HAR-13 in HCjE cells [19]. In a polarized immortalized 
endocervical epithelial cell model, the rocking method of Ct infection facilitation only 
achieved 25% infection whereas the centrifugation method achieved >95% infection 
[12]. The production of mucins by polarized immortalized endocervical epithelial cells 
[35] was thought to explain why the rocking method was less efficient [12]. One might 
speculate that the same would be true for HCjE cells due to their own mucin 
expression profile [18], however, given that attachment and entry stages might be 
limiting factors for Ct infection of HCjE cells, alternative infection methods such as the 
rocking method and centrifugation and DEAE-Dextran in combination [33] should be 
investigated. Miyairi et al., also infected HCjE cells 24 hours after seeding [19], 
however cells could be left to differentiate and stratify in culture for 7-10 days before 
addition of Ct. HCjE cells could also be blind passaged with a strain such as A2497, 
with addition of much higher IFUs of Ct, to try and force adaptation to this cell line. 
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Purposefully forcing selection in this way however could negate the objective of 
obtaining physiological and clinically relevant data from an in vitro model. Alternatively, 
another conjunctival cell line could be used. ChWK cells are thought to be 
contaminated by HeLa cells and were transcriptionally more dissimilar to conjunctival 
epithelium and primary conjunctival epithelial cells than IOBA-NHC cells [15,16]. IOBA-
NHC cells or primary conjunctival epithelial cells could be investigated as an alternative 
to HCjE cells.  
 
The HEp-2 cells described herein had a complete PRR expression profile and 
upregulated appropriate innate immune response genes following Ct infection. These 
data contrast some of the reported literature about the limitations of this cell line, 
suggesting that they are an acceptable (although not ideal) cell line in which to perform 
investigations of the host response to Ct infection. Unfortunately it was not possible to 
achieve productive Ct infection in HCjE cells. In order to investigate miRNA expression 
and EMT induction in vitro in response to Ct infection, HEp-2 cells were used for 
subsequent experiments. Whilst HEp-2 cells were able to respond appropriately by the 
parameters tested, the results of these in vitro experiments should be interpreted with 
an understanding of their limitations.  
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individuals with active trachoma and 
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5.1 Study site  
 
The Bijagós Archipelago of Guinea-Bissau is a group of ~88 islands found 
approximately 60km from the coast of Guinea-Bissau, West Africa (Figure 5.1). 
Guinea-Bissau has a human development index (HDI) of 0.396 and is ranked 177/196 
in the world based on 2014 estimates [1]. The gross domestic product (GDP) estimate 
for 2014 was $598 per capita [2]. Infrastructure links and healthcare access in the 
Bijagós are poor and generally worse than on the mainland due to difficulties in 
accessibility; travel from Bissau to Bubaque, the capital of the Bijagós, can take ~10 
hours by local dugout boat. Bad weather, strong tides and a lack of navigational aids or 
phone signal can make the journey dangerous. The inhabitants of the Bijagós are 
largely subsistence farmers and fishermen. The climate of the Bijagós Archipelago is 
humid and warm with an average daytime temperature of 27.30C and a rainy season 
between June and October. An initial population-based trachoma survey carried out on 
four islands in 2012 found that the overall prevalence of active trachoma was 11% and 
Ct infection was 18% [3]. In 1 to 9 year olds the prevalence of active trachoma was 
22% and the prevalence of Ct infection in was 25% [3]. These rates are extremely high, 
particularly for an area that has adequate water access; trachoma is thought to be 
more prevalent in hot arid environments [4]. This prevalence of TF qualified the Bijagós 
for mass drug administration (MDA) with Azithromycin. The current World Health 
Organization (WHO) recommendations are to treat with three annual rounds of MDA all 
members of a district where the prevalence of active trachoma in 1-9 year olds (TF1-9) 
is between 10-29%, alongside implementation of other components of the SAFE 
strategy [5]. Following three years of MDA TF1-9 should be reassessed with an impact 
survey, after which a decision is made whether to continue MDA (if TF1-9 remains 
>10%) or stop (if TF1-9 <5%). If a district has TF1-9 between 5-10%, within-district 
communities should be assessed and treated separately by the same principles and 
promotion of facial cleanliness and environmental improvements should continue. This 
fieldwork was planned so that samples could be collected from individuals on Islands 
that were treatment naïve i.e. before the initiation of MDA, which took place as 
scheduled immediately after collection of these samples (April 2014). 
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Figure 5.1. Map of Guinea-Bissau, West Africa. Source: [6]. 
 
5.2 Study design 
 
The aim of this study was to investigate miRNA expression in the conjunctiva of 
individuals with TF and concurrent Ct infection (TF Ct+) and in healthy controls with no 
clinical evidence of trachoma (N). Based on our knowledge of TF and Ct prevalence in 
this population before MDA treatment [3], we aimed to collect matched case-control 
samples from 200 children aged between 1 and 9. By collecting 100 samples from 
children with TF, we expected ~50 TF Ct+ and ~50 TF cases without current Ct 
infection (TF Ct-). Control samples were collected from children matched by age, 
gender and village. There were no prior data on miRNA expression in active trachoma 
upon which to base power calculations. We therefore used data from our previous 
study on miRNA expression in adults with scarring and inflammatory trachoma to 
calculate the sample size required (Chapter 6 [7]). Using these data we calculated that 
a sample size of 49 cases and 49 controls would give 81% power to detect a 2.3 fold 
change in miR expression in 1-9 year olds with 99% confidence (alpha = 0.0025). This 
alpha level would allow for adjustment for multiple comparisons of 20 miRNA and 
would still maintain power and confidence to detect the effect size.  
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Informed consent forms, spare data collection forms and certificates of ethical approval 
from both the LSHTM ethics committee and the Comitê Nacional de Ética e Saúde of 
Guinea-Bissau are attached in the appendix.   
 
5.3 Logistics of sample collection  
 
5.3.1 Field team, travel and equipment 
 
The field base was on the largest island in the Bijagós Archipelago, Bubaque. The field 
team and fieldwork infrastructure were established previously by Dr Anna Last and 
included a boat and local skipper for travel to and from study islands. The field study 
was coordinated through The Gambia MRC Unit. Travel from The Gambia MRC Unit to 
Bissau, the capital of Guinea-Bissau, by road took ~7 hours, travelling through Senegal 
and then into Guinea-Bissau. Travel from Bissau to Bubaque by speedboat then took 
~2 hours. A liquid nitrogen dry shipper was brought from The Gambia MRC Unit for 
sample storage in Bubaque. Due to the need to maintain a cold-chain, the field team 
returned to Bubaque at the end of each day of fieldwork to transfer samples into the 
dry shipper.  
Travel to and from the islands each day by boat often took several hours. Many of the 
islands in the Bijagós Archipelago are surrounded by mangroves (Figure 5.2) and the 
skipper identified suitable landing sites where the field team could walk to the nearest 
village. This often involved walking through deep mud and forests. Tides had to be kept 
in mind to ensure access to the boat upon returning from the village; therefore the time 
available to collect samples on each island was often very limited. There was minimal 
or no mobile phone reception.  
The field team consisted of a trained examiner that performed clinical grading and took 
swab samples (Dr. Anna Last), a nurse who collected informed consent and recorded 
initial screening data (Eunice Cassama or Eduardo Muscate), a clinical photographer 
who took conjunctival photographs (Rod Markham-David) and a data collector 
(Tamsyn Derrick). Data was collected using Eyescores ([8]; attached in appendix) an 
electronic system that was modified for the particular requirements of this field study. 
Equipment brought to each study site included: a laptop for running Eyescores, back-
up data collection paper forms, consent forms, boxes containing tubes for swabs (pre-
filled with RNAlater® and with unique ID labels attached), a cool-box, envelopes for 
buccal swabs with unique ID labels, buccal brushes and ocular swabs, examination 
gloves, ethanol spray, a wipe-clean tablecloth, a 2.5X binocular magnifying loupe for 
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clinical examination, a camera for clinical photography (including spare batteries) and 
waste disposal bags (which were brought back to the field base for appropriate 
disposal).  
 
Figure 5.2. Fieldwork in the Bijagós Archipelago. Clockwise from top left: walking to the 
boat through the mangroves; collecting samples from children in a village; searching 
for the boat; walking to a village on the island of Orangozinho.  
 
5.3.2. Participant enrolment 
 
The most time and cost-efficient way to collect samples from 1-9 year olds was to visit 
schools, however individual households were visited if this was not possible. On arrival 
at a school or household permission was requested from the headmaster or parent to 
screen children for trachoma. Headmasters are the children’s guardians whilst they are 
at school and ethically, headmasters have the authority to give consent to take 
samples. Children were invited to have their eyes screened for evidence of active 
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trachoma using the WHO simplified grading system [9]. Cases were defined as 
individuals with trachomatous inflammation – follicular (TF) in both eyes. Controls were 
defined as individuals with no clinical evidence of follicles, papillary inflammation or 
cicatricial scarring. Upon identification of a case, informed consent was requested from 
the parent or headmaster. If consent was given the individual was graded for trachoma 
using the more detailed FPC grading system [10] and two swabs and a photograph 
were taken from their left tarsal conjunctiva. A buccal brush sample was taken for DNA 
analysis. Upon enrollment of a case, a control individual of the same age and gender 
(identified through screening) was invited to participate. If an exact age and sex match 
could not be found or did not wish to participate, a sample from the closest match was 
obtained. The examiner changed gloves between examination of each participant. 
 
5.3.3 Sample collection and maintenance of the cold chain 
 
Two swab samples were taken from the inverted left tarsal conjunctiva of each study 
participant using standard methodology [3,11]. Swabs were horizontally passed across 
the tarsal conjunctiva three times, rotating the swab by 1/3rd with each pass. Swabs 
were immediately and individually placed into sterile tubes filled with 250μl RNAlater® 
(Ambion) and were stored in a cool-box filled with ice packs. Control swabs were pre-
marked and selected at random (1 per 50 samples) and were passed three times 10cm 
in front of the eye, ensuring no contact was made. Control swabs were processed 
identically to sample swabs. Samples were transferred to a liquid nitrogen dry shipper 
within 8 hours. Every week the liquid nitrogen dry shipper containing samples was 
transported to Bissau on the mainland by speedboat or plane. To coincide with this trip 
a colleague from The Gambia MRC Unit drove to Bissau and brought a new empty 
liquid nitrogen dry shipper. Dry shippers were exchanged and samples were taken 
back to The Gambia MRC Unit for storage at -800C. Buccal brush samples were stored 
in envelopes (unsealed to allow them to dry) and were stored and transported at room 
temperature. Samples were subsequently shipped at -800C from The Gambia MRC 
Unit to LSHTM.  
 
5.3.4 Summary 
 
Sample collection took three weeks in total. One hundred and sixty three samples (81 
cases, 82 controls) were collected from children living on 7 islands, 6 islands of which 
were treatment-naïve at the time of sample collection.  
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5.4 Optimization of total RNA and DNA extraction from clinical swabs 
 
5.4.1. Methods 
 
Cell culture  
 
Human epithelial type 2 (HEp-2) cells were cultured in Minimum Essential Medium 
(MEM) (Gibco, ThermoFisher Scientific) supplemented with 1% gentamicin (Gibco), 
10% fetal bovine serum (FBS) (Gibco), and 1% L-glutamine (Gibco) and were 
incubated at 37°C in 5% atmospheric CO2. HEp-2 cells were infected with 0.5 MOI of 
Ct strain L2/434/Bu [12]. Cells were scraped into RNAlater® (Ambion, ThermoFisher 
Scientific) 48 hours post infection and homogenate was stored at -800C. Where 
indicated in the text, ocular swab samples were taken from the conjunctivae of healthy 
volunteers at LSHTM using standard methodology (described above) and were stored 
at -800C in 250µl RNAlater® until use.  
 
Nucleic acid purification 
 
Extraction of nucleic material was performed using the Qiagen AllPrep 
RNA/DNA/miRNA Universal kit (Qiagen), Norgen total RNA/DNA purification kit 
(Norgen Biotek), Zymo Quick-RNA™ MiniPrep kit (Zymo Research) and the Zymo 
Direct-zol RNA MiniPrep kit (Zymo Research) where described and following the 
manufacturers instructions. β-mercaptoethanol was added to lysis buffers to inhibit 
RNAses where it was recommended by the kit manufacturer. RNA was quantified 
using Qubit® fluorometric quantitation (ThermoFisher Scientific) and NanoDrop 
spectrophotometry (ThermoFisher Scientific) and quality was assessed using an 
Agilent RNA 6000 nano kit on a 2100 Bioanalyzer instrument (Agilent technologies). 
Bead beating was performed using MP Bio lysing matrices and an MP Bio FastPrep-24 
bead beater (MP Biomedicals).  
 
Droplet-digital PCR assay for DNA quantitation 
 
Droplet-digital PCR (ddPCR) was carried out to quantitate the Ct chromosomal gene 
omcB and Homo sapiens RNase P/MRP 30-kDa subunit gene (RPP30), as described 
previously [13,14]. Human RPP30 primer and probe sequences were forward: 5’ 
AGATTTGGACCTGCGAGCG 3’, reverse: 5’ GAGCGGCTGTCTCCACAAGT 3’, probe: 
5’ [HEX] TTCTGACCTGAAGGCTCTGCGCG [BHQ1] 3’. Ct omcB primer and probe 
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sequences were forward: 5’ GACACCAAAGCGAAAGACAACAC 3’, reverse: 5’ 
ACTCATGAACCGGAGCAACCT 3’, probe: 5’ [FAM] 
CCACAGCAAAGAGACTCCCGTAGACCG [BHQ1] 3’. ddPCR mix had a final volume 
of 20µl and contained final concentrations of 1X ddPCR supermix (Bio-Rad), 0.3µM of 
primer and probes and 4.95µl sample DNA. Droplet generation and droplet reading 
was carried out according to the manufacturers instructions. Thermal cycling conditions 
were as follows: 95C hold for 10 minutes, followed by 40 cycles of 95C for 10 
seconds and 60C for 20 seconds with a final hold of 98C for 12 minutes. ddPCR was 
performed on a Bio-Rad QX100 Instrument and data were collected using Quantalife 
software (Bio-Rad). DNA copy number was calculated in R (https://www.r-project.org) 
using a previously published script [13]. 
Quantitative polymerase chain reaction (qPCR) for RNA quantitation 
 
Total RNA was reverse transcribed using miScript RTII kits with the HiFlex buffer 
(Qiagen) to synthesize a cDNA library containing miRNA and mRNA. Six µl RNA was 
added to the reverse transcription reaction, which had a final volume of 20µl. Reverse 
transcription was performed following the manufacturers instructions. Ten µl cDNA was 
diluted in 100µl dH2O for use in qPCR in order to dilute out components of the reverse 
transcription reaction. Upon initial optimization of qPCR, optimal exponential curves 
were achieved by diluting the cDNA 1:10. 
 
qPCR for mRNA was performed with Power SYBR Green PCR master mix 
(ThermoFisher Scientific) according to the manufacturers instructions, using mRNA 
specific primers for Homo sapiens Ribosomal Protein Large P0 gene (RPLP0). Primers 
were designed using using NCBI gene data (http://www.ncbi.nlm.nih.gov/gene/), 
Primer3 (http://primer3.wi.mit.edu) and SIM4 (http://pbil.univ-
lyon1.fr/members/duret/cours/inserm210604/exercise4/sim4.html) software. RPLP0 
primer sequences were forward: 5’ ATCTGCTTGGAGCCCACAT 3’ and reverse: 5’ 
GCGACCTGGAAGTCCAACTA 3’. mRNA qPCR mix had a final volume of 5µl and 
contained final concentrations of 1X Power SYBR green master mix, 0.25µM of forward 
and reverse primers and 0.5µl sample cDNA. Cycling conditions were 10 minutes at 
95°C followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C.  
 
qPCR for miRNA was performed using the miScript SYBR Green PCR kit with a 
miScript Primer Assay for the endogeneous control small nucleolar RNA U6 (Qiagen), 
as described previously (Chapter 6; [7]). miRNA qPCR mix had a final volume of 5µl 
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and contained 2.5µl miScript SYBR green PCR master mix, 0.5µl of specific miR 
forward primer assay, 0.5µl universal reverse primer assay, 0.5µl sample cDNA and 
1µl dH20.  
 
All qPCR was performed on a 7900HT thermal cycler (Applied Biosystems, 
ThermoFisher Scientific) and 4 technical repeats were performed for each 
sample/assay. Raw cycle thresholds were analyzed in R.  
 
5.4.2. Purpose of optimization 
 
The purpose of this fieldwork was to obtain clinical samples for small RNA analysis by 
Illumina TruSeq small RNA sequencing and qPCR. For Illumina TruSeq small RNA 
sequencing a total RNA starting input of 1μg in 5μl and an RNA Integrity Number (RIN) 
≥8 was required. DNA was also required from these samples for the diagnosis of Ct 
infection and for possible future DNA methylation studies or Ct genome sequencing. 
For methylation studies buccal brush samples were collected to provide a DNA 
background sample for each individual and these buccal samples were processed 
separately. In our previous study on miRNA expression using genetic material from 
clinical swab samples, 23/63 (35.6%) samples tested on low density Taqman qPCR 
arrays were discarded from the analysis due to a low concentration of genetic material 
(Chapter 3 [7]). The isolation of total RNA and DNA of a high quality and quantity from 
ocular swabs was therefore imperative.  
 
Two swab samples were taken from the left conjunctiva of each individual in order to 
maximize the quantity of genetic material that could be isolated. The two swabs could 
be pooled together for extraction of total RNA and DNA (most cost efficient), or they 
could be processed separately, in which case RNA could be isolated from one swab 
and DNA from the other, or RNA and DNA could be isolated from both. A variety of 
commercial kits are available for genetic material extraction. It is thought that a lower 
yield is achieved when isolating multiple fractions from one sample, particularly for 
miRNA, which is already at low concentration. This is likely due to the increased 
number of washes the sample undergoes. The risk of sample loss, especially when 
using filter columns, is also higher when samples are of a lower concentration. In this 
case a higher yield and quality might be obtained by extracting total RNA only from one 
swab (and DNA from the other). It is unclear however what variation exists in the 
cellular fractions collected by the first and second swab and what impact this might 
have when diagnosing and quantifying Ct from one swab and relating it to 
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transcriptional data from the other. Summaries of the extraction kits compared during 
optimization are given in Table 5.1.  
 
Table 5.1. Summary of the commercially available extraction kits tested.  
Kit Fractions obtained Format Lysis method  
Qiagen AllPrep 
RNA/DNA/miRNA 
Universal kit 
 
RNA, DNA, miRNA Spin-column Guanidinium thiocyanate 
Norgen total 
RNA/DNA 
purification kit 
 
Total RNA, DNA Spin-column Guanidinium thiocyanate 
Zymo Quick-
RNA™ MiniPrep kit 
 
Total RNA Spin-column Guanidinium thiocyanate 
Zymo Direct-zol 
RNA MiniPrep kit 
Total RNA Spin-column Trizol (Guanidinium 
thiocyanate-phenol-
chloroform) 
 
Should sufficient DNA remain after the primary objectives these samples could also be 
of use for future analysis of the ocular microbiome. Bead beating aids the lysis of some 
bacterial cell walls during the lysis stage of DNA purification. Small beads were added 
to the sample tube with lysis buffer and the tube was vortexed in a specialized tissue 
homogeniser (MP Bio FastPrep-24 bead beater (MP Biomedicals)) at high intensity. 
Bead beating is thought to be an essential step for obtaining high yields of DNA 
(particularly from gram-positive bacteria) and for obtaining an accurate representation 
of bacterial species present in clinical samples [15]. Bead beating was tested in this 
optimization process in order to permit future microbiome analysis in these samples.  
 
The material used for optimization was derived from cultured cells or from ocular swabs 
taken from colleagues at the LSHTM. DNA carriers can enhance sample recovery of 
low concentration samples during the extraction process, however they were not used 
in case of interference with downstream applications and to enable quantitation of true 
sample concentration.  
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5.4.3 Qiagen and Norgen extraction kits with MP Bio Lysing matrix beads  
 
Qiagen and Norgen kits that purify multiple fractions were tested with inclusion of a 
bead beating step in the initial lysis stage. A variety of different bead matrices are 
commercially available, optimized for various extraction goals. Upon consultation with 
MP Biomedicals, lysing matrices A and E were recommended for this application of 
miRNA, RNA and DNA extraction from ocular swab samples. Lysing matrix E (LE) 
contains 1.4 mm ceramic spheres, 0.1 mm silica spheres, and one 4 mm glass bead. 
Lysing matrix A (LA) contains garnet matrix and one 1/4 inch ceramic sphere. Ct (L2) 
infected HEp-2 cells were scraped into RNAlater® and stored in aliquots at -800C. One 
hundred microliters of this human cell/Ct homogenate was pipetted onto Dacron swabs 
and swabs were placed in a 2ml tube containing 250μl RNAlater®, using the exact 
procedure and reagents used in the field.  
 
Four swabs were extracted using the Norgen total RNA/DNA purification kit, two of 
which were lysed with LE and two with LA. Another four swabs were extracted using 
the Qiagen Universal RNA/DNA/miRNA kit, two of which were lysed with LE and two 
with LA. Swabs were removed from RNAlater® and were added to 2ml tubes 
containing lysing matrices. Six hundred microliters of Qiagen or Norgen lysis buffer 
was added to ensure the swab was completely submerged. All 8 swabs were bead 
beaten for 2 1-minute pulses at 6.0m/s. This was advised to be long enough to 
pulverize the swab without causing damage to the genetic material. Two 1-minute 
pulses were performed with a 5 minute interval in-between to prevent over-heating 
(sample temperature is thought to increase by 100C for every minute of bead beating). 
Tubes were centrifuged at 4°C for 10 minutes to pellet debris. The lysate was collected 
and added to the filter column of the relevant purification kit. Genetic material was 
extracted following the manufacturers instructions. ddPCR was performed to quantify 
human and chlamydial DNA. Total RNA (Norgen kit) and miRNA (Qiagen kit) fractions 
were reverse transcribed and qPCR was performed for the endogenous control small 
nucleolar RNA U6 and miR-146a to determine miRNA concentration. NanoDrop was 
performed on RNA and DNA (data not shown). Results are shown in Table 5.2.  
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Table 5.2. Yield and quality of miRNA and DNA obtained using two bead beating 
methods with Qiagen and Norgen extraction kits.  
Lysis and ddPCR DNAa qPCR miRNAb 
extraction 
method Ct omcB Human RPP30 U6 miR-146a 
 1 LE Qiagen 0.00 0.00 30.49 ≥ 40 
 2 LE Qiagen 0.00 0.76 ≥ 40 ≥ 40 
 1 LA Qiagen 18.62 0.72 ≥ 40 ≥ 40 
 2 LA Qiagen 61.77 1.29 33.32 ≥ 40 
     1 LE Norgen* 1275.43 45.77 22.70 32.24 
 2 LE Norgen 172.87 6.22 24.05 32.60 
 1 LA Norgen 31.55 2.08 24.64 32.49 
 2 LA Norgen 38.17 1.67 24.15 33.39 
Swabs used in this experiment were spiked with cultured cells. 
a DNA concentration in copies/μl of extracted DNA is shown 
b Mean cycle threshold is shown of four technical repeats 
LE: Lysing matrix E, LA: Lysing matrix A.  
1 and 2 = first and second repeat of each condition. 
* Sample was processed with amendments to the protocol 
 
RNA and DNA yields were poor from the four extraction variations. Despite adding 
600μl lysis buffer, very little lysate was recovered from the bead beaten tubes even 
after centrifugation. Beads and swab debris took up most of the space in the 2ml tube, 
particularly the large glass and ceramic beads. One Norgen LE sample was 
accidentally lost during the extraction process. It was repeated with amendments: the 
large ceramic bead was removed from the tube, 800μl lysis buffer was added and it 
was pulsed for 40 seconds at 6.0m/s rather than 2 minutes (sample indicated with a *). 
Much more lysate was recovered from this swab and DNA and miRNA concentrations 
were ~10 fold higher.  
 
NanoDrop data (not shown) was highly variable and did not correlate with ddPCR and 
qPCR values. NanoDrop is inaccurate at low concentrations as values are highly 
affected by the presence of contaminants. Three Qiagen RNA samples had very good 
concentrations by NanoDrop, however the absorbance was high and peaks were 
apparent at 230nm for these three samples. Guanidine isothiocyanate absorbs at 
230nm therefore this peak was likely due to buffer carryover. Guanidine isothiocyanate 
is a chaotropic agent and a protein denaturant, therefore its presence in the RNA 
sample could have inhibited the enzymes used in reverse transcription and qPCR, 
which might explain why miRNA was barely detected in these samples by qPCR. 
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Guanidine isothiocyanate is also present in the Norgen lysis buffer however no carry-
over was detected. 
 
5.4.4 Norgen extraction kit with and without bead beating 
 
In order to validate these results the effect of bead beating was investigated further 
using the Norgen purification kit. Eight ocular swabs (two from each volunteer) were 
taken from colleagues by a clinician (Dr Anna Last) using the same method and 
reagents used in the field. Four swabs (one from each volunteer) were removed from 
RNAlater® and placed into LE tubes containing 600μl Norgen lysis buffer. These were 
bead beaten for 40 seconds at 6.0m/s and centrifuged at 4°C for 30 seconds at full 
speed. Roughly 500μl lysate was recovered from these swabs. The other four swabs 
were placed into a 2ml tube containing 600μl Norgen lysis buffer and were vortexed for 
1 minute without beads. Roughly 600μl lysate was recovered from these swabs. Total 
RNA and DNA was extracted from all 8 swabs following the manufacturers instructions 
and DNA concentration was quantified by ddPCR (Table 5.3). 
 
Table 5.3. DNA yield obtained using the Norgen kit with and without bead beating. 
Lysis method Human RPP30a 
LE 1 80.44 
LE 2 27.69 
LE 3 10.58 
LE 4 23.42 
Vortex 1 419.07 
Vortex 2 604.38 
Vortex 3 428.85 
Vortex 4 755.48 
a DNA concentration in copies/μl of extracted DNA is shown 
LE: Lysing matrix E, Vortex: Vortex only  
1-4: Volunteer ID 
 
Around 10 fold less DNA was obtained by bead beating relative to vortexing alone. 
This loss could be due to the high temperature and additional processing to which 
samples were exposed, the lower volume of lysis buffer recovered or to shearing and 
damage of nucleic acids by the mechanical force and abrasion of beat beating (aimed 
at lysing tough bacterial or fungal cell walls). Beat beating is advantageous for 
investigation of the microbiome or for lysis of tough sample material. As this was not 
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necessary and was not a primary research objective for these samples, bead beating 
was excluded from further use. 
 
5.4.5 Comparison of extraction kits with one or two swabs per tube during lysis   
 
The next step was to determine whether the two swabs from each individual should be 
lysed and extracted together or separately. Lysing swabs separately before pooling 
might increase the risk of cross-contamination however it might increase yield. Material 
from HEp-2 cells scraped into RNAlater® and stored at -800C was used. One hundred 
microliters of this material was pipetted onto each swab and swabs were added to 
tubes containing 250μl RNAlater®. Tubes were stored at -800C until extraction. All 
swabs were extracted within one day.  
 
Norgen total RNA/DNA purification, Qiagen Universal RNA/DNA/miRNA and Zymo 
Quick-RNA™ MiniPrep kits were compared. Three repeats were performed of two 
variations: a) one swab was placed into a tube containing 600μl lysis buffer and b) two 
swabs were placed into one tube containing 600μl lysis buffer and were extracted as 
one. The Qiagen kit was included for the one swab condition only in order to validate 
previous results (Table 5.2). Swabs in lysis buffer were vortexed for 1 minute then 
centrifuged at 4°C for 1 minute. Extraction was performed following the manufacturers 
instructions. Roughly the same quantity of lysate was recovered from tubes containing 
one and two swabs.  
 
The concentration and quality of RNA was assessed using NanoDrop (data not 
shown), Qubit and Agilent bioanalyser. DNA was quantified by ddPCR and mRNA and 
miRNA concentration were measured by qPCR for the endogenous controls RPLP0 
and U6. Results are shown in Table 5.4. The highest yield and quality of miRNA, RNA 
and DNA were obtained by vortexing one swab individually and extracting material 
using the Norgen total RNA/DNA purification kit, despite there being double the input 
material in the two-swab condition. The Qiagen kit performed well for DNA but very 
poorly for RNA (no additional RNA wash steps were included). Zymo Quick-RNA™ 
MiniPrep kit performed worse than the Norgen kit and purified RNA only.  
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Table 5.4. Comparison of three extraction kits with one or two swabs per tube during 
lysis 
Lysis and 
extraction method 
DNA 
RPP30a  
mRNA 
RPLP0b  
miRNA U6b  
Agilent 
RIN 
Agilent 
RNA pg/ul 
Qubit  RNA 
ng/ml 
Norgen:   
     
1 swab 114.21 22.66 18.93 9.4 4722.9 246 
1 swab 67.99 23.65 20.7 9.3 6285 108 
1 swab 108.43 22.14 19.66  
 
199 
       
2 swabs 51.55 26.15 21.33 NA 30 97 
2 swabs 44.00 33.15 25.44 8.9 878 <20 
2 swabs 38.80 ≥ 40 ≥ 40  
 
<20 
       
Zymo Quick-Prep: 
      
1 swab - 30.86 ≥ 40 9.1 51 30 
1 swab - 24.33 30.6 NA 2.3 <20 
1 swab - 36.81 ≥ 40  
 
<20 
       
2 swabs - 29.1 26.06 7.2 211 46.6 
2 swabs - 35.02 29.55 NA 9 21 
2 swabs - ≥ 40 ≥ 40  
 
<20 
       
Qiagen: 
      
1 swab 103.55 ≥ 40 ≥ 40 NA 3.2 28.4 
1 swab 28.31 ≥ 40 ≥ 40 NA 5.7 <20 
1 swab 401.74 ≥ 40 ≥ 40  
 
<20 
Swabs used in this experiment were spiked with cultured cells. 
a DNA concentration in copies/μl of extracted DNA is shown 
b Mean cycle threshold is shown of four technical repeats 
 
5.4.6. Comparison of Norgen and Zymo Direct-zol extraction kits and lysis methods 
 
The Norgen kit was compared to the Zymo Direct-zol total RNA extraction kit, which 
differs to the others in that it uses Trizol. Conditions were: a) One swab vortexed and 
processed individually in 600μl lysis buffer and b) two swabs vortexed in separate 
tubes in 400μl lysis buffer and the 800μl combined lysate was pooled for extraction on 
one column. Two swabs were vortexed and processed as one in 600μl lysis buffer 
again using the Norgen kit, which confirmed the poor results using this method (Table 
5.5). Surprisingly no RNA was detected using the Zymo Direct-zol kit. Lysing two 
swabs in individual tubes and combining the lysate for extraction on one column 
provided the highest quality and quantity of miRNA, RNA and DNA. RNA extracted 
using the Norgen kit had RIN values ≥8, sufficient for small RNA sequencing.  
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Table 5.5. Comparison of lysis methods using Norgen and Zymo Direct-Zol kits 
Lysis and 
extraction method 
DNA 
RPP30a  
mRNA 
RPLP0b 
miRNA 
U6b 
Agilent 
RIN 
Agilent 
RNA pg/ul 
Qubit RNA 
ng/ml 
Norgen: 
      
1 swab 600l LB 377.74 22.59 19.34 8.4 24160 411 
1 swab 600l LB 247.53 23.52 25.78 8.2 9716 306 
       
(1 swab 400l LB)*2  559.94 22.19 18.55 8 11433 477 
(1 swab 400l LB)*2  343.08 21.5 17.36 8 18515 620 
       2 swabs 600l LB 213.31 22.92 18.65 8.2 11179 470 
2 swabs 600l LB 217.31 25.28 20.1 3.5 880 177 
       
Zymo Direct-zol: 
      1 swab 600l LB 
 
≥ 40 ≥ 40 NA 11 <20 
1 swab 600l LB 
 
≥ 40 ≥ 40 NA 21 <20 
       
(1 swab 400l LB)*2  
 
≥ 40 ≥ 40 NA 5.4 <20 
(1 swab 400l LB)*2    ≥ 40 ≥ 40 NA 9 <20 
Swabs used in this experiment were spiked with cultured cells. 
a DNA concentration in copies/μl of extracted DNA is shown 
b Mean cycle threshold is shown of four technical repeats 
LB: Lysis buffer 
 
Zymo Direct-zol RNA samples had a small peak at 270nm on the absorbance 
spectrum by NanoDrop (data not shown) characteristic of phenol contamination. 
Contamination with Trizol or chaotropic agents could inhibit the PCR, however the RNA 
concentration was also very low using fluorometric (Qubit) and spectrophotometric 
(NanoDrop) methods. Despite swabs being removed from RNAlater® before addition 
to the Tri-reagent, it is possible that excess RNAlater® carryover interfered with the 
extraction chemistry such that the RNA did not enter the aqueous phase. This was not 
investigated further as adequate results for total RNA and DNA were obtained using 
the Norgen kit and the Zymo Direct-zol kit isolates RNA only.  
 
5.4.7. Optimization summary 
 
For the samples tested in this study, vortexing swabs individually, pooling the lysate 
and extracting total RNA and DNA using the Norgen purification kit was the most cost-
efficient method and yielded high quality and quantity nucleic acids. Bead beating was 
detrimental to yield and quality of nucleic acids and would perhaps only be worthwhile 
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for these samples if isolating DNA from bacteria for microbiome analysis. A previous 
microbiome study using material from ocular swabs used Mo Bio extraction and bead 
beating kits and did not isolate more fragile RNA species from the same samples [16]. 
The study achieved an average read depth of 7684 per sample using Roche-454 deep 
sequencing and retained 84% (220/260) samples after quality control. It is possible 
there is a trade-off of a loss of overall (or host) DNA in order to obtain DNA from a 
representative sample of the bacterial species present, however this finding may be 
limited to the reagents tested in this study, which was not fully optimized for bead 
beating. The Qiagen kit yielded a good quantity of DNA but guanidine isothiocyanate 
carryover was detected in the RNA, which likely inhibited downstream reactions. The 
Zymo Quick-prep mini kit yielded RNA of a lower concentration and quality to Norgen 
and the Zymo Direct-zol kit did not work at all in these experiments. This is unlikely to 
be an accurate reflection of the kit, as Trizol is thought to extract RNA of the highest 
quality and yield. Further optimization of this kit could reveal it’s true potential, however 
this was not undertaken in the current study due to the disadvantage of the kit only 
isolating RNA.  
 
5.5 Summary  
 
All clinical samples were subsequently processed by lysing two swabs from each 
individual separately and pooling the lysate for extraction with the Norgen kit. Gloves 
and workspace were cleaned between processing of each sample to minimize cross-
contamination. Of the 163 clinical samples extracted, 51 had a total RNA RIN value ≥ 
8. None of the 163 samples had a total RNA concentration sufficient to meet the 
Illumina input requirements of 1μg in 5μl total RNA. The highest sample concentration 
was 74.6ng/μl (373ng in 5μl). Ten case-control samples were chosen of the highest 
RNA concentration and quality and were normalized to the concentration of the lowest 
sample (120ng in 5μl) for entry into the sequencing pipeline. The sample selection 
process is described in Figure 5.3. Illumina TruSeq small RNA sequencing was 
performed successfully and results are described in Chapter 5.  
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Figure 5.3. Sample selection process for small RNA sequencing. Ct+ = Ct positive,   
Ct- = Ct negative.  
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Abstract 
Background: Trachoma, a preventable blinding eye disease, is initiated by ocular 
infection with Chlamydia trachomatis (Ct). We previously showed that microRNAs 
(miR) -147b and miR-1285 were up-regulated in inflammatory trachomatous scarring. 
During the initial stage of disease, follicular trachoma with current Ct infection, the 
differential expression of miR has not yet been investigated.   
 
 Methods: Conjunctival samples were collected from 163 children aged 1-9 years old 
living in a trachoma-endemic region of Guinea Bissau, West Africa. Small RNA 
sequencing (RNAseq) was carried out on samples from five children with follicular 
trachoma and current Ct infection and five children with healthy conjunctivae and no Ct 
infection. Small RNAseq was also carried out on human epithelial cell lines infected 
with ocular Ct strains A2497 and isogenic plasmid-free A2497 in vitro. Results were 
validated by quantitative PCR (qPCR) in 163 clinical samples. 
 
Results: Differential expression of RNAseq data identified 12 miR with changes in 
relative expression during follicular trachoma, of which 9 were confirmed as 
differentially expressed by qPCR (miR-155, miR-150, miR-142, miR-181b, miR-181a, 
miR-342, miR-132, miR-4728 and miR-184). MiR-155 and miR-184 expression had a 
direct relationship with the degree of clinical inflammation. MiR-155 was up-regulated 
(OR=2.533 ((95% CI = 1.291 – 4.971); P=0.0069) and miR-184 was down-regulated 
(OR=0.416 ((95% CI = 0.300 – 0.578); P= 1.61*10-7) as the severity of clinical 
inflammation increased. Differential miR expression was not detected in HEp-2 or HCjE 
epithelial cells 48 hours post infection with Ct in vitro. HCjE cells, a conjunctival 
epithelial cell line, had a markedly different miR background expression compared to 
HEp-2 cells.  
 
Conclusions: In follicular trachoma, expression of miR-155 and miR-184 is correlated 
with the severity of inflammation. This likely reflects host regulation of the immune 
response and a prolonged period of wound healing following the clearance of Ct. 
Prolonged healing may be associated with subsequent development of scarring 
trachoma. 
 
 
Keywords: Chlamydia trachomatis; trachoma; miRNA; Inflammation; RNAseq; miR-
155; miR-184; follicular trachoma. 
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Background 
 
Trachoma is the leading infectious cause of blindness worldwide and is initiated by 
infection of the conjunctival epithelium with the obligate intracellular bacterium 
Chlamydia trachomatis (Ct). In trachoma-endemic areas children suffer repeated 
episodes of infection and the effects of the associated immune response, which is 
characterized by a follicular conjunctivitis. In some individuals this triggers a chronic 
inflammatory response, causing scarring of the eyelid over the course of the lifetime of 
the individual, often in the absence of detectable Ct infection [1]. Conjunctival fibrosis 
causes entropion (in-turning of the lid margin) and subsequent trichiasis, the inward 
turning of eyelashes, which scratch the cornea causing mechanical damage leading to 
blinding corneal opacification in a proportion of cases. The mechanisms of fibrotic 
progression in the absence of Ct infection and the reason why only some individuals in 
trachoma-endemic communities develop scarring despite similar exposure to infection 
are unknown.  
 
Trachoma is endemic in 51 countries and is associated with visual impairment in 2.2 
million people worldwide (of whom 1.2 million are irreversibly blind) [2]. The World 
Health Organization (WHO) strategy for the elimination of trachoma (“SAFE”) consists 
of mass distribution of antibiotics (MDA) to communities to treat infection, surgery for 
trichiasis, promotion of facial hygiene and environmental and sanitation improvements 
such as provision of latrines to reduce transmission [3].  
 
Whilst MDA is generally effective, there are concerns regarding its efficacy in hyper-
endemic settings such as Ethiopia, where trachoma prevalence remains high despite 
>5 years of biannual MDA in some districts [4]. High recurrence rates of trichiasis 
following lid margin rotation surgery [5] and the presence of follicular trachoma and 
incident scarring in populations where Ct infection prevalence has been controlled [1, 
6] are also of concern. In order to develop an anti-Ct vaccine that invokes a protective 
immune response and to design therapeutic treatments to halt progressive scarring, a 
better understanding of the immunopathology of chlamydial disease is required.  
 
Experimental conjunctival Ct infection of human volunteers found the incubation period 
to be between 2 and 19 days post inoculation [7, 8], whilst mathematical models based 
on data from disease and infection studies in trachoma-endemic communities 
estimated this period as around 17 days [9]. Although some infected individuals remain 
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asymptomatic, many will develop clinical signs of follicular trachoma, such as lymphoid 
follicles and papillary inflammation. The median duration of follicular trachoma has 
been observed to decrease with age; from 13.2 weeks in 0-4 year olds to 1.7 weeks in 
individuals of 15 years or more [10]. The cumulative incidence rate of follicular 
trachoma is also reduced threefold with age, implying that some degree of protective 
immunity is acquired [10]. There is a lag time between the clearance of infection and 
the disappearance of clinical signs of follicular trachoma on both an individual (median 
time of five weeks [9]) and population level [11, 12].  
 
MicroRNA (miR) are small single-stranded RNA species that regulate gene expression 
post-transcriptionally. MiR can have profound effects on health and disease and there 
are many examples in which abnormal expression of a single [13] or small number [14] 
of miR are associated with disease. We have previously found that miR-147b and miR-
1285 are up-regulated in adult cases of scarring and inflammatory trachoma [15]. 
Others have investigated the miR response to Ct and C. muridarum (Cm) in the murine 
genital tract [16–18], but the miR response to Ct in human disease has not yet been 
reported. In this study we examine the miR response in clinical cases of follicular 
trachoma with Ct infection and during Ct infection of cultured human epithelial cells.  
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Methods 
 
Ethics, consent and permissions 
 
The study was conducted in accordance with the declaration of Helsinki and was 
approved by the Ethics committee of the London School of Hygiene and Tropical 
Medicine (reference: 6433) and the Comité Nacional de Ética em Saúde of Guinea 
Bissau (reference: 012/CNES/INASA/2013). Written informed consent was obtained 
from a parent or guardian before participants were enrolled in the study. 
 
Clinical sample collection  
 
Prospective samples were collected from children aged from 1 to 9 years residing on 
seven islands of the Bijagos Archipelago, Guinea Bissau, 6 islands of which were 
trachoma treatment naïve at the time of sample collection. Children were screened for 
clinical signs of trachoma by a trained clinician using the WHO 1981 FPC scoring 
system [19]. Individuals presenting with follicular trachoma scores of “F2” or “F3” were 
roughly equivalent to  “Trachomatous Inflammation − Follicular (TF)” in the WHO 
simplified trachoma grading system [20] and are hereafter referred to as TF cases. 
Individuals with pronounced papillary hypertrophy and diffuse infiltration (score “P3“) 
were equivalent to “Trachomatous Inflammation − Intense (TI)” in the WHO simplified 
grading system. Individuals with no clinical signs of follicles (F0), papillary hypertrophy 
(P0) or conjunctival scarring (C0) were classed as normal healthy controls (N). A case 
was defined as a child with TF in both eyes irrespective of P score. A healthy control 
was enrolled for each TF case where a case was defined as an individual with an F-
score F2. Cases and controls were matched by age, gender and village.  
 
Two conjunctival samples were taken from the left upper tarsal conjunctiva of each 
participant with Dacron swabs (Puritan, Guilford, ME, USA) using standard 
methodology [21, 22]. Swabs were stored in RNAlater (Ambion, Life technologies, 
Carlsbad CA, USA) and kept in a cold chain in the field before subsequent storage at -
80°C. The two swabs from each individual were pooled for RNA and DNA extraction.  
 
In vitro culture and Ct infection of human epithelial cell lines  
 
Human epithelial type 2 (HEp-2) cells were cultured in Minimum Essential Medium 
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(MEM) (Gibco, Life Technologies) supplemented with 1% gentamicin (Gibco), 10% 
fetal bovine serum (FBS) (Gibco), and 1% L-glutamine (Gibco). For the in vitro 
experiments, cells were seeded in 12 well plates at 3x105 cells per well in MEM. An 
immortalized human conjunctival epithelial cell line (HCjE) was cultured in Keratinocyte 
serum free medium (K-sfm) (Gibco) supplemented with 25g/ml bovine pituitary extract 
(Gibco), 0.2ng/ml epidermal growth factor (Gibco), 0.4mM CaCl2 (Sigma, St. Louis, 
MO, USA) and 5% gentamicin and incubated at 37°C with 5% atmospheric CO2. For 
experiments, HCjE cells were seeded in 12 well plates at 3x105 cells per well in 1:1 K-
sfm [with supplements]: Dulbecco’s Modified Eagle Medium: Nutrient Mixture F12 
(DMEM/F12) [with 10% FBS, 1% gentamicin and 1% L-glutamine] (Gibco) and were 
switched to DMEM/F12 [with supplements] upon infection 24 hours later.  
 
HEp-2 and HCjE cells were infected with 3 different ocular-derived serovar A Ct 
strains: A2497 (described in [23]), its plasmid cured counterpart (A2497P-) [24] and 
A/HAR-13 [23]. Cells were infected 24 hours after seeding at a multiplicity of infection 
(MOI) of 1 and without the addition of cycloheximide. Ct cultures and mock-infected 
cells were centrifuged at 1800 r.p.m. for 1 hr to facilitate infection and were then 
incubated at 37°C in 5% CO2. Six replicates were carried out for each biological 
condition. At 48 hours post-infection (hpi), media was removed and cells were washed 
in 1X phosphate-buffered saline (PBS) (Sigma). Productive infection was measured by 
digital PCR, as detailed below, and through visualization of inclusions using confocal 
microscopy. 
 
Microscopy  
 
Cell monolayers were seeded on glass coverslips and at 48 hpi media was removed 
and cells were washed in 1X PBS. 200 l ice cold 100% methanol was added to each 
well for 10 minutes. In order to block the cells, they were washed in 1X PBS and 
incubated in 200 l 1% w/v bovine serum albumin (BSA)/PBS for 30 minutes at room 
temperature. Cells were then incubated for 30 minutes in the dark with 100 l of a 1% 
v/v solution of anti-Chlamydia trachomatis MOMP antibody (FITC) (ab30951, Abcam, 
Cambridge, UK) in 1% w/v BSA/PBS. Cells were washed 3x in 1X PBS for 5 minutes 
each wash. DAPI dilactate (1g/ml (Sigma)) was added for 5 minutes. Cells were 
washed 3x in 1X PBS. Slides were mounted with coverslips and viewed on a Zeiss 
LSM510 confocal microscope at 40X magnification. Images were captured using the 
tile function in Volocity, V5.5.1 (PerkinElmer, Waltham, MA, USA).   
 124 
 
Nucleic acid extraction  
 
For in vitro cultures 300l lysis buffer (Norgen Biotek, Thorold, ON, Canada) was 
added to each well and cells were harvested by scraping. Ocular swabs were thawed 
and added to a 1.5 ml microcentrifuge tube containing 300 l lysis buffer (Norgen 
Biotek) and were vortexed for one minute. Total RNA and DNA were extracted from 
both sample types using the Norgen RNA and DNA purification kit according to the 
manufacturers instructions. Total RNA was quantified using Qubit® fluorometric 
quantitation (Life Technologies) and quality was assessed using an Agilent RNA 6000 
pico kit on a 2100 Bioanalyzer instrument (Agilent technologies, Santa Clara, CA, 
USA).  
 
Ct infection load by droplet digital PCR  
 
A droplet-digital PCR assay was carried out to diagnose Ct infection, as described 
previously [25, 26] with the following modifications. Forward and reverse primers were 
used at 0.9M and probes were used 0.2M.  Eight microlitres of sample DNA was 
added to each reaction. For clinical samples, an initial diagnostic assay detecting Ct 
plasmid and human RPP30 endogenous control was carried out on all samples. Ct 
omcB and plasmid DNA was then quantified in positive samples to determine Ct load. 
This assay was also performed on in vitro samples to quantitate Ct omcB load and to 
check that there was no cross contamination of plasmid competent Ct in plasmid-free 
Ct cultures. Primer and probe sequences are described elsewhere [26]. Thermal 
cycling conditions were as follows: 95C hold for 10 minutes, followed by 40 cycles of 
95C for 10 seconds and 60C for 20 seconds with a final hold of 98C for 12 minutes. 
ddPCR was performed on a Bio-Rad QX100 Instrument and data were collected using 
Quantalife software (Bio-Rad, Hercules, CA, USA). Copy number was calculated in R 
using previously published scripts [25].  
 
Small RNA Sequencing  
 
Small RNA libraries were prepared using TruSeq® Small RNA sample preparation kit 
(Illumina, San Diego, CA, USA), carried out following the manufacturer’s instructions. 
In vitro-derived samples chosen for sequencing had an RNA Integrity number (RIN; 
where 0 = fully degraded RNA and 10 = best possible quality) > 8 and a concentration 
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of at least 0.2 µg/µl total RNA. Sample concentrations were normalized prior to small 
RNA library preparation. Clinical samples chosen for sequencing had an RIN > 8 and 
were normalized to the sample with the lowest concentration (24 ng/µl). Libraries were 
sequenced on a MiSeq desktop sequencer (Illumina).  Sequencing reads were 
analyzed as described previously [27] with an amendment such that only reads with a 
Phred33 score of 30 or more were retained. Differential analysis was performed on 
read count data using two analysis packages in R, DESeq (which is believed to be 
conservative) and EdgeR [28–30]. In both methods miR with an average read count 
across all samples of less than five were excluded from each analysis. P values were 
adjusted for false discovery rate (FDR) using the Benjamini-Hochberg procedure [31]. 
Raw and processed sequencing data along with processing workflows are deposited in 
the NCBI GEO public database (GSE69837). 
 
MiR qPCR and statistical analysis  
 
Total RNA was reverse transcribed and expression levels were quantified by 
quantitative PCR (qPCR) using the MiScript system (Qiagen, Venlo, Limburg, 
Netherlands) as described previously [15]. Thermal cycling conditions were 95°C for 15 
minutes followed by 40 cycles of 94°C for 15 seconds, 55°C 30 seconds, and 70°C 30 
seconds. Data was collected at 70°C. Cycle thresholds were calculated using an 
automatic baseline and a threshold of 0.1 for all clinical and in vitro samples. 
Differential expression analysis of cycle threshold values was carried out as described 
previously [15]. FDR adjusted P values were calculated using the Benjamini-Hochberg 
procedure. 
 
The relationship between conjunctival papillary inflammation (P) score and the 
expression of miR that were significantly differentially expressed in TF versus N by 
qPCR was examined using ordinal logistic regression models in R (MASS package 
[32]). Clinical scores P2 and P3 were combined due to the low number of P3 scores 
(n=6) and individuals were classified as P0 (n=84), P1 (n=53) and P2/P3 (n=29) as an 
ordinal response variable. Age, gender and the natural logarithm of Ct omcB load were 
included in the model and miR expression levels (40-delta cycle threshold (∆CT) value) 
were included as independent variables. This value (40-∆CT) was used so that an 
odds ratio (OR) >1 would reflect an up-regulation of miR expression and vice versa. 
Univariable ordinal regression was performed for each miR and miR with a P value < 
0.05 were included in the final multivariate model. F and P scores were tested for 
collinearity: A high kappa score and a covariance matrix value near zero indicates 
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collinearity (0= perfect colinearity, 1= no colinearity). Post-hoc analyses were carried 
out on miR with a P value <0.05 in the multivariate model. Kruskal-Wallis and post-hoc 
Kruskal Nemenyi tests (Tukey method) were carried out in R using the PMCMR 
package [33] to detect pairwise differences between miR expression and collapsed 
papillary inflammation score. Kruskal Nemenyi test P values were adjusted using the 
Benjamini-Hochberg procedure. 
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Results 
 
In vitro infections  
 
HEp-2 and HCjE epithelial cell lines were infected in vitro with 3 different serovar A 
ocular strains of Ct; A/HAR-13, A2497 and plasmid-cured A2497. In HEp-2 cells, 
virulent A2497 plasmid-competent Ct had the highest mean genome copy number at 
48 hpi, which was slightly higher than that of isogenic plasmid-free A2497 (A2497P-) 
(Figure 1). A/HAR-13 growth was considerably less efficient in these experiments. All 3 
strains were substantially less productive in HCjE cells compared to HEp-2 cells, as 
measured by omcB load and microscopy of inclusions (Figure 6.1 and Additional file 
6.1). Due to the low productivity of A/HAR-13 infection in HEp-2 and HCjE cells, these 
samples were not carried forward for small RNA sequencing. A2497 and A2497P- 
infected HCjE cells were sequenced despite the poor infection productivity in order to 
contrast small RNA expression between infected HEp-2 and HCjE cells. Small RNA 
sequencing was performed on mock-infected, A2497 and A2497P- infected HEp-2 and 
HCjE cells.  
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Figure 6.1. Yield of three ocular Ct strains in two epithelial cell lines. Chlamydial 
genome copy number of three ocular Ct strains (A2497, A2497p- and A/HAR-13) in 
HEp-2 and HCjE cells at 48 hpi. Cells were infected at an MOI of 1. Mock-infected cells 
(-VE) were treated identically except for the addition of Ct inoculum. The mean of the 
total OmcB genome copy number per well of 6 biological replicates is shown. OmcB 
copy number is shown on a log(10) scale. Boxplots show the median (horizontal red 
line), interquartile range (grey or black solid-filled box) and the maximum and minimum 
values (dotted lines). Grey: HEp-2 cells, Black: HCjE cells.  
 
In HEp-2 cells, 885 miR were detected in mock-infected cells, 894 miR were detected 
in A2497 infected cells and 856 miR were detected in A2497P- infected cells. 
Differential expression of read count data (miR with an average read count <5 
excluded) was carried out using EdgeR and DEseq to account for variance in the 
normalization method. No miR were differentially expressed (Padj <0.01) using either 
method between mock-infected and A2497 infected (377 miR tested) or between 
mock-infected and A2497P- infected (378 miR tested) HEp-2 cells (Additional file 6.2). 
!
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In HCjE cells, 853 miR were detected in mock-infected cells, 840 miR were detected in 
A2497 infected cells and 872 miR were detected in A2497P- infected cells. No miR 
were differentially expressed using EdgeR or DESeq (Padj <0.01) between mock-
infected and A2497 infected (357 miR tested) or between mock-infected and A2497P- 
infected (372 miR tested) HCjE cells (Additional file 6.3). 
 
The miR profile of mock-infected HEp-2 and HCjE cells was analyzed in order to 
investigate differences between these two cell lines. Four hundred and seven miR had 
an average read count > 5 in mock-infected HEp-2 and HCjE cells. Strikingly, DESeq 
identified 136 out of the 407 miR tested with an adjusted P value (Padj) < 0.01 and 
EdgeR identified 217 miR with Padj < 0.01 (Additional file 6.4). The top 3 most 
differentially expressed miR were members of the miR-200 family: miR-200b-3p 
(Padj=2.11 x 10-51, log2FC=12.3), miR-141-5p (Padj=1.1 x 10-32, log2FC=9.2), and miR-
429 (Padj=1.1 x 10-32, log2FC= ∞), which were all highly expressed in HCjE cells relative 
to HEp-2 cells. MiR-429 was detected at an average read count of 379 in mock-
infected HCjE cells, whereas it was not detected at all in HEp-2 cells at the sequencing 
depth achieved. 
 
Clinical sample details  
 
Conjunctival swab samples were collected from 81 cases of TF and 82 clinically normal 
healthy controls. A summary of sample phenotypes is shown in Table 6.1. Five out of 
82 controls and 47/81 cases were positive for Ct DNA  (Chi2  = 55.93, P = 0.0005). The 
proportion of Ct infected individuals in each clinical category increases with the severity 
of trachomatous inflammation, both follicular and papillary. Two clinical cases had 
evidence of conjunctival scarring; one sample was F2, P1, C1 (Ct positive) and the 
other was F3, P2, C2 (Ct negative). The median Ct plasmid copy number was 1.5 
(range 0.4-14.6). 
 
 
  
 130 
Table 6.1. Trachoma grade and Ct infection load of clinical samples 
 
aCt omcB median calculated from Ct positive individuals only   
bIQR= inter-quartile range. 
 
Fifty-one of the 163 clinical samples from which total RNA was extracted had an 
RIN > 8. Five of the 51 RIN > 8 samples with the highest RNA concentration that had 
TF with current Ct infection were chosen for sequencing. Five control samples 
(F0,P0,C0) with the highest RNA concentration and the closest age and sex match to 
the 5 TF samples were also sequenced. Total RNA concentration of all 10 samples 
was normalized to the sample with the lowest concentration (24 ng/µl) prior to library 
preparation. The mean age of the 5 controls was 6.4 years old and the group consisted 
of 2 males and 3 females. The mean age of the TF group was 6.2 years old and the 
group consisted of 3 males and 2 females. In the TF group, the sample phenotypes 
were F2,P1,C0 (n=2), F2,P2,C0 (n=1), F3,P1,C0 (n=1) and F3,P2,C0 (n=1).   
 
 
FPC 
score 
 
Total (% 
Male) 
 
Ct positive 
 
Ct omcB mediana 
copies/swab (IQR)b 
Human RPP30 
median 
copies/swab (IQR) b 
Controls (N) 
F0P0C0 82 (41%) 5/82 (6%) 345 (42-1078) 
19290 (13310-
25810) 
TF cases: Breakdown by follicular score 
F2 46 (48%) 
20/46 
(43.5%) 703 (370-25870) 
23900 (15670-
39440) 
F3 35 (31%) 27/35 (77%) 6050 (1451-15350) 
35250 (19120-
43250) 
TF cases: Breakdown by papillary hypertrophy score 
P1 53 (38%) 22/53 (71%) 656 (433-5238) 
23280 (15380-
34500) 
P2 22 (55%) 19/22 (86%) 12950 (3638-42880) 
37750 (21560-
48560) 
P3 6 (17%) 6/6 (100% 11480 (4169-15720)  
43620 (37750-
53440) 
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MiR expression in clinical samples by RNAseq  
 
Deep sequencing of conjunctival small RNA from 10 clinical samples identified 860 
miR. MiR-21-5p was the most highly expressed miR in the conjunctiva of both N and 
TF cases (Additional file 6.5). MiR with an average read count < 5 in all ten samples 
were removed. EdgeR revealed 43 miR (Padj < 0.01, FC > 1.5) and DEseq identified 12 
miR (Padj < 0.01 FC > 1.5 (Additional file 6.6)) that were differentially expressed 
between TF cases and controls. All of the significant miR identified by DEseq were also 
significant using EdgeR.  
 
The differential expression of the 12 miR that were significant in both DESeq and 
EdgeR analyses was investigated in 163 clinical samples using qPCR. Two miR that 
were previously found to be up-regulated in inflammatory trachomatous scarring (miR-
147b and miR-1285) [15] were also tested by qPCR in these samples. Results were 
analyzed using the ΔΔCt method [34]. Differential expression was tested in 3 
independent clinical phenotype comparisons: TF  (n=81) against normal healthy 
controls (N, n=82), TF with detectable Ct infection (TF Ct+ n=47) against normal 
healthy controls without detectable Ct infection (N Ct-, n=77), and TF with detectable 
Ct infection (TF Ct+, n=47) against TF cases without detectable Ct infection (TF Ct-, 
n=34). Results are shown in Table 6.2. MiR-155, miR-150, miR-142, miR-181b, miR-
181a and miR-342 were up-regulated in all 3 comparisons (Figure 6.2). MiR-155, miR-
150, miR-142, miR-181b, miR-181a, miR-342 and miR-132 were differentially 
expressed during current Ct infection. MiR-184 and miR-4728 were down-regulated in 
TF independently of Ct infection. MiR-184 was the only miR that was significantly 
differentially expressed between uninfected normal healthy controls (n=77) and Ct 
negative TF cases (TF Ct- (n=34), Padj = 0.00165, FC = 0.315, data not shown). These 
results are consistent with the small RNA sequencing results (Additional file 6.6). MiR-
147b and miR-1285, which were up-regulated in inflammatory trachomatous scarring 
[15], were not differentially expressed between TF/TI and N.  
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Table 6.2. Differential expression analysis of miR by qPCR in 163 clinical samples, in three independent phenotype comparisons.  
 
 TF (n=81) v N (n=82) TF Ct+ (n=47) V TF Ct- (n=34) TF Ct+ (n=47) V N Ct- (n=77) 
 P value Adj Pa FCb P value Adj Pa FCb P value Adj Pa FCb 
miR-184 5.69*10-8 7.96*10-7 0.30 0.7571 0.7571 0.88 3.06*10-7 1.07*10-6 0.28 
miR-142-5p 6.46*10-7 4.52*10-6 1.82 1.63*10-5 7.58*10-5 2.53 2.3*10-12 3.22*10-11 2.83 
miR-155-5p 1.56*10-5 7.29*10-5 1.73 9.45*10-6 6.62*10-5 2.50 1.18*10-9 5.51*10-9 2.58 
miR-150-5p 0.0003 0.0011 1.56 1.41*10-6 1.98*10-5 3.24 8.56*10-10 5.51*10-9 2.71 
miR-181b-5p 0.0010 0.0028 1.33 0.0018 0.005 1.74 1.58*10-6 4.44*10-6 1.70 
miR-342-3p 0.0041 0.0096 1.12 0.0076 0.0178 1.50 0.0001 0.0002 1.34 
miR-4728-3p 0.0103 0.0207 0.75 0.0353 0.0617 0.72 0.0005 0.0008 0.65 
miR-181a-5p 0.0120 0.0211 1.30 0.0151 0.0301 1.40 0.0003 0.0006 1.54 
miR-375 0.0871 0.1355 0.80 0.3054 0.3887 0.81 0.0615 0.0862 0.75 
miR-132-3p 0.1628 0.2279 1.09 0.0009 0.0031 1.45 0.0023 0.0035 1.27 
miR-10a-5p 0.2654 0.3378 1.16 0.6729 0.7247 0.92 0.3454 0.4030 1.15 
miR-146b-3p 0.5491 0.6406 0.95 0.3666 0.4277 1.15 0.9425 0.9425 1.02 
miR-147b 0.6203 0.6680 1.07 0.1073 0.1669 1.44 0.2394 0.3047 1.21 
miR-1285 0.8683 0.8683 0.98 0.2095 0.2933 0.83 0.4434 0.4775 0.91 
 
Tests for difference were conducted with a T test or Wilcoxon signed rank test if data were not normally distributed. N= Normal, TF= 
follicular trachoma, Ct+ = Ct infected, Ct- = no Ct infection detected. 
 aP adj= Adjusted P value, bFC= Fold chang
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Figure 6.2. Patterns of differential miR expression according to clinical 
phenotype. MiR expression was measured using qPCR in 163 clinical samples. MiR 
that were significantly up (upward arrow) or down (downward arrow) regulated inhabit 
the circles of the phenotype comparisons in which they were differentially regulated. 
MiR labeled with double arrows had significant differences between groups (Padj < 0.05, 
FC>1.5). MiR with single arrows had significantly different expression (Padj < 0.05) but 
had a FC <1.5 in 2 or 3 of the comparisons shown.  
 
 
Relationship between clinical papillary inflammation and miR expression 
  
We investigated the relationship between clinical papillary inflammation and miR 
expression using an ordinal logistic regression model, which allowed us to adjust for 
confounding variables and estimate the contribution of miR expression to inflammation. 
Ct load was adjusted for in order to detect miR associated with papillary inflammation 
independently of Ct infection. Follicular trachoma and papillary hypertrophy were highly 
collinear (Kappa score = 5.8*1015, determinant of covariance matrix = 1.92*10-21) 
!
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therefore F score was not included as an independent variable in this analysis as the 
purpose of this model was to investigate papillary inflammation. MiR-150, -142, -4728, 
-181A and -181B were up-regulated in follicular trachoma in response to current Ct 
infection (Figure 2) and were associated with papillary inflammation in univariate 
regression analyses, but they had no association with papillary inflammation after 
adjustment for Ct infection load (Additional file 6.7). MiR-155 (OR = 2.533 (95% CI= 
1.291 – 4.971), P = 0.007) and miR-184 (OR= 0.416 (95% CI=0.300 – 0.578), P = 
1.61*10-7) were significantly associated with papillary inflammation (Additional file 6.7). 
MiR-155 expression increases with papillary inflammation score (Figure 6.3). 
Significant differences in miR-155 expression were found between P0 and P1 (Padj = 
0.03), P1 and P2/3 (Padj = 0.019) and P0 and P2/3 (Padj = 3.6*10-6). MiR-184 
expression decreased with papillary inflammation score (Figure 3). Significant 
differences in miR-184 expression level were found between P0 and P1 (Padj = 5.5*10-
5) and between P0 and P2/3 (Padj = 4.2*10-5). In separate univariate multinomial logistic 
regression analyses, no associations were found between miR expression and plasmid 
copy number in Ct positive individuals (data not shown). Exclusion of the two samples 
with evidence of trachomatous scarring did not change the outcomes of the differential 
expression or regression analyses (data not shown). 
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Figure 6.3. MiR expression correlates with clinical inflammation score. Expression 
of miR-155 and miR-184 for 163 clinical samples plotted against clinical trachoma 
papillary hypertrophy score. P2 and P3 categories were combined due to the low 
number of P3 cases. ∆CT values were calculated by subtracting the endogenous 
control (snoRNA U6) cycle threshold (CT) value from the CT value of each miR for 
each individual sample. ∆CT values were inverted (40-∆CT) in order to show the 
direction of miR expression. Boxplots show the median (horizontal red line), 
interquartile range (grey or black solid-filled box) and the maximum and minimum 
(dotted lines or empty circles) 40-∆CT values for all samples in each clinical 
inflammation score group. Grey: miR-155, Black: miR-184.  
  
!
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Discussion 
 
During Ct infection of the conjunctiva in vivo 7 miR were up-regulated. Two miR were 
down-regulated during follicular trachoma in the absence of Ct. After adjusting for the 
relationship between miR and Ct infectious load, we found that miR-155 and miR-184 
were independently associated with inflammation. We also found that isolated epithelial 
cells in culture did not differentially regulate miR expression in response to Ct infection. 
 
The Ct plasmid is a known virulence factor [35, 36]. In a non-human primate model of 
trachoma A2497P- infection is attenuated relative to A2497 and does not lead to ocular 
pathology [24]. Attempts to elucidate the mechanism of this attenuation are ongoing 
[37, 38]. In order to understand the contribution of the epithelium, Porcella et al. (2015) 
recently characterized the in vitro transcriptome response of HeLa cells infected with 
A2497 and A2497P- (at an MOI of 1) [39]. Similar transcriptional profiles were induced 
by A2497 and A2497P- and only modest increases in cytokine and chemokine levels 
were detected in response to virulent A2497. The authors suggested that their data 
supports the hypothesis that Ct is a stealth pathogen [40], due to the limited innate pro-
inflammatory response induced. We did not detect differential regulation of miR by 
deep sequencing in HEp-2 or HCjE epithelial cells at 48 hpi with A2497 and A2497P- 
(also at an MOI of 1). This result is not surprising in HCjE cells due to the lack of 
productive infection achieved, however more differences might have been expected 
upon productive infection of HEp-2 cells, particularly as Porcella et al., found the 
largest transcriptional changes occurred in response to A2497 and A2497P- at 48hpi 
[39]. Our data could also be interpreted as evidence in support of the stealth pathogen 
hypothesis and suggests that Ct avoids stimulation of a miR response in epithelial 
cells. Infection of HeLa cells with Salmonella typhimurium revealed the largest changes 
in miR expression at 4hpi, with minimal changes detected at 24hpi despite infecting 
with an MOI of 10 [41]. Therefore, it is also possible that changes in epithelial cell miR 
expression in response to Ct are limited to early time points post infection. Limitations 
of this experiment were that despite infecting with an MOI of 1 we achieved <50% 
infectivity (Additional file 6.1) and we sequenced three biological repeats per condition. 
The expression changes in infected cells were therefore likely diluted by the lack of 
expression change in neighboring uninfected cells and it is possible that we did not 
have the statistical power to detect small expression differences. 
 
HEp-2 cells originated from a human laryngeal carcinoma but it is known that many 
laboratory stocks of HEp-2 cells are contaminated with HeLa cells, which are derived 
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from a glandular adenocarcinoma of the cervix [42]. HCjE cells are an immortalized cell 
line generated from a primary conjunctival epithelial culture [43] and may represent an 
in vitro model that better mimics conjunctival epithelial cells in vivo. A previous study 
infected HCjE and HeLa cells with A/HAR-13 at an MOI of 0.3 and reported that 
A/HAR-13 achieved higher infectious load in HCjE cells compared to HeLa cells [44]. In 
contrast we were unable to maintain productive infections of 3 ocular strains in HCjE 
cells, whereas productive infection of HEp-2 cells with A2497 and A2497P- was 
achieved. These differences could reflect culture adaptation of HCjE cells [45–48] or Ct 
strains [49] over time or a natural resistance of the HCjE line to infection, perhaps due 
to expression of mucins or innate antimicrobial effectors [50]. Comparison of mock-
infected HEp-2 and HCjE cell lines revealed significant differences in miR profile. 
Amongst the miR that were most significantly up-regulated in HCjE cells relative to 
HEp-2 cells were several members of the miR-200 family (Additional file 6.4), which are 
known to be highly enriched in epithelial tissues [51]. This would suggest that HEp-2 
cells present an environment to Ct that is different to conjunctival epithelial cells and 
might indicate that caution should be used when interpreting data generated from 
these cultures in comparison to the in vivo response.  
 
In vivo, we found that miR-21-5p was the most abundant miR in the conjunctiva of both 
follicular trachoma cases and healthy control individuals (Additional file 6.5). MiR-21 is 
transactivated by NFκB [52] and is thought to act in a positive feedback loop in 
epithelial cells by increasing NFκB activity [53]. The high expression of miR-21 at this 
mucosal site may reflect NFκB stimulation in an environment of frequent microbial 
exposure. We previously found that miR-21 was abundant (Ranked 19/503) in the 
conjunctiva of Gambian adults with and without scarring trachoma [15]. This slight 
reduction in the relative abundance of miR-21 in adults may reflect the fact that the 
conjunctival microbiome of adults in The Gambia has reduced richness and diversity of 
species compared to Gambian children [54] and thus a lower level of microbial 
stimulation. The reduction in abundance could also be due to differences in microbial 
exposure between The Gambia and Guinea Bissau, or the different technical 
approaches used in the two studies such as small RNA purification and quantitation.  
 
In follicular trachoma, the miR expression signature reflects the presence of the 
immune response. MiR-155, miR-150 and miR-142 are thought to be specific for 
hematopoietic cells [55] (although miR-155 expression has been reported in epithelial 
cell lines [56, 57]) and miR-155, miR-150, miR-181a, miR-146 and miR-10a have roles 
in hematopoiesis (reviewed in [58]). MiR-155 in particular has wide-ranging and 
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profound effects on the development and function of immune cells (reviewed in [59]). 
MiR-181b, miR-132, miR-10a and miR-146b negatively regulate inflammation following 
TLR or NFκB stimulation in order to prevent excessive inflammation and pathology. A 
brief summary of roles that have been described for these differentially regulated miR 
relating to inflammation or fibrosis is presented in Additional file 6.8. The expression of 
these miR following stimulation of innate pathogen recognition pathways explains their 
up-regulation in response to Ct in this study. We found that expression of miR-150, -
181a, -181b, -142 and -4728 were each independently associated with increasing 
inflammatory score, however, these associations were no longer significant after 
adjustment for Ct load and miR-co-expression. MiR-155 and miR-184 alone had a 
strong and direct association with papillary inflammatory score after adjustment for 
these factors. Pathway analysis was not carried out due to the relatively small and 
manageable number of differentially expressed miR and the inherent bias of current 
miR-based pathway analysis software [60].  
 
A number of the miR that were differentially regulated in Ct positive follicular trachoma 
cases have previously been linked to chlamydial disease. MiR-155-5p, miR-142-5p, 
miR-142-3p, miR-132-3p and miR-147-3p amongst others were up-regulated during 
Cm infection of the murine cervix in response to an attenuated strain of Cm, relative to 
a virulent strain of Cm [16]. The roles attributed to these miR in dampening 
inflammation possibly explain the reduced pathology observed upon avirulent infection. 
Another study found that miR-146a was up-regulated in the murine genital tract 6 days 
post infection with Cm [17]. We did not find miR-147b or miR-1285 to be differentially 
expressed in Ct positive or Ct negative follicular trachoma cases. This could reflect 
differences in the inflammatory phenotype between adults with trachomatous scarring 
and inflammation (TI) that continues in the absence of Ct, compared to younger 
individuals with chlamydial-induced inflammation (TF and TI). MiR-147b is also 
hypothesized to dampen inflammation upon LPS and TNFα stimulation [61, 62], 
therefore regulation of inflammation is a key theme in both stages of trachomatous 
disease. No differentially regulated miR were detected in healthy control adults versus 
individuals with scarring trachoma in our previous study; differences were only 
detected in comparisons against trachomatous scarring with inflammation [15]. These 
data, combined with recent evidence that inflammation is a significant risk factor for 
progressive scarring [1], support the hypothesis that inflammatory cells are required to 
drive pathological responses in the epithelium. This hypothesis perhaps also explains 
the lack of miR response in our infected epithelial cell model and suggests that 
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inflammatory cell stimuli are required for a miR response in the epithelium in vivo, as 
might be the case for miR-184.  
 
We found that miR-184 and miR-4728-3p were down-regulated in follicular trachoma 
irrespective of Ct infection. MiR-184 was the only miR differentially expressed in 
uninfected cases of follicular trachoma versus uninfected healthy controls and was 
highly associated with papillary hypertrophy score after adjustment for Ct load. MiR-
184 is known to be enriched in the corneal epithelium [63] and it is the fourth most 
abundant miR in control individuals (F0P0C0). We previously found that miR-184 was 
highly abundant (5/502) in a pool of normal healthy adults and adults with scarring 
trachoma [15], suggesting tissue specific expression does not vary with age. A single 
base substitution in the seed region of miR-184 is associated with severe keratoconus 
(thinning of the cornea) [64–66]. In the cornea miR-184 is expressed in basal and 
supra-basal epithelial cells [63], under which the stromal thinning occurs. MiR-184 is 
strongly down-regulated during acute corneal injury and expression is restored in the 
re-epithelialized cornea upon healing [63]. MiR-184 also targets the Wnt receptor 
frizzled-7 and negatively regulates the Wnt pathway; down-regulation of miR-184 is 
associated with aberrant activation of the Wnt pathway in ischemia-induced 
neovascularization of the murine retina [67]. Delivery of miR-184 was able to inhibit 
induction of the Wnt pathway, conferring miR-184 with significant therapeutic potential. 
Activation of the canonical Wnt pathway has previously been demonstrated in Ct 
infected epithelial cells in ex-vivo fallopian tube tissue [68], with a paracrine effect that 
resulted in a loss of epithelial homeostasis. Altogether, these data suggest that a 
down-regulation of miR-184 in follicular trachoma once Ct has been cleared reflects a 
prolonged wound healing process and activation of the Wnt pathway, possibly 
contributing to pathology. Prolonged down-regulation of miR-184 may also contribute 
to epithelial thinning, which is observed in trachoma, potentially predisposing 
individuals more to subsequent bacterial infections. Future work should focus on the 
expression of miR-184 and activity of the Wnt pathway in a longitudinal set of clinical 
samples to determine the contribution of this pathway to the development of 
trachomatous pathology.   
 
There was considerable variation in load between the Ct infected follicular trachoma 
cases in this study. Conjunctival cells obtained by a swab are expected to be 
heterogeneous in the number of infected and uninfected epithelial cells and the number 
of immune cells.  The majority of epithelial cells are likely to be uninfected; reducing 
our power to detect miR expression differences in infected epithelial cells and perhaps 
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explaining why the majority of differentially regulated miR detected in vivo were 
hematopoietic cell-associated. This heterogeneity is a caveat of using clinical samples.  
In order to investigate the host miR response of Ct infected epithelial cells in vivo 
infected cells could be isolated and subjected to single cell miRNA expression analysis 
[69].  
 
Conclusions 
 
We identified 7 miR that were up-regulated by current chlamydial infection during 
follicular trachoma. MiR-184 and miR-4728 were down-regulated during follicular 
trachoma in the absence of Ct. MiR-155 and miR-184 were inversely correlated with 
pathological inflammation, which is known to be a major risk factor for scarring 
trachoma. Future studies using more sophisticated in vitro models (such as co-culture) 
involving miR silencing or overexpression coupled with longitudinal studies in vivo will 
help develop our understanding of the functions of these miR, their use as predictive 
biomarkers of scarring trachoma and their potential as novel treatment targets.
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Additional files: 
 
File name: Additional file 6.1 (see figures 4.2 and 4.4) 
File title: Chlamydial infection of HEp-2 and HCjE cell lines with three ocular Ct strains. 
File description: HEp-2 cell monolayers infected with Ct strains A2497 (A), A2497P- 
(B) and A/HAR-13 (C), and HCjE cell monolayers infected with Ct strains A2497 (D), 
A2497P- (E) and A/HAR-13 (F) at 48 hpi. Cell nuclei are stained with DAPI (blue) and 
Ct inclusions are stained with anti-C. trachomatis MOMP antibody (FITC (green)). Cells 
were infected with an MOI of 1 and viewed at 40X magnification. Representative 
photographs were taken from one of three replicates for each condition. 
 
File name: Additional file 6.2 
File format: XLS 
File title: Differential expression analysis of miR from A2497 and A2497P- infected 
HEp-2 cells. 
File description: Results of DESeq differential expression analysis of sequencing read 
count data for uninfected HEp-2 cells versus HEp-2 cells infected with A2497 and 
A2497P- strains of Chlamydia trachomatis at 48hpi. MiR with an average read count <5 
were excluded. Three biological replicates of each condition were sequenced and 
analyzed. MRC = Mean read count, -VE= mock-infected cells. 
 
File name: Additional file 6.3 
File format: XLS 
File title: Differential expression analysis of miR from A2497 and A2497P- infected 
HCjE cells. 
File description: Results of DESeq differential expression analysis of sequencing read 
count data for uninfected HCjE cells versus HCjE cells infected with A2497 and 
A2497P- strains of Chlamydia trachomatis at 48hpi. MiR with an average read count <5 
were excluded. Three biological replicates of each condition were sequenced and 
analyzed. MRC = Mean read count, -VE= mock-infected cells. 
 
File name: Additional file 6.4 
File format: XLS 
File title: Differential expression analysis of miR from uninfected HCjE versus HEp-2 
cells. 
File description: Results of DESeq differential expression analysis of sequencing read 
count data for uninfected HEp-2 cells versus uninfected HCjE cells at 48hpi. MiR with 
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an average read count <5 were excluded. Three biological replicates of each condition 
were sequenced and analyzed. MRC = Mean read count, -VE= mock-infected cells. 
 
  
 
 File name: Additional file 6.5 
File title: Relative abundance of miR in the conjunctiva of cases of follicular trachoma 
(TF) and controls (N). 
File description: Relative abundance of miR detected in 5 TF cases and 5 controls by 
small RNA sequencing. MiR with a mean read count in TF cases or controls < 5 were 
excluded. MiR were ranked by mean read count across all five samples of each 
phenotype group.  
 
File name: Additional file 6.6 
File format: XLS 
File title: Differential expression analysis of miR from individuals with follicular 
trachoma versus healthy controls. 
File description: Results of DESeq differential expression analysis of sequencing read 
count data for normal healthy controls (N) versus cases of follicular trachoma (TF) with 
current Chlamydia trachomatis (Ct) infection (five samples of each). MiR with an 
average read count <5 were excluded. MRC = Mean read count. 
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Additional file 6.7. Multivariable regression model of the contribution of miR expression 
to clinical papillary hypertrophy score. 
Collapsed papillary hypertrophy score (P0, P1 or P2/3, as defined by the WHO 1981 
FPC scoring system) was used as an ordinal outcome variable to define trachomatous 
inflammation in 163 clinical samples. Age, gender, Ct load and inverted ∆CT values 
(40-∆CT) of miR are included as independent variables. Model AIC (Akaike information 
criterion) is 227.3725. Significant P values are highlighted in bold font.  
aOR= Odds ratio, bCI= confidence intervals, cCt load is defined as log-(e) omcB 
copies/swab. 
 
 
 
  
  
Independent variable 
Adjusted 
ORa  95% CIb  P value 
Age (years) 1.247 1.034 – 1.503  0.0210 
Gender (Male) 1.145 0.536 – 2.446 0.7266 
Ct loadc 1.256 1.053 – 1.498 0.0113 
miR-155 2.533 1.291 – 4.971 0.0069 
miR-184 0.416 0.300 – 0.578  1.61*10-7 
miR-150 0.654 0.349 – 1.227 0.1861 
miR-181a 1.195 0.600 – 2.382 0.6118 
miR-181b 1.623 0.779 – 3.381 0.1962 
miR-142 1.369 0.794 – 2.357 0.2582 
miR-4728 0.718 0.479 – 1.076 0.1084 
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Chapter 7: Investigating the use of 
miRNA expression as classifiers of 
trachomatous disease 
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7.1 The use of miRNA as classifiers 
miR are post-transcriptional regulators of gene expression. Individual miR can regulate 
hundreds of genes [1] and single or small numbers of miR can have profound roles in 
the regulation of biological processes in health and disease (examples include cancer 
[2,3], organ aging [4], fibrosis [5] and inflammation [6–8]). In addition to aiding our 
understanding of the complex transcriptional patterns associated with disease 
mechanisms, miRNA can be used as predictors or biomarkers of disease. miR are of 
particular use when measured in longitudinal samples to predict disease progression 
[9]. The use of miR as prognostic biomarkers of infertility has previously been 
investigated in chlamydial disease in the murine genital tract [10]. Mice were infected 
with two strains of C. muridarum (Cm) that differ in virulence, however miRNA 
expression was only assessed at 24 hours post infection [10].  
 
It is thought that all (or the vast majority) of individuals living in trachoma-endemic 
communities are exposed to Ct throughout childhood and that repeated episodes of Ct 
infection and associated inflammatory episodes (TI) lead to scarring progression and 
eventually blindness. It is not understood why only some exposed individuals progress 
to scarring disease where others do not. A miR transcriptional signature that could 
classify those at risk of scarring progression before the onset of clinical signs could 
help target treatment options to prevent or halt progressive scarring. miR could also be 
used as biomarkers of protective or adverse effects in response to a Ct vaccine if one 
was made available for testing in human populations.  
 
An association between a biomarker and disease can be tested using regression 
(Chapter 6). When predicting a binary outcome (disease or no disease), a basic 
approach to evaluate the performance of the biomarker as a diagnostic test is to use 
Receiver-Operator Characteristic (ROC) analysis. A ROC curve is a plot of the true 
positive rate (sensitivity) against the false positive rate (1-specificity), which illustrates 
the ability of the predictor to diagnose disease as the discrimination threshold varies. 
The area under the curve (AUC) or ‘C statistic’ defines the performance of the 
predictor, with a large AUC (maximum 1) indicative of a perfect test and an AUC 0.5 
meaning that the predictor is no better than chance.  
 
Once a predictor or set of predictors is identified, their performance should be 
evaluated. Essentially a model is fitted to a ‘training’ data set to detect associations 
between the predictor and the disease outcome, then the model is tested in a different 
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dataset and the fit of the model to the new dataset is measured. A perfect predictor 
would be able to classify cases and controls in the new dataset with complete 
accuracy. These ‘training’ and ‘testing’ steps can be performed within the same dataset 
by splitting it half, however the fit of the model might depend on how the dataset is 
split. An alternative approach is to split and test the dataset many times, such as with 
‘leave one out cross validation’ (LOOCV). The model is trained on all samples but one 
and then tested on that one sample. This is done for every sample in turn therefore the 
number of dataset splits is as large as the number of samples in the dataset. The 
optimum method of validating a predictor however, if possible, is to use an external 
dataset, ideally from a different population.  
7.2 miR associated with scarring and inflammatory trachoma as classifiers 
The goal of using classifiers in trachoma would be to find one or a few miR that could 
predict scarring progression. Scarring progression is strongly associated with TI, so 
miR that associated with TSI (Chapter 3) and TI (Chapter 6) were tested for their ability 
to classify disease in the same datasets. ROC curves were generated using 
expression data (delta cycle threshold values) for one or more miR (the classifier). 
Data were analysed using the Deducer package in R [11]. 
7.2.1. miR associated with TSI 
 
miR-147b was upregulated in TSI relative to healthy controls (FC = 2.3, P = 0.03) and 
miR-1285 was upregulated in TSI relative to TS alone (FC = 4.6, P = 0.005) in a cohort 
of 194 adults (Chapter 3 [12]). Controls were defined as N (F0, P0, C0, n=93) and 
cases were defined as individuals with TS in the absence of inflammation (C1/2/3, 
P0/1, n=74). Both miR performed very poorly at diagnosing TS (miR-147b AUC = 0.5; 
miR-1285 AUC = 0.56) and were no better in combination (AUC = 0.53 (Figure 7.1)). 
Performance was no better when classifying cases as individuals with TS and TSI 
(C1/2/3, P1/2/3, n=96) (miR-147b AUC = 0.54; miR-1285 AUC = 0.49; miR-147b and 
miR-1285 AUC = 0.51 (data not shown)).  
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Figure 7.1. ROC curves showing the ability of miR-1285 and miR-147b to diagnose TS. 
The red line shows an AUC of 0.5. The black line tracks the performance of the 
predictor as the discrimination threshold varies. Sensitivity is plotted on the Y-axis and 
1-Specificity is plotted on the X-axis.  
 
7.2.2. miR associated with TI 
 
miR-184 (P = 1.61*10-7, OR = 0.4) and miR-155 (P = 0.007, OR = 2.53) were strongly 
associated with TI in a cohort of 163 children aged between 1-9 years old (Chapter 6 
[13]). Individuals were classified as controls (P0 or P1 using the 1981 WHO FPC 
trachoma grading system [14], n=135) or TI cases (P2 or P3, n=28). miR-155 (AUC = 
0.78) and miR-184 (AUC = 0.74) were both good classifiers of TI independently, 
however the combined expression of miR-184 and miR-155 had an approximate 
classification accuracy of 91.3% to predict or diagnose TI (AUC = 0.913, Figure 7.2).  
 
Figure 7.2. ROC curves showing the ability of miR-155 and miR-184 to diagnose TI. 
The red line shows an AUC of 0.5. The black line tracks the performance of the 
predictor as the discrimination threshold varies. Sensitivity is plotted on the Y-axis and 
1-Specificity is plotted on the X-axis. 
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7.3 Summary 
 
miR-147b and miR-1285 were upregulated in individuals with TSI and not in TS alone 
[12], which perhaps explains why they were poor classifiers of TS. This remains true 
even when cases were defined as individuals with TS and TSI, as the TSI group was 
much smaller than the TS group. These individuals already had established scarring 
however. Given that inflammation is a major risk factor for scarring progression [15], 
miR-147b and miR-1285 may be better able to classify individuals at risk of progressive 
scarring at an earlier stage of disease. miR-184 and miR-155 in combination were 
good classifiers of TI, however the number of individuals with TI in this ‘training’ cohort 
was small (n=28). The expression of miR-155, miR-184, miR-147b and miR-1285 will 
be quantified in a longitudinal cohort of 506 Tanzanian individuals with progressive 
scarring trachoma. Individuals were aged between 6 and 10 at the time of enrollment 
and were assessed quarterly over the course of four years. The ability of miR-155, 
miR-184, miR-147b and miR-1285 to classify individuals with progressive scarring 
relative to non-progressors will be investigated in this cohort, which is also large 
enough to split into training and testing datasets for appropriate validation. In addition 
to qualifying the use of these miR as biomarkers of progressive scarring, the results will 
further our understanding of the role of these miR in chlamydial disease.  
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Chapter 8: Induction of inflammation 
and EMT in Chlamydia trachomatis 
infected HEp-2 epithelial cells 
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8.1 Introduction  
 
Epithelial cells are thought to play a large role in the immunopathology of chlamydial 
pathogenesis [1]. Epithelial cells infected with Ct in vitro produce a number of pro-
inflammatory cytokines (IL-6, IL-8, IL-11, IL-18, IL-1 and granulocyte-macrophage 
colony-stimulating factor (GM-CSF)), chemokines (CXCL1, CXCL2, CXCL3) and 
growth factors such as fibroblast growth factor (FGF) [2–5]. Genes involved in cell 
growth, differentiation, immune suppression and apoptosis have also been shown to be 
expressed [3]. Pro-inflammatory factors were expressed throughout the developmental 
cycle of Ct (2-4 days) and required bacterial protein synthesis [2]. More recent 
evidence in a polarized endocervix-derived epithelial cell model showed that IL-1, 
which is thought to amplify the pro-inflammatory response [2], was not expressed until 
72 hours post infection (hpi) with Ct [5]. Interestingly, IL-1ra (IL-1 receptor antagonist) 
was constitutively expressed from the apical membrane in both Ct infected and mock-
infected cells, whereas Ct-induced IL-11 expression was localized to the basolateral 
membrane. In contrast to earlier reports, protein levels of IL-8 and IL-6 were not 
different between infected and mock-infected cells at any timepoint throughout the 
developmental cycle, up to 120 hours [5]. What is more, Ct infection suppressed the 
constitutive expression of T-cell chemokines [5]. This immune evasion strategy 
presumably protects Ct and promotes growth, possibly increasing pathology long term 
by preventing prompt clearance of infection and promoting low levels of chronic 
inflammation. This study ([5]) also highlights the differences in host response to Ct 
infection between different cell lines and culture conditions. The role of epithelial cells 
in the immunopathology of chlamydial disease is further supported by studies carried 
out in individuals with TF, TS and TT. Expression of a number of pro-inflammatory 
mediators (IL17A, IL1B, CXCL5, S100A7 (psoriasin), growth factors (CTGF (connective 
tissue growth factor)) and matrix metalloproteinases (MMP7, MMP9) were upregulated 
in TF/TI, TS and TT [6–10]. In TS and TT this occurred even in the absence of 
detectable Ct infection [6,7,9,8]. Immunohistochemistry (IHC) studies using tissue from 
a small number of individuals with TF/TI previously found that CTGF, IL-1 and IL-1β 
were increased in the conjunctival epithelium [11,12]. 
 
EMT-2 (EMT) is the process by which an epithelial cell differentiates into a 
mesenchymal cell upon chronic inflammatory stimulation. Cells undergoing EMT lose 
their apical-basal polarity, degrade the basement membrane and migrate into the 
subepithelial layer where they can contribute to fibrosis [13]. Pro-inflammatory 
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cytokines, growth factors and MMPs have been shown to stimulate EMT in vivo and in 
vitro [14–16]. Phenotypic changes related to EMT have previously been observed in 
response to Ct infection. In Ct infected epithelial cells the N-cadherin/β-catenin 
complex (a key structural component of adherens junctions) was broken down and β-
catenin was recruited to the chlamydial inclusion, associated with a loss of cell-cell 
adhesion and cell polarity [17,18]. β-catenin is also a Wnt signaling transducer and the 
paracrine Wnt pathway was activated in Ct infected ex vivo fallopian tube tissue [18]. 
The Wnt pathway has also been shown to stimulate EMT [19], including in response to 
viral and intracellular bacterial infections [20,21]. A role for the Wnt pathway in 
trachomatous pathogenesis has also been hinted at in several clinical studies through 
pathway analysis of transcriptional data [22–24]. It is therefore plausible that Ct-
induced epithelial inflammation stimulates EMT, which subsequently contributes to the 
fibrotic pathology associated with chlamydial disease. 
 
Ct has a 7.5Kb plasmid which was found to be maintained in clinical ocular strains at a 
median copy number of 5.34 (range 1-18) [25]. Variation in plasmid copy number has 
been observed and genital strains are thought to have a slightly lower plasmid:genome 
ratio with a mean around 4 [26]. The chlamydial plasmid has been shown in ocular 
non-human primate (NHP) and murine genital model systems to be a virulence factor 
[27–29]. A plasmid-free Ct serovar F strain in a urogenital murine model had reduced 
infectivity and virulence relative to a plasmid-competent isogenic strain [27]. Plasmid-
free Ct serotype A and L strains had identical growth kinetics to their plasmid-
competent counterparts in vitro, however, virulence in vivo was reduced [28,29]. The 
impact of the Ct plasmid on virulence appears to be binary, as plasmid copy number 
did not associate with Ct load, papillary hypertrophy or lar score [25]. Plasmid-free Ct 
did not induce inflammatory pathology in an ocular NHP model [29] and plasmid-free 
C. muridarum (Cm) failed to induce inflammatory pathology in a murine genital tract 
model and did not stimulate TLR2-dependent cytokine production [30]. In contrast to 
plasmid-competent Cm, plasmid-free Cm did not induce IL-8 expression in two 
epithelial cell lines and this was associated with a reduction in neutrophil infiltration into 
the murine genital tract [30]. IL-8 is chemotactic for neutrophils, the presence of which 
has been directly correlated with the degree of oviduct pathology in Cm infected mice 
[31]. This implies a model whereby IL-8 expression is increased following TLR2-
mediated recognition of the chlamydial plasmid, leading to neutrophil infiltration and 
pathology. The plasmid is not a virulence factor however in a murine C. psittaci 
intraperitoneal infection model and in a C. caviae urogenital infection model in guinea 
pigs [32,33]. A recent study examined the impact of the Ct plasmid in a NHP urogenital 
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model for the first time and found that, in contrast to the ocular Ct NHP model and 
murine Ct and Cm urogenital models, Ct serovar D plasmid-free and plasmid-
competent strains had equal infectivity and induced equal pathology [34]. This might 
suggest that the impact of the Ct/Cm plasmid varies depending on the chlamydial 
strains, animal model and anatomical sites under investigation. 
 
Recently a gene expression microarray analysis was performed in an epithelial cell line 
(HeLa) infected with a serovar A strain of Ct (A2497) and the plasmid-cured isogenic 
counterpart (A2497P-) [3]. These strains differed in virulence in the ocular NHP model 
[29]. Gene expression was assessed at 30 minutes, 2, 4, 24, 48 and 72 hours post 
infection (hpi). Relative to uninfected cells, differences in gene expression were not 
detected until 24 hpi, where more genes were differentially expressed (DE) in A2497 
infected cells relative to A2497P-. The total number of DE genes was highest at 72 hpi 
and was comparable between A2497 and A2497P-. Differences in DE genes between 
A2497 and A2497P- were greatest at 48 hpi, with higher expression in A2497 infected 
cells of CSF2 (GM-CSF), CXCL1/2/3, IL1A, IL6 and IL8 [3]. Overall fold changes and 
differences between A2497 and A2497P- were modest. 
 
Infected epithelial cells clearly play an important role in orchestrating the immune 
response to Ct. The Ct plasmid appears to affect the magnitude of this response, 
resulting in increased pathology at the infection site with potential implications for later 
scarring sequelae. The aim of the work presented in this chapter was to investigate the 
induction of inflammation in Ct infected epithelial cells and to ascertain whether this 
stimulated EMT. The production of pro-inflammatory mediators, growth factors and 
EMT biomarkers was assessed by gene expression analysis in epithelial cells infected 
with plasmid-competent and plasmid-free strains of Ct, in order to understand the 
contribution of the plasmid to EMT induction. Motility of infected cells was measured 
using a scratch wound assay. If induction of EMT was detected, the aim was then to 
test for epigenetic changes and differences in specific protein expression. Due to the 
failure to achieve productive growth of Ct in a conjunctival epithelial cell line, 
experiments were performed in HEp-2 (HeLa) cells.  
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8.2 Methods 
 
In vitro culture and Ct infection of human epithelial cell lines  
 
Human epithelial type 2 (HEp-2) cells were cultured in Minimum Essential Medium 
(MEM) (Gibco, Life Technologies) supplemented with 1% gentamicin (Gibco), 10% 
fetal bovine serum (FBS) (Gibco), and 1% L-glutamine (Gibco). For in vitro 
experiments, cells were seeded in 12 well plates at 3x105 cells per well in MEM.  
 
HEp-2 were infected with 3 different ocular-derived serovar A Ct strains: A2497 
(described in [35]), the plasmid cured counterpart (A2497P-) [29] and A/HAR-13 [35]. 
Cells were infected 24 hours after seeding at a multiplicity of infection (MOI) of 1 and 
without the addition of cycloheximide. EMT positive control cells were treated with 10 
mg/ml TGFβ2 and 10 mg/ml EGF (Peprotech) 24 hours after seeding. Ct infected cells, 
TGFβ2 & EGF treated cells and mock-infected cells were centrifuged at 1800 r.p.m. 
(750g) for 1 hr to facilitate infection and were incubated at 37°C in 5% CO2. Six 
replicates were carried out for each biological condition. At 48 hours post-infection 
(hpi), media was removed and cells were washed in 1X phosphate-buffered saline 
(PBS) (Sigma). Three hundred microliters of lysis buffer (Norgen Biotek, Thorold, ON, 
Canada) was added to each well and cells were harvested by scraping. Total RNA and 
DNA were extracted using the Norgen RNA and DNA purification kit according to the 
manufacturers instructions. Total RNA was quantified using Qubit® fluorometric 
quantitation (Life Technologies).  
 
Confocal microscopy and ddPCR were performed as described previously (Chapter 4).  
 
Scratch wound assay 
 
HEp-2 cells were seeded in 12 well plates at 1x105 cells per well in MEM [with 
supplements]. Cells were infected 24 hours after seeding with A2497 and A2497P- (as 
described above) at an MOI of 0.5. Positive control wells were treated with 10 mg/ml 
TGFβ2 and 10 mg/ml EGF and negative control wells received fresh media alone. 
Triplicate wells were performed for each condition. Twenty-four hours after infection or 
addition of TGFβ2 & EGF cells were scratched down the center of the well using a 20µl 
pipette tip. Media was not changed and cells were not washed. Three marks were 
made on the underside of each well along the length of the scratch using permanent 
marker. A photograph was taken of the scratch on the microscope in exactly the same 
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position at 0, 24 and 48 hours post scratch. Photographs were taken using an 
OptixCam Summit OCS-10.0X 10MP camera on a Nikon inverted microscope under 
4/0.10 objective. Photographs were viewed in OCView software (v1.1). The area of the 
scratch wound on each image was measured in ImageJ 
(http://rsb.info.nih.gov/ij/index.html) using the polygon selection tool to outline the 
leading edge of the monolayer and obtain the area of the scratch. The rate of wound 
closure was calculated using the equation [(Tn/T0)*100] to express wound area at 
each timepoint (Tn) as a percentage of the area at timepoint zero (T0).  
Quantitative polymerase chain reaction (qPCR) 
 
Total RNA was reverse transcribed using MiScript RTII kits with the HiFlex buffer 
(Qiagen) to make a cDNA library. qPCR was performed on total RNA extracted from 
infected, TGFβ2 & EGF treated and mock-infected HEp-2 cells. Primers were designed 
using NCBI gene data (http://www.ncbi.nlm.nih.gov/gene/), Primer3 
(http://primer3.wi.mit.edu) and SIM4 (http://pbil.univ-
lyon1.fr/members/duret/cours/inserm210604/exercise4/sim4.html) software. All primers 
were designed in a standard way for this study and sequences are shown in Table 8.1. 
Primers were mRNA specific such that the primer sequences either crossed an intron-
intron boundary or if that was not possible the DNA amplicon size was deemed too 
large for amplification using Power SYBR master mix. Ten µl cDNA was diluted in 
100µl dH2O for use in qPCR. Primer efficacy was tested and qPCR was optimized 
using HEp-2 cell cDNA on an HT7900 thermal cycler (Thermo Fisher Scientific) with 
Power SYBR Green PCR master mix (Thermo Fisher Scientific). Cycling conditions 
were 10 minutes at 95°C followed by 40 cycles of 15 seconds at 95°C and 1 minute at 
60°C. An initial dissociation curve was included to evaluate primer performance and 
ensure specificity.  
 
Statistical analysis 
 
Data were analysed in R (www.R-project.org). Fold difference in cycle threshold values 
were calculated using the 2(-Delta Delta CT) method [36], normalizing to the reference 
ribosomal gene RPLP0. If data were normally distributed, assessed by using a Shapiro 
Wilk test for normality, differential expression between infections and mock-infected 
cells were tested using a students t -test. Wilcoxon signed ranks test was used where 
data were not normally distributed. P values were adjusted for false discovery rate 
according to Benjamini-Hochberg [37].  
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Table 8.1. Primers sequences used for qPCR 
Target name (Gene 
symbol) 
Forward primer Reverse primer 
Product 
size  
Endogenous control: 
RPLP0 ATCTGCTTGGAGCCCACAT GCGACCTGGAAGTCCAACTA 101 
EMT biomarkers: 
E-cadherin (CDH1) TATTCCTCCCATCAGCTGCC AGCGTGAGAGAAGAGAGTGT 232 
αSMA (ACTA2) CGGGACTAAGACGGGAATCC TCACCCACGTAGCTGTCTTT 211 
SNAIL (SNAI1) GTGGTTCTTCTGCGCTACTG TGCTGGAAGGTAAACTCTGGA 153 
Fibronectin (FN1) TGGGTGACACTTATGAGCGT TCAAAACACTTCTCAGCTATGGG 241 
SLUG (SNAI2) CGAACTGGACACACATACAGT GAGGTGTCAGATGGAGGAGG 225 
N-cadherin (CDH2) TGTTTGACTATGAAGGCAGTGG TCAGTCATCACCTCCACCAT 152 
TWIST (TWIST1) AGGGCCGGAGACCTAGATG CACGCCCTGTTTCTTTGAAT 152 
FSP-1 (S100A4) CGTGTTGATCCTGACTGCTG GCTGTCCAAGTTGCTCATCA 214 
Vimentin (VIM) GATGCCCTTAAAGGAACCAA AGGCGGCCAATAGTGTCTT 104 
ZO-1 (TJP1) AAGAGAAAGGTGAAACACTGCTGA GGAAGACACTTGTTTTGCCAGGT 127 
Inflammatory genes: 
IL-1β (IL1B) CCTGAAGCCCTTGCTGTAGT AGCTGATGGCCCTAAACAGA 112 
S100A7 (S100A7) TCTTGTCATCACGTCTGGTGT CTACTCGTGACGCTTCCCA 121 
IL-1 (IL1A) CTTAGTGCCGTGAGTTTCCC TGTGACTGCCCAAGATGAAG 118 
CXCL1 (CXCL1) CTTCCTCCTCCCTTCTGGTC CCAAACCGAAGTCATAGCCA 133 
GM-CSF (CSF2) GTCTCACTCCTGGACTGGCT ACTACAAGCAGCACTGCCCT 140 
CTGF (CTGF) TGGAGATTTTGGGAGTACGG TACCAATGACAACGCCTCCT 128 
IL-6 (IL6) CTGCAGCCACTGGTTCTGT CCAGAGCTGTGCAGATGAGT 143 
IL-8 (IL8) AGCACTCCTTGGCAAAACTG CAAGAGCCAGGAAGAAACCA 137 
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8.3 Results 
 
8.3.1 Ct growth in HEp-2 cells 
 
HEp-2c cells infected with A2497 and A2497P- achieved comparable yields at 48 
hours post infection (hpi), measured by omcB load and by observation of chlamydial 
inclusions (Figures 4.1 and 4.2 (Chapter 4)). Plasmid DNA was not detected in DNA 
extracted from plasmid-free cultures by ddPCR (data not shown). A/HAR-13 did not 
achieve a comparable yield and was excluded from further qPCR analysis.  
 
8.3.2 Inflammatory gene expression in Ct infected HEp-2 cells 
  
The expression of a number of pro-inflammatory cytokines (IL-1, IL-1β, IL-6, GM-
CSF), chemokines (CXCL1, IL-8), the anti-microbial peptide S100A7 and CTGF was 
quantified in HEp-2 cells infected with A2497 and A2497P- at 48 hpi. These targets 
were chosen based on their roles from the literature on Ct infection models and in 
various stages of trachoma.  
 
CTGF, CXCL1, IL1A, IL6 and IL8 were upregulated in A2497 and A2497P- infected 
HEp-2 cells relative to mock-infected cells (Figure 8.1, Table 8.2). CTGF, CXCL1 and 
IL6 expression were greater in A2497 infected cells compared to A2497P- infected 
cells. The results of differential gene expression analysis are shown in Table 8.2. 
S100A7 expression in infected cells was comparable to mock-infected cells and CSF2 
was slightly downregulated relative to mock-infected cells. IL1B had a mean cycle 
threshold value >35 for each of the conditions tested therefore it was excluded from the 
analysis.  
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Table 8.2. Differential expression of inflammatory genes in A2497P- and A2497 
infected HEp-2 cells relative to uninfected cells, ordered by Padj. 
 
A2497P- A2497 
Target Padj FC Padj FC 
CTGF 0.096 1.76 0.015 1.91 
IL6 0.059 2.19 0.015 3.12 
CXCL1 0.143 2.20 0.024 2.73 
IL8 0.085 2.17 0.146 2.07 
IL1A 0.189 3.70 0.126 4.05 
S100A7 0.881 1.29 1.000 1.34 
CSF2 0.654 0.65 0.758 0.90 
FC: Fold change 
 
 
Figure 8.1. Gene expression of pro-inflammatory mediators and growth factors in HEp-
2 cells infected with A2497 and A2497P- at 48 hpi. The log(10) fold change is shown 
relative to target expression in mock-infected cells. The dotted line represents a fold 
change of one, equivalent to no change in expression. Boxplots show the median (thick 
red horizontal line), the interquartile range (solid black or grey box) and the minimum 
and maximum values (dotted lines) of the six replicates for each target and infection. 
Grey: A2497P-, Black: A2497.  
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8.3.3 EMT biomarker expression in Ct infected HEp-2 cells 
 
HEp-2 cells were treated with TGFβ2 and EGF in order to stimulate the induction of 
EMT [38]. Mesenchymal cell markers Fibronectin (FN1), N-cadherin (CDH2), Vimentin 
(VIM), αSMA (ACTA2), FSP-1 (S100A4), epithelial cell marker ZO-1 (TJP1) and EMT 
transcription factors TWIST (TWIST1), SLUG (SNAI2) and SNAIL (SNAI1) were tested 
in HEp-2 cells by qPCR every 24 hours for 5 days to detect those which were 
characteristic of EMT in this in vitro model. CDH2, VIM and FN1 were upregulated in 
the in vitro model with expression peaking at 48 hours post stimulation (data not 
shown). Cells appeared more fibroblastic and motile compared to untreated epithelial 
cells, which had a pavement-like morphology (Figure 8.2A and B). These changes 
were evident as early as 17 hours post stimulation (data not shown). SNAI1 was 
slightly upregulated and S100A4, ACTA2, TJP1, TWIST1 and SNAI2 were not 
differentially expressed in this positive control model.  
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Figure 8.2. Morphology of cells undergoing EMT and Ct infected HEp-2 cells. At 120 
hours post stimulation, untreated cells (A) have epithelial pavement-like morphology 
whereas TGFβ2 and EGF treated cells (B) have acquired and maintained a fibroblastic 
phenotype. At 48 hours post infection, A2497P- (C) and A2497 infected cells (D) 
appear to maintain epithelial morphology. Images (A) and (B) were taken of live cells in 
areas of sub-confluence to show cell morphology more clearly. Images (C) and (D) are 
phase images derived from confocal microscopy of infected cells. Cells were near 
confluent therefore it was more difficult to observe cell morphology, however, A2497 
infected cells (D) did not appear to be migrating into the space. Images (C) and (D) 
were taken at 40X magnification. 
 
Expression of VIM, CDH2 and FN1 was quantified in A2497 and A2497P- infected, 
TGFβ2 and EGF treated and mock-infected HEp-2 cells at 48 hours post infection or 
stimulation (Figure 8.3). In TGFβ2 and EGF treated cells FN1 (Padj = 0.00045, FC = 
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16.64), CDH2 (Padj = 0.016, FC = 3.9) and VIM (Padj = 0.034, FC = 8.8) were 
significantly upregulated relative to untreated cells. A2497 and A2497P- infected cells 
did not differentially express EMT biomarkers in this in vitro model at 48 hpi. FN1 was 
slightly upregulated in A2497P- infected cells but the difference was not significant (Padj 
= 0.283, FC = 2.02). Infected cells at 48 hpi appeared to have epithelial pavement type 
morphology, however, this was difficult to assess as cells were near confluent and 
images were taken at an earlier timepoint than positive control images (Figure 8.2).  
 
Figure 8.3. Expression of EMT biomarkers in Ct infected and TGFβ2 & EGF treated 
HEp-2 cells at 48 hpi. The log(10) fold change is shown relative to target expression in 
mock-infected cells. The dotted line represents a fold change of one, equivalent to no 
change in expression. Boxplots show the median (thick black horizontal line), the 
interquartile range (solid coloured box) and the minimum and maximum values (dotted 
line or circles) of the six replicates for each target and condition. Red: A2497P-, Yellow: 
A2497, Blue: TGFβ2 & EGF.  
 
8.3.4 Cell motility in Ct infected HEp-2 cells 
 
Increased motility and migration is a hallmark of cells undergoing EMT and these can 
be measured a using scratch wound assay [39]. The motility of HEp-2 cells infected 
with A2497 and A2497P- was measured by scratching the monolayer of infected cells 
at 24 hpi and recording the rate of wound closure. TGFβ2 and EGF treated cells closed 
 174 
the wound significantly faster than untreated cells at 24 (Padj = 1.32*10-15) and 48 (Padj 
= 2.26*10-12) hours post scratch (Figure 8.4). Cells infected with A2497 and A2497P- 
had equal rates of wound closure to untreated cells at 24 (A2497P- Padj = 0.35; A2497 
Padj = 0.086) and 48 (A2497P- Padj = 0.61; A2497 Padj = 0.35) hours post scratch (72 
hours post infection).  
 
 
Figure 8.4. Speed of wound closure in A2497 and A2497P- infected, TGFβ2 & EGF 
treated and uninfected/untreated HEp-2 cells. Cells were scratched 24 hours post 
infection/treatment and the area of the wound was measured in ImageJ at 0, 24 and 48 
hours post scratch. The remaining area at each time point is expressed as a 
percentage of the wound area at 0 hours. Three measurements were made per well of 
three replicate wells per experiment. The results of three experiments are shown. 
Boxplots show the median (thick black horizontal line), the interquartile range (solid 
coloured box) and the minimum and maximum values (dotted line or circles). Red: 
A2497P-, Yellow: A2497, Blue: Media (untreated), Pink: TGFβ2 & EGF.  
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8.4 Discussion 
 
A modest induction of inflammatory cytokines was observed upon infection of HEp-2 
cells with A2497 and A2497P-. Infected cells upregulated expression of IL1A, IL6, IL8, 
CXCL1 and CTGF. CTGF, CXCL1 and IL6 were significantly upregulated in response 
to A2497 and expression levels were greater in response to A2497 relative to A2497P-. 
S100A7 and CSF2 were not differentially expressed in response to infection and IL1B 
was expressed at very low levels overall. Optimization of an in vitro model of EMT in 
HEp-2 cells revealed that FN1, VIM and CDH2 were upregulated, with expression 
peaking at 48 hours post stimulation. Despite the induction of inflammatory stimuli and 
CTGF in A2497 and A2497P- infected HEp-2 cells, EMT was not detected by qPCR at 
48 hpi and cell motility was equal to uninfected cells at 72 hpi.  
 
The significant upregulation of IL6 and CXCL1 and the (non-significant) upregulation of 
IL8 and IL1A in Ct infected epithelial cells was concordant with the results of other 
studies [2–5]. IL-8 and CXCL1 are chemoattractant to neutrophils, which kill infected 
cells and bacteria at the infection site but can also cause collateral tissue damage [31]. 
IL-6 and IL-1α initiate fever, amplify pro-inflammatory responses and stimulate 
production of acute phase proteins and neutrophils in the bone marrow. IL6, CXCL1 
and CTGF expression was highest in response to A2497, despite comparable Ct 
genome copy numbers in both infections. Porcella et al., reported increased expression 
of IL6, CXCL1 and IL8 in response to A2497 relative to A2497P- infected cells [3], 
however in contrast to this and other reports [30] no difference was observed in IL8 
expression between A2497 and A2497P- infected cells in this study. Surprisingly, 
CSF2 was not upregulated in HEp-2 cells in response to A2497 or A2497P-. Porcella 
et al., reported that CSF2 was upregulated in HeLa cells infected with A2497 and 
A2497P- at 72 hpi but there was minimal difference in gene expression relative to 
mock-infected cells at 48 hpi [3], supporting this result. IL1B was expressed at very low 
levels. IL-1β is translated into an inactive protein and is cleaved into the active form by 
activated caspase 1; therefore transcription levels may not accurately represent levels 
of active protein. This could be assessed using ELISA, immunocytochemistry or 
immunohistochemistry (performed on TT biopsy tissue in Chapter 11 (not in response 
to Ct)). S100A7 is an antimicrobial peptide that is upregulated in the conjunctiva of 
individuals with TF/TI, TS and TT [6,8–10]. S100A7 expression was induced in 
progesterone-primed endometrial cells in response to Ct [40], however no difference in 
expression was identified in this study, or by Porcella et al., [3]. These differences 
could be due to the cell lines and stimuli used. CTGF has not previously been reported 
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to be upregulated in response to Ct infection of epithelial cells, however it was 
upregulated in TF/TI, TS and TT [8,32,34, chapter 10]. CTGF can directly induce 
fibrosis and EMT [15,41,42] and its upregulation has been reported in epithelial cells in 
response to other bacteria [43]. The finding that CTGF expression is upregulated in 
response to A2497 and A2497P- could provide a possible direct mechanism for Ct 
induced fibrosis and could contribute to early stage scarring in individuals with TF/TI.  
 
EMT can be induced directly in response to pathogen virulence factors (within 24 
hours) [21,44], or as a result of pathogen-induced inflammation [14,45]. The 48 hpi 
timepoint was used to assess EMT biomarker expression in this study as it was the 
point at which up-regulation of EMT biomarkers in the in vitro positive control model 
and reported transcriptional differences between A2497 and A2497P- were greatest 
[3]. This therefore offered the best chance to detect differences in response to the two 
strains. It is possible that this timepoint was too early for EMT to develop in vitro in 
response to Ct, although there were no differences in cell motility relative to uninfected 
cells at 72 hpi. CDH2, VIM and FN1 were not differentially expressed in A2497 or 
A2497P- infected HeLa cells at any of the timepoints studied by Porcella et al., up to 72 
hpi [3]. There was also no consistent decrease in CDH1 (E-cadherin) expression [3], 
which is considered to be an early sign of EMT induction [46]. Transepithelial electrical 
resistance (TEER) can be used to measure epithelial tight junction integrity and a 
reduction in TEER occurs during EMT [47]. A slight decrease in TEER was detected 
between 0 and 4 days post infection of a polarized endocervical epithelial cell model 
with Ct serovar D, however the decrease was not significant and the TEER 
measurement remained above the threshold for a polarized epithelium [5,48]. In 
contrast to this result, CDH1 and occludin localization were disrupted in ex vivo 
fallopian tube tissue 48 hours post infection with Ct serovar D, reflecting a loss of cell-
cell adhesion and polarity [18]. These differences could relate to the cellular milieu of 
the infected cells; it is possible that factors and signals from other cell types may be 
required to stimulate EMT in response to Ct infection. In an analysis of miRNA 
expression in the conjunctiva of individuals with TF and current Ct infection versus 
healthy controls (Chapter 5, supplementary information (DEseq analysis)), miR-204-5p 
(Padj = 0.018, FC = 0.13), miR-200b-3p (Padj = 0.078, FC = 0.39) and miR-429 (Padj = 
0.04, FC = 0.36) were among the top 26 most significantly differentially regulated 
miRNA out of the 860 miRNA detected. Down-regulation of these miRNA stimulates 
EMT induction [49,50]. The data also hinted at activation of the Wnt pathway through 
downregulation of miR-184 [51] (Chapter 5). The expression of EMT biomarkers and 
members of the Wnt pathway could be investigated further using RNA from individuals 
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with TF/TI and current Ct infection in order to determine whether a combination of cell 
types and inflammatory signals, combined with prolonged Ct infections in vivo, are 
required to stimulate EMT.  
 
Despite the induction of inflammation in Ct infected HEp-2 cells, EMT was not detected 
by expression of EMT biomarkers or changes in cell motility. This data and that of 
others [3,5] suggest that EMT is not directly stimulated by Ct or Ct-induced 
inflammation at early timepoints post-infection of epithelial cells in vitro. It does not rule 
out however that EMT might occur in response to Ct in vivo. Future in vitro work should 
assess the induction of EMT in polarized ocular epithelial/fibroblast co-culture systems 
or in an engineered conjunctiva (epithelial cells-collagen basement membrane-stromal 
cells [52]) that includes inflammatory cell stimuli or in ex vivo tissue [53] and at later 
timepoints post infection, to better mimic the in vivo inflammatory environment during 
active trachoma. 
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9.1 Introduction 
 
Gene expression studies performed using conjunctival swab samples from many 
different clinical stages of trachoma have revealed a number of genes that are 
consistently differentially expressed. These include pro-inflammatory cytokines and 
chemokines (IL17A, IL1B, CXCL5), antimicrobial peptides (S100A7), growth factors 
(CTGF), matrix metalloproteinases (MMP7, MMP9), which were upregulated in TF/TI, 
TS and TT [1–5]. Expression changes were generally higher when TI was also present 
[2–5]. In individuals with TS or TT, Ct infection was very rarely detected [3–6].  
 
Many of the cytokines differentially expressed in trachoma are indicative of an active 
pro-inflammatory epithelium, supporting the cellular model of chlamydial pathogenesis 
[7]. However, this is also likely to reflect the large number of epithelial cells collected by 
a swab sample. Two studies that performed flow cytometry on cells collected from the 
tarsal conjunctiva of healthy donors by brush cytology showed that 67.9% and >95% 
cells were of epithelial origin [8,9]. In both studies ~4% intra-epithelial lymphocytes 
were detected. Expression patterns of epithelial-derived cytokines and factors are 
crucial for determining the role of the epithelium in the pathogenesis of chlamydial 
disease, as a pro-inflammatory epithelium is likely to drive fibrotic changes in the 
underlying stroma [7], where scarring occurs. However, by collecting swab samples 
from the tarsal conjunctiva, the behavior and expression patterns of the cells in the 
underlying stroma remain relatively hidden.  
 
There have been a number of IHC studies performed using tissue from individuals with 
TF/TI [10–14], TS and TT [15–17]. In tissue from normal conjunctiva, collagen types I 
and III were limited to the substantia propria and collagen type V was absent, whereas 
in TF/TI and TS increased collagen type IV was detected in the thickened basement 
membrane and new collagen type V was deposited in the upper substantia propria 
[13,15]. Collagen types I and III were increased amongst epithelial cells in TF/TI and 
were reduced in TS [15]. Increased overall numbers of inflammatory cells were 
detected in TF/TI and TS [11,14,16,17]. In TF/TI, CTGF, basic fibroblast growth factor 
(bFGF), platelet derived growth factor (PDGF), MMP9, IL-1α, IL-1β and TNFα were 
upregulated in monocytes/macrophages infiltrating the substantia propria [10–12]. 
Vascular epithelial growth factor (VEGF) was upregulated in vascular and epithelial 
cells, increased tenascin (extracellular matrix glycoprotein) was noted in the upper 
substantia propria and angiogenesis was more apparent [12]. MMP9 was upregulated 
in intravascular polymorphonuclear cells and increased IL-1α and IL-1β were present in 
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the conjunctival epithelium [10,11]. The expression of cytokines and growth factors was 
only assessed in individuals with TF/TI and the number of cases and controls used in 
these studies was small (<10 of each group) [10–12]. More recent work using in vivo 
confocal microscopy (IVCM) and IHC in TS has revealed enhanced inflammatory cell 
infiltrates in the upper substantia propria, the presence of ‘dendritiform’ cells (which fail 
to stain with the CD83 dendritic cell marker) and connective tissue arranged into 
discrete bands or sheets [18–20]. The cellular localization of inflammatory cytokines 
and growth factors in TS has not yet been addressed.  
 
9.2 Biopsy sample processing, IHC staining optimization and grading 
 
The aim of the study described in Chapter 10 was to characterize the expression of 
EMT biomarkers and targets that were consistently upregulated in trachoma gene 
expression studies at the protein level, and to identify their cellular localization in TS 
and TT. Biopsy samples were collected from Tanzanian individuals with TT whilst 
undergoing tarsal rotation surgery and from controls undergoing ocular surgery for 
alternative reasons such as cataract or retinal detachment (and who otherwise had 
healthy conjunctivae). Biopsy samples were formalin fixed and paraffin embedded 
(FFPE) in Tanzania and brought to London for processing. FFPE samples can be 
stored indefinitely at room temperature, however formalin fixation can denature 
proteins through the cross-linking process. Antigen retrieval via heating or enzymatic 
digestion of the sample is often required to re-expose the antigen for the antibody to 
bind. For each antibody used in this study, a range of dilutions and retrieval methods 
were first tested on positive control tissue (any available human tissue that expressed 
the antigen) in order to find the most specific staining pattern. Example images of 
positive staining in TT or control conjunctival tissue, for each antibody, after 
optimization of individual dilution and retrieval protocols (listed in Chapter 10), are 
shown in Figure 9.1. MMP7 was not detected in any of the 36 conjunctival samples.    
 
Despite reasonable numbers of TT cases (n=20) and controls (n=16) in the study, a 
limitation was that the biopsy tissue samples were extremely small and did not all 
contain the same tissue components. For example, some sections did not contain 
epithelium and others had very little stroma. Only 1/36 samples had enough tissue 
present to see the “T-sign” of collagen deposition described in sections of conjunctival 
tissue [18]. Another limitation of the small tissue size was that as few as 20-25 4μm 
sections could be cut from some samples. For the MMP7 antibody the staining pattern 
in the positive control tissue was limited to secretions in the lumen of kidney tubules; 
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no positive staining was detected in any of the other tissues tested (tonsil, appendix, 
liver, colon, kidney, pancreas and prostate cancer). A broader staining pattern might 
have been expected however and this could reflect poor antibody sensitivity or 
inaccessibility of the epitope due to protein folding or denaturation. The lack of any 
MMP7 staining in TT cases and controls (Chapter 10) might therefore be misleading 
and requires confirmation with a different antibody. Very few clinical samples stained 
positive for IL-6 (2/36) and IL-17A (5/36) and those that were positive had a diffuse 
blush in the epithelium (Figure 9.1). IL-17A is produced by activated T cells (amongst 
other innate immune cells; neutrophils, macrophages, NK cells and γδ T cells) and in 
the positive control (colon tissue) staining was limited to individual immune cells that 
had infiltrated the epithelium (Figure 9.2). Although epithelial cells secrete IL-6, the 
staining pattern in the positive control was also more specific (Figure 9.3). The staining 
pattern of IL-17A and IL-6 in clinical samples therefore appears to be non-specific and 
is perhaps an artifact.  
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Figure 9.1. Examples of positive staining (pink) in TT case or control conjunctival tissue 
for each antibody. Images were taken at 200X original magnification. 
  
 
Figure 9.2. IL-17A staining (brown) in a section of human colon. Image was taken at 
200X original magnification. 
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Figure 9.3. IL-6 staining (pink) in a section of human appendix. Image was taken at 
200X original magnification. 
 
De-waxing, antigen retrieval and IHC staining were automated on a Leica BOND 
instrument. This was done to improve staining accuracy and efficiency; a total of 36 
samples were stained with 15 antibodies, plus optimization and control slides (around 
700 slides in total). Positive and negative control sections were performed for each 
antibody on each run. Despite the automated process there was occasionally some 
variation in staining intensity, due to errors in the machines protocol (due to performing 
up to 30 separate protocols simultaneously) or to fresh antibody dilutions. These 
staining variations were likely reduced by automation however, relative to processing 
this number of samples by hand. Positive control slides and sections were stored in 
runs, such that when masked grading was performed the grader could ‘normalize’ 
grading of staining intensity to that of the positive control section for each batch. Due to 
the size of the sections some lifted off the slide or folded slightly and stained more 
intensely or non-specifically as a result. There was not sufficient biopsy material to 
repeat all sections that had lifted slightly or where there was some background, 
therefore the experience and discretion of the grader was crucial. Due to these 
limitations and those described above relating to the size and composition of each 
specimen, it was not practical to grade these samples using an automated grading 
system [21]. Samples were graded by a single masked grader using the systems 
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described below (Table 9.1).  Antibody staining in each section was graded separately 
for the epithelial and subepithelial compartments. EMT biomarkers (Vimentin, E-
cadherin and αSMA) were scored in the epithelial compartment only in order to detect 
epithelial cells acquiring a mesenchymal phenotype.  
 
A limitation of IHC is the inability to perform multiplex staining. Double staining is 
possible by using red and brown dyes, however it is often technically difficult; the 
staining procedure is performed for each dye sequentially on a single slide, so the two 
antibodies should require the same antigen retrieval methods for optimal staining. Due 
to this complexity double staining was not performed in the current study. This was a 
disadvantage; the ability to identify cells undergoing EMT would be greatly enhanced 
by double staining for E-cadherin and Vimentin for example, enabling the grader to 
identify transitioning cells. It was therefore not possible to phenotype the cells 
producing the cytokines and growth factors of interest. This could be performed using 
flow cytometry, however it would then not be possible to identify tissue localization of 
expression. Another study was conducted in parallel with this one, which investigated 
the phenotypes of immune cells infiltrating the conjunctiva during trichiasis (staining for 
CD3 (T cells), CD4 (helper T cells), CD8 (cytotoxic T cells and NK cells), NCR1 (NK 
cells), CD20 (B cells), CD45 (nucleated hematopoietic cells), CD56 (T and NK cells), 
CD68 (macrophages/monocytes) and CD83 (mature dendritic cells)). The biopsy 
samples used in both studies were collected as part of an ongoing study at Kilimanjaro 
Christian Medical Centre, Tanzania. The results of both studies in combination, 
although limited by the lack of multiplex staining, will increase our understanding of the 
phenotypes of immune cells infiltrating the conjunctiva and the distribution of cytokines, 
chemokines and growth factors in trichiasis tissue.  
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Table 9.1. Systems for grading Hematoxylin & eosin and IHC staining patterns in 
conjunctival biopsy tissue. 
 Grade 
0 1 2 3 
Hematoxylin & eosin 
Epithelial atrophy No atrophy Minor atrophy Moderate atrophy Severe atrophy 
Inflammatory cells, 
Myofibroblasts  
No visible 
staining 
Few cells Moderate number of cells Abundant cells 
Fibrosis pattern 
(polarised light): 
Block, Wavy, Fine 
None Focal patches Abundant areas Extensive 
Immunohistochemistry 
Subepithelial compartment 
IL-6, IL-1β, IL-17A, IL-
22, CXCL5, S100A7, 
CC1, PDGF, CTGF, 
TGFβ2, MMP7, MMP9 
No visible 
staining 
Few cells Moderate number of cells Abundant cells 
Epithelial compartment    
IL-6, IL-1β, IL-17A, IL-
22, CXCL5, S100A7, 
CC1, PDGF, CTGF, 
TGFβ2, MMP7, MMP9,  
Vimentin, αSMA 
No visible 
staining 
Few cells Moderate number of cells Abundant cells 
E-cadherin* 0-25%  26-50%  51-75%  76-100%  
* The percentage of the epithelium that stained positive for E-cadherin was graded 
quarterly on a scale of 1-4 (rather than 0-3).  
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Abstract 
 
Purpose: To characterize the histological appearance and expression of pro-
inflammatory mediators, growth factors, matrix metalloproteinases and biomarkers of 
epithelial-mesenchymal transition (EMT) in healthy control and trachomatous trichiasis 
(TT) conjunctival tissue.  
 
Methods: Conjunctival biopsies were taken from 20 individuals with TT and from 16 
individuals with healthy conjunctiva, which served as controls. Study participants were 
of varying ethnicity and were living in a trachoma-endemic region of northern Tanzania. 
Formalin-fixed paraffin-embedded tissue sections were stained using hematoxylin and 
eosin or by immunohistochemistry using antibodies against: IL-1β, IL-6, IL-17A, IL-22, 
CXCL5, S100A7, cleaved caspase 1 (CC1), PDGF, CTGF, TGFβ2, MMP7, MMP9, E-
cadherin, vimentin, and αSMA.  
 
Results: Tissue from TT cases had a greater inflammatory cell infiltrate relative to 
controls and greater disruption of collagen structure. CTGF and S100A7 were more 
highly expressed in the epithelium and IL-1β was more highly expressed in the 
substantia propria of TT cases relative to controls. Latent TGFβ2 was slightly more 
abundant in the substantia propria of control tissue. No differences were detected 
between TT cases and controls in the degree of epithelial atrophy, the number of 
myofibroblasts or expression of EMT biomarkers.  
 
Conclusions: These data indicate that the innate immune system is active in the 
immunopathology of trachoma, even in the absence of clinical inflammation. CTGF 
might provide a direct link between inflammation and fibrosis and could be a suitable 
target for therapeutic treatment to halt the progression of trachomatous scarring.    
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Author summary 
 
Progressive scarring of the conjunctiva in individuals with trachoma causes the eyelids 
to contract, drawing the eyelashes inwards (trichiasis) so that they scratch the cornea, 
causing pain and eventually blindness. Disease is initiated in childhood by repeated 
conjunctival infection with Chlamydia trachomatis (Ct), however, infection is not 
commonly found in adults, yet chronic inflammation and fibrosis progress throughout 
the lives of many individuals. A better understanding of the mechanisms driving 
inflammation and fibrosis are required in order to develop treatments to halt disease 
progression. The tissue expression and localization of a number of pro-inflammatory 
cytokines, growth and matrix factors were investigated in eyelid tissue from 20 
individuals with trichiasis and from 16 control individuals. By staining tissue sections 
with dyes and specific antibodies, pro-inflammatory signaling molecules IL-1β and 
S100A7 and pro-fibrotic growth factor CTGF were found to be more highly expressed 
in individuals with trichiasis. CTGF and S100A7 were highly expressed in the 
epithelium; the outermost layer of the conjunctiva, whereas IL-1β was more highly 
expressed deeper in the tissue, where scarring occurs. Numerous inflammatory cells 
were found in the tissue of trichiasis patients even in the absence of clinically apparent 
inflammation. Future research should seek to describe a causative mechanism linking 
these factors. 
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Introduction 
 
Trachoma is a blinding disease initiated by infection of the conjunctival epithelium with 
the intracellular bacterium Chlamydia trachomatis (Ct). Individuals living in trachoma-
endemic communities are repeatedly infected with Ct, which causes a follicular 
conjunctivitis. Chronic, recurrent inflammation, even in the absence of detectable Ct 
infection, is associated with progressive scarring [1]. The fibrotic response results in 
the inward turning of the lid margin (entropion) and abrasion of the cornea by the 
eyelashes (trichiasis). Mechanical damage to the cornea and subsequent opportunistic 
infections eventually lead to corneal opacity and blindness.  
 
Trachoma is endemic in 51 countries and impairs the eyesight of 2.2 million people 
worldwide, 1.2 million of whom are irreversibly blind [2]. Although trachoma control 
programs have made good progress in reducing active disease, there is now some 
evidence that established scarring disease continues to progress even when 
chlamydial infection appears well controlled [1]. Therefore, a large number of people 
remain at risk of developing incident trichiasis, especially in areas where mass drug 
administration has had a partial effect [3,4]. In order to develop a vaccine or 
therapeutic treatments to prevent the progression to trichiasis, a better understanding 
of the immunopathology of scarring trachoma is required. 
 
A number of clinical studies have shown that transcriptional signatures in trachomatous 
scarring (TS) and trichiasis (TT) are consistent with a pro-inflammatory epithelial 
response and tissue remodeling, supporting the cellular paradigm of chlamydial 
disease pathogenesis [5]. The gene expression of a number of pro-inflammatory 
mediators (IL17A, IL1B, CXCL5, S100A7 (psoriasin), growth factors (CTGF (connective 
tissue growth factor)) and matrix metalloproteinases (MMP7, MMP9) were up-regulated 
in TS and TT [1,6–9]. Expression was increased further when clinical inflammation was 
present [1,6,7]. Immunohistochemistry (IHC) studies using tissue from a small number 
of individuals with active trachoma have shown that MMP9, CTGF, platelet derived 
growth factor (PDGF) and IL-1β were up-regulated in infiltrating 
monocytes/macrophages and that IL-1β was increased in the conjunctival epithelium 
[10–12].  
 
Inflammatory mediators, growth factors and MMPs can stimulate epithelial cells to 
differentiate into pro-fibrotic mesenchymal cells, a process known as epithelial-
mesenchymal transition (EMT) [13–15]. Epithelial cells undergoing EMT lose 
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expression of E-cadherin and gain mesenchymal ‘expression’ markers vimentin and α-
smooth muscle actin (αSMA) as they migrate through the basement membrane into the 
stroma, where they contribute to fibrosis [16]. Inflammation-induced EMT normally 
ceases when inflammation resolves; therefore EMT only becomes pathological in an 
environment of chronic inflammation. The evidence of chronic pro-inflammatory 
cytokine and growth factor expression in various stages of trachoma combined with a 
fibrotic tissue response suggests that EMT may contribute to the pathology of 
trachoma. 
 
The aim of this IHC study of trachomatous conjunctival tissue was to investigate the 
relative protein level and tissue localization of pro-inflammatory mediators, growth 
factors, EMT biomarkers and MMPs and to characterize the changes in tissue 
architecture that occur in TT. Molecular markers studied include factors that were 
previously shown to be up-regulated in TS/TT (S100A7, IL-1β, IL-17A, CXCL5, CTGF, 
MMP7/9), EMT biomarkers (αSMA, vimentin, E-cadherin) and other factors that may 
play a role in immunopathology (IL-6 (pleiotropic pro-inflammatory cytokine), IL-22 
(mucosal defense and epithelial integrity), PDGF, transforming growth factor beta 2 
(TGFβ2) (both growth factors associated with fibrosis), and cleaved Caspase 1 (CC1), 
a marker of inflammasome activation).  
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Methods 
 
Ethical permission 
 
This study adhered to the tenets of the Declaration of Helsinki and was approved by 
the London School of Hygiene and Tropical Medicine Ethics Committee, the Tanzanian 
National Institute of Medical Research Ethics Committee and the Kilimanjaro Christian 
Medical Centre Ethics Committee. Written, informed consent was obtained from 
individuals before enrollment in the study. 
 
Clinical assessment and biopsy sampling  
 
Study participants were examined using a bright torch and x2.5 loupes. The clinical 
phenotype of individuals for follicles, papillary inflammation and trichiasis was graded 
using the World Health Organization 1981 FPC trachoma grading system [17]. 
Conjunctival scarring was graded in finer detail using the system described by Hu et al 
[18]. Biopsy samples were collected from individuals undergoing bilamellar tarsal 
rotation surgery for TT (cases) and from individuals without clinical evidence of 
trachoma undergoing cataract surgery (controls), matched by age and sex where 
possible. The eyelid was anaesthetized with an injection of 2% lignocaine (Vital 
Healthcare, Mumbai, India) and the eye was cleaned with 5% povidone iodine. Biopsy 
samples were taken from the upper tarsal conjunctiva using a 3mm trephine: 2mm 
from the lid margin at the junction of the medial ⅔ and lateral ⅓ of the everted lid. 
Samples were fixed in 10% neutral buffered formalin and subsequently embedded in 
paraffin wax.  
 
Staining 
 
Formalin-fixed paraffin-embedded (FFPE) samples were cut perpendicular to the 
conjunctival surface in 4µm thick sections. Sections were stained with hematoxylin and 
eosin (H&E) for examination of tissue health and composition. Sections for IHC 
staining were dewaxed and stained with antibodies for pro-inflammatory cytokines and 
chemokines (IL-6, IL-1β, IL-17A, IL-22, CXCL5), antimicrobial peptide psoriasin 
(S100A7), cleaved caspase 1 (CC1), growth factors (PDGF, CTGF, TGFβ2), matrix 
metalloproteinases (MMP7, MMP9) and biomarkers of EMT (E-cadherin, vimentin, 
αSMA). Antibodies and retrieval methods used are listed in Table S10.1. IHC staining 
was automated and performed using Novocastra Bond Polymer Refine Red Detection 
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reagents on a Leica BOND instrument (Leica Biosystems, Milton Keynes, UK). 
Sections were covered with a cover-slip for microscopic examination.  
  
H&E grading protocol 
 
Tissue sections were graded by an ophthalmic pathologist masked to the clinical status 
of the samples. Where more than one H&E section was available for a sample the slide 
with the most tissue was analyzed. H&E slides were graded on a scale of 0 to 3 for the 
degree of epithelial atrophy (where 0 is none and 3 is severe atrophy), the number of 
inflammatory cells present and the number of myofibroblasts present (0= no visible 
staining, 1= few cells, 2= moderate number of cells and 3= abundant cells). H&E 
sections were viewed under cross-polarized light in order to view collagen fiber 
deposition and grade fibrosis. Fibrotic scarring was graded for 3 patterns, ‘block’, 
‘wavy’ and ‘fine’, each on a scale of 0 to 3: 0=none seen, 1=focal patches, 2=abundant 
areas and 3=extensive. 
 
IHC grading protocol 
 
Antibodies were graded according to strength and location of staining. For each 
antibody the section was graded separately for the epithelial and the subepithelial 
compartments. The subepithelial compartment (substantia propria) contained the 
stroma and inflammatory cell infiltrate if present. Antibody staining was recorded on a 
scale of: 0=no visible staining, 1= few cells, 2= moderate number of cells and 3= 
abundant cells. For the antibodies targeting E-Cadherin, vimentin and αSMA staining 
was recorded in the epithelial compartment only. For E-cadherin, the total area of the 
epithelium that stained positive was recorded in quartiles: 0-25% = 1, 26-50% = 2, 51-
75% = 3 and 76-100% = 4.  
 
Data analysis 
 
Data were analysed in R (https://www.r-project.org). Fishers Exact Tests were used to 
test for differences between case-control status and: age (categorized by decade), sex, 
ethnic group, H&E and IHC scores. IHC targets were excluded from the analysis where 
≤2/36 sections had a grade >0. Radial plots were generated by calculating the average 
score per person for TT cases and controls for each antibody or H&E feature. 
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Results 
 
Sample phenotypes 
 
Thirty-six conjunctival biopsy specimens were collected from 20 individuals with TT 
(cases) and 16 individuals with no clinical signs of trachoma (controls). The 
demographic and clinical phenotypes of individuals whose samples were used in this 
study are described in Table 10.1. There was no significant difference in sex (P=0.31) 
or age (P=0.074) between cases and controls. There was a significant difference in 
ethnic groups between cases and controls (p<0.0001); 18/20 cases were of the Massai 
ethnic group whereas only one control subject was Massai. No follicles were detected 
in cases or controls. One TT case had a papillary inflammation grade of 3, equivalent 
to trachomatous inflammation – intense using the simplified grading system [19]. All 
cases had varied degrees of conjunctival scarring. None of the controls had papillary 
inflammation, scarring or trichiasis (Table 10.1). 
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Table 10.1. Demographic and clinical characteristics of samples 
Variable 
Cases Controls 
N = 20 N = 16 
Gender, male (%)  7 (35%) 9 (56%) 
   Age, mean in years (range) 74.6 (41-91) 70.3 (50-83) 
   Ethnic group 
  
 
Massai 18 1 
 
Chagga 2 7 
 
Other 0 8 
 
 
  Scarring grade 
  
 
0 0 16 
 
S1b 4 0 
 
S1c 8 0 
 
S2 3 0 
 
3 5 0 
 
 
  Papillary Inflammation grade 
  
 
0 9 16 
 
1 8 0 
 
2 2 0 
 
3 1 0 
 
 
  Trichiasis Grade 
  
 
0 2 16 
 
1 1 0 
 
2 9 0 
 
3 8 0 
Footnote: 2 TT cases that scored 0 for trichiasis grade had marked entropion and had 
epilated lashes. 
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Tissue morphology 
 
H & E staining was used to visualize tissue structure and prevalence of inflammatory 
cells in sections. There was no difference in the degree of epithelial atrophy or in the 
number of myofibroblasts between cases and controls (Table 10.2). There were 
significantly more inflammatory cells evident in cases (P=0.001). Three patterns of 
subepithelial tissue deposition became apparent when sections were viewed under 
cross-polarized light: “block”, “wavy” and “fine”. Representative photographs of these 
phenotypes are shown in Figure S10.1. Tissue from cases had significantly more wavy 
(P=0.0075) and fine patterns (P=0.0005) of subepithelial tissue deposition, whereas 
individuals with healthy conjunctiva had more block type patterns (P = 0.0005), Table 
10.2 and Figure 10.1.   
 
 
Table 10.2. Sample characteristics by Hematoxylin and Eosin staining 
 
Cases Controls P value* 
Epithelial Atrophy 
  
0.65 
 
0 6 7 
 
 
1 7 3 
 
 
2 5 4 
 
 
3 1 0 
 
 
NA† 1 2 
 
 
 
   Inflammatory cell infiltrate 
 
0.0025 
 
0 0 1 
 
 
1 7 13 
 
 
2 12 1 
 
 
3 1 1 
 
 
 
   Myofibroblasts 
  
1 
 
0 2 2 
 
 
1 8 7 
 
 
2 8 6 
 
 
NA† 2 1 
 
 
 
   Fibrosis: Block pattern 
 
0.0005 
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0 5 0 
 
 
1 11 1 
 
 
2 3 4 
 
 
3 1 11 
 
 
 
   Fibrosis: Wavy pattern 
 
0.0075 
 
0 6 13 
 
 
1 10 3 
 
 
2 4 0 
 
 
 
   Fibrosis: Fine pattern 
 
0.0005 
 
0 0 9 
 
 
1 15 6 
 
 
2 5 1 
 * Fishers exact test was used to test for differences between groups.  
† Sections received “NA” when there was not enough tissue present to grade a 
parameter and were not included in the significance calculation. 
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Figure 10.1. Radial plots summarizing overall changes in tissue morphology and 
expression of molecular markers. Molecular marker expression was quantified by IHC 
in the epithelial and subepithelial compartments. The average score per person for TT 
cases (blue) and controls (red) was plotted for each target or H&E feature.  
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Distribution and localization of molecular markers in conjunctival tissue 
 
The relative expression of the different molecular markers detected by IHC in the 
epithelial and subepithelial compartments were analysed by case-control status and 
the results are shown in Table 10.3. The average IHC score per person for TT cases 
and controls for each molecular marker is also represented in Figure 10.1. Staining 
was generally highest in the epithelium of TT cases. CTGF, IL-1β and CC1 had greater 
average expression in TT cases in both epithelial and subepithelial compartments.  
 
Table 10.3.  Expression of specific molecular markers in the epithelial and subepithelial 
compartments by IHC.  
 
  Epithelial Compartment Subepithelial Compartment 
Category Target 
Cases 
(N=20) 
Controls 
(N=16) 
P* 
Cases 
(N=20) 
Controls 
(N=16) 
P* 
Pro-
inflammatory 
mediators 
IL-1β  
    
0.312 
  
0.012 
  0 9 9   11 14   
  1 1 3   1 2   
  2 8 4   7 0   
  3 2 0   1 0   
  IL-17A     1 
  
NA 
  0 17 14   20 16   
  1 2 1   0 0   
  2 1 1   0 0   
  3 0 0   0 0   
  CXCL5      0.241 
  
NA 
  0 14 14   20 16   
  1 4 0   0 0   
  2 2 2   0 0   
  3 0 0   0 0   
  S100A7     0.009 
  
NA 
  0 11 16   20 16   
  1 5 0   0 0   
  2 1 0   0 0   
  3 3 0   0 0   
  IL-22      0.280 
  
0.806 
  0 9 11   16 14   
  1 9 3   1 1   
  2 2 2   3 1   
  3 0 0   0 0   
  IL-6     NA 
  
NA 
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  0 19 15   20 16   
  1 1 1   0 0   
  2 0 0   0 0   
  3 0 0   0 0   
Inflammasome CC1      0.213     0.197 
  0 9 12   11 14   
  1 4 3   5 1   
  2 4 1   2 1   
  3 3 0   2 0   
Growth 
Factors 
PDGF  
    
0.689 
  
0.541 
  0 12 7   15 12   
  1 4 4   3 3   
  2 4 4   2 0   
  3 0 1   0 1   
  TGFβ2     0.359 
  
0.037 
  0 13 7   19 12   
  1 1 4   0 4   
  2 4 4   0 0   
  3 2 1   1 0   
  CTGF     0.008 
  
0.099 
  0 2 10   5 7   
  1 6 2   8 5   
  2 11 3   2 4   
  3 1 1   5 0   
Matrix  MMP9      0.263     0.556 
  0 11 8   15 10   
  1 3 0   2 1   
  2 6 7   3 5   
  3 0 1   0 0   
  MMP7     NA 
  
NA 
  0 18 16   20 14   
  1 2 0   0 2   
  2 0 0   0 0   
  3 0 0   0 0   
EMT  
E-
Cadherin      
0.314 
     0 1 0   
     1 0 3   
     2 2 2   
     3 3 1   
     4 14 10   
     Vimentin      0.180 
     0 0 3   
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  1 7 5   
     2 8 7   
     3 5 1   
     αSMA      1 
     0 12 11   
     1 1 0   
     2 5 4   
     3 2 1   
   * Fishers exact test was used to test for differences between groups. To account for 
the burden of repeated statistical tests applied, critical p-value thresholds of (0.05/13) 
<0.004 for the epithelial compartment and  (0.05/7) <0.007 in the subepithelial 
compartment would be required.  
 
CTGF expression was greater in the epithelium of TT cases relative to controls (P = 
0.0085). Of the samples that scored >0 for CTGF, 10/23 had a clinical papillary 
inflammation grade >0. Epithelial expression of CTGF was localized in 14/24 of the 
samples that stained positive. In 4/24 CTGF positive samples (two cases, two controls) 
expression was more concentrated in the deep epithelium (Figure 10.2A). CTGF 
expression was slightly greater in the subepithelial tissue of cases but the difference 
was not significant. 
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Figure 10.2. Example images of IHC staining. CTGF in the deep epithelium of TT 
cases (A) and controls (B), IL-1β in TT cases (C) and controls (D), S100A7 in a 
pseudogland of Henle of a TT case (E) and S100A7 staining in controls (F) and TGFβ2 
staining in TT cases (G) and in controls (H). Images were taken at 200x original 
magnification. 
 
 213 
 
Significantly more expression of IL-1β was detected in the subepithelial tissue of TT 
cases relative to controls (P = 0.012). IL-1β expression was localized around the 
inflammatory cell infiltrate (Figure 10.2C), however, only 5/11 of samples that stained 
>0 for IL-1β had a clinical papillary grade >0. Expression of IL-1β tended to be higher in 
the epithelium of TT cases but the difference was not statistically significant. 
 
S100A7 expression was significantly higher in the epithelium of TT cases (P = 0.0095). 
Expression of S100A7 within the epithelium was patchy and in 2 samples expression 
was localized to pseudoglands of Henle (Figure 10.2E). All controls stained negative 
for S100A7. Six of the nine samples that scored >0 for S100A7 had a clinical papillary 
grade >0. S100A7 was not detected in the subepithelial tissue in any sample.  
 
TGFβ2 expression was slightly greater in the subepithelial tissue of controls (P = 
0.037). Four controls were weakly positive (Figure 10.2H) and one case (papillary 
grade 3) had stronger expression of TGFβ2 in the subepithelial tissue. For the 
remaining 31 samples TGFβ2 was not detected in the subepithelial tissue. Epithelial 
expression of TGFβ2 was not different between cases and controls. 
 
There were no statistical differences in the expression of EMT biomarkers E-cadherin, 
vimentin and αSMA in the epithelium between cases and controls. There were also no 
statistical differences between cases and controls in epithelial or subepithelial tissue 
expression of CC1, MMP9, PDGF, IL-17A, IL-22 and CXCL5 (Table 10.3). IL-17A and 
CXCL5 were not detected in the subepithelial tissue in any samples. IL-6 and MMP7 
were detected in ≤2 of the 36 samples tested.  
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Discussion 
 
In this study we found that conjunctival tissue of TT cases had significantly greater 
S100A7 and CTGF expression in the epithelium and significantly greater IL-1β 
expression in the subepithelial tissue. The average expression of CTGF, IL-1β and 
CC1 was greater in TT cases in both epithelial and subepithelial compartments. 
Controls tended to have more expression of TGFβ2 in the subepithelial tissue. We did 
not detect an increase in the expression of EMT biomarkers in the epithelium of 
samples from individuals with TT. We found that individuals with TT had different 
patterns of collagen deposition and an increased inflammatory cell infiltrate in the 
subepithelial compartment relative to individuals without clinical evidence of trachoma.  
 
In this study the age distribution of cases and controls was comparable. There were 
more females among the TT cases, however, this was not a statistically significant. 
There were substantially more Maasai people among the cases. This probably reflects 
greater environmental and behavioral risk factors [20,21]. Maasai people live in close 
contact with their livestock (flies are often abundant) and in areas with fairly limited 
access to water. Furthermore the uptake of antibiotics for trachoma control may be 
lower in these communities [22]. Although genetic risk factors in Maasai people cannot 
be excluded, the behavioral and environmental risk factors leading to increased 
exposure to C. trachomatis infection probably account for the higher proportion of 
Maasai among TT cases.  
 
Changes in tissue morphology were clearly evident with a transition from a “block” type 
pattern of collagen deposition in controls to “wavy” and “fine” type patterns in cases. 
This probably reflects the progressive disruption of normal connective tissue. 
Degradation of organized bundles of collagen fibers running parallel with the epithelium 
(“block” type) by MMPs or oedema could create the fragmented “wavy” and “fine” 
patterns observed. A similar observation has previously been shown in the 
subepithelial tissue of individuals with scarring trachoma and was found to correlate 
with tissue scarring determined by in vivo confocal microscopy (IVCM) [23]. There is an 
apparent mismatch in the features of TS when tissue is observed by the 2 different 
methods; using IVCM, defined bands of scarring were observed, whereas by histology 
collagen bundles appear fragmented and amorphous. It is possible that the bands of 
scarring (observed by IVCM in 3 dimensions) disrupt the parallel collagen bundles 
(seen on a section in 2 dimensions) to produce wavy and fine patterns of collagen in 
cases. It was not possible to grade fibrosis in subepithelial tissue with the same 
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grading system described in Hu et al [23] as tissue sections were not sufficient in size. 
The baseline “T” collagen structure indicative of healthy tissue in controls was visible 
only in one control section.  
 
More inflammatory cells were identified in tissue from TT cases. This result is in 
keeping with the range of clinical inflammatory grades observed in cases, whereas all 
controls had a clinical inflammation grade of 0. It is perhaps surprising that epithelial 
atrophy, thought to be a common feature of scarring trachoma, and the number of 
myofibroblasts were not different between cases and controls. Epithelial atrophy has 
been reported in two studies that used samples from 11 and 29 individuals with TT and 
entropion, however neither study included controls [24,25]. The same two studies also 
reported epithelial hyperplasia and psuedogland formation [24,25]. Persistent and 
recurrent conjunctival inflammation and associated hyperplasia are thought to promote 
the formation of pseudoglands of Henle, which are crypts formed by invagination of the 
epithelium [26]. Bacteria and debris can become trapped by mucus within these crypts 
and entrapped secretions within pseudoglands were observed in individuals with TT 
[24,26]. Myofibroblasts have contractile properties therefore one might speculate that 
they have an increased role during TS and TT. In line with our observations we did not 
detect any significant differences in the epithelial expression of the EMT biomarkers 
vimentin, αSMA or E-cadherin between cases and controls, although vimentin 
expression was slightly increased in TT cases. The number of samples in this study 
was relatively small and there was only one sample from an individual with 
trachomatous inflammation – intense, therefore it is possible we did not have sufficient 
power within the study to detect subtle, transient or rare events. We only graded loss of 
E-cadherin and gain of vimentin and αSMA expression in the epithelium, as it would 
not be possible to distinguish cells expressing vimentin and αSMA in the subepithelial 
tissue from normal fibroblasts/myofibroblasts. Future work such as multiplex staining or 
application of new techniques such as laser ablation mass cytometry are required to 
distinguish complex cell phenotypes and rare events such as cells undergoing EMT 
[27]. 
 
IHC staining was generally greater in the epithelial compartment relative to the 
subepithelial compartment. CC1, CTGF and IL-1β were increased in both epithelial and 
subepithelial compartments in TT cases (Figure 1) and S100A7 was increased in the 
epithelium. CC1 cleaves IL-1β into its active form and the concomitant upregulation of 
CC1 and IL-1β reflects activation of the inflammasome [28]. In the subepithelial tissue 
of TT cases IL-1β was localized around the inflammatory cell infiltrate. Just over half of 
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the samples that stained positive for IL-1β in the subepithelial tissue had no evidence 
of clinical inflammation; therefore considerable levels of IL-1β were expressed in the 
absence of clinical signs. Recent evidence showed that IL-1β expression was weakly 
associated with progressive scarring trachoma and strongly associated with 
inflammatory episodes [1]. It is possible that IL-1β remains up-regulated in the 
subepithelial tissue in individuals without evidence of clinical inflammation, as this 
study might suggest, but that cytokines expressed in the subepithelial tissue are less 
readily detected when samples are collected using a superficial conjunctival swab. 
Chronic IL-1 induced inflammation is known to result in tissue remodeling [29,30]. 
  
CTGF modulates the interaction of cells with the extracellular matrix; promoting 
collagen deposition, mesenchymal cell activation and differentiation (including EMT) 
and tissue remodeling [14,31]. CTGF was previously shown by IHC to be upregulated 
in infiltrating monocytes/macrophages of children with active trachoma [12], however 
we demonstrate an upregulation of CTGF in both the subepithelium and epithelium of 
TT cases. This difference could reflect the different clinical stages of trachoma in the 
samples studied. TGFβ induces CTGF expression in fibroblasts and epithelial cells 
therefore it is surprising that we did not see a concomitant up-regulation of TGFβ in TT 
cases alongside CTGF [32–34]. A number of bacteria have been shown to stimulate 
CTGF expression in epithelial cells via the lysophosphatidic acid receptor [35], 
therefore it is possible that CTGF is directly induced in the epithelium by the altered 
ocular microbiota observed in individuals with trachoma [18,36]. Over-expression of 
CTGF drives fibrosis in a number of diseases [32,37,38] and it has become apparent 
that epithelial-derived CTGF can drive fibrosis in the underlying subepithelial tissue 
[34,39]. CTGF was detected in the basal epithelium in four samples (Figure 2A). CTGF 
staining in the basal epithelium has previously been reported in the context of gingival 
fibrosis, where it was thought to have a role in cell proliferation and epithelial 
hyperplasia [40]. This could drive the formation of pseudoglands in addition to driving 
fibrosis in the underlying tissue. CTGF was strongly associated with clinical 
inflammation in adults with progressive scarring trachoma [1], however in the present 
study CTGF did not appear to be preferentially detected in adults with evidence of 
clinical inflammation.  
 
S100A7 is a pro-inflammatory antimicrobial peptide secreted by epithelial cells. 
S100A7 was only detected in the epithelium of TT cases in this study and expression 
was generally patchy, possibly suggesting a localized antimicrobial response. In 
addition to direct antibacterial action, S100A7 recruits CD4+ T cells and neutrophils 
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and amplifies pro-inflammatory cytokine responses [41–43]. In two samples staining 
was detected around pseudoglands of Henle, possibly reflecting a local inflammatory 
response to bacteria that had accumulated within the pseudogland. Positive staining of 
the epithelium around these pseudoglands was also noted for IL-1β in 4 TT cases. No 
positive staining was detected around pseudoglands in control tissue for any of the 
antibodies tested. Due to the small size of the tissue sections it was not possible to 
compare the number of pseudoglands between cases and controls. Further study is 
required to identify whether trachomatous inflammation promotes pseudogland 
formation and whether bacteria trapped within pseudoglands have a role in 
exacerbating inflammation.  
 
Latent TGFβ2, PDGF and MMP9 expression tended to be slightly higher in controls. 
TGFβ2 expression in controls was relatively weak and non-specific therefore could be 
attributed to a high background. The antibody used detected the latent form of TGFβ2, 
therefore it is possible that more latent TGFβ2 was present in controls whereas cases 
had activated and released TGFβ2. Despite having a well-defined role in tissue 
fibrosis, no previous associations have been found between TGFβ2 and trachoma at 
both expression and protein levels (Holland, Mabey and Bailey; personal 
communication) [44]. Full characterization of the role of TGFβ2 in trachoma has been 
limited due to its complex post-translational modifications.  
 
IL-17A, CXCL5, PDGF, MMP7 and MMP9 have previously been associated with 
various stages of trachoma (trachomatous inflammation – follicular [10,11,44,45], TS 
[1,6,7] and TT [8,9]) at mRNA and protein expression levels, however they were not 
demonstrably up-regulated in TT cases in the present study. MMP7, CXCL5 and IL-
17A were strongly associated with inflammatory episodes but not with progressive 
scarring in two large cohorts of individuals with trachoma [1]. The failure to detect 
differences in staining in this study could be due to the lack of clinical inflammation in 
the individuals from whom samples were obtained, or due to a lack of study power to 
detect more subtle differences. It could also be biological and might suggest that 
differences at the expression level are not maintained at the protein level. The failure to 
detect MMP7 and IL-6 could likewise be due to a lack of clinical inflammation, a lack of 
expression or due to the sensitivity of the antibodies used. IL-22 is released alongside 
IL-17 by Th17 cells and contributes to mucosal defense and maintenance of epithelial 
integrity but also to the pathogenesis of psoriasis [46,47]. Although IL-22 has not 
previously been associated with trachoma we hypothesized it might have a role in 
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conjunctival epithelial inflammation or health [48], however no differences in expression 
were detected.  
 
We did not to collect swabs for C. trachomatis PCR because the swabbing process 
would have probably altered the surface tissue appearance. However, from 
contemporary studies it is known that the prevalence of C. trachomatis infection in this 
region among individuals with trachomatous scarring is very low, and therefore it is 
likely that few if any of these case would have been infected [1]. Similarly, it was not 
possible to collect conjunctival swab samples for mRNA gene expression analysis from 
these individuals as this would have affected the histological analysis. Our previous 
gene expression work used mRNA collected from surface swabs. Therefore, we would 
not necessarily expect these to exactly correspond to this immunohistochemistry study, 
which is assessing protein mostly in deeper levels. 
 
We have demonstrated that individuals with TT had significantly increased levels of 
CTGF and S100A7 in the epithelium and IL-1β in the subepithelial tissue, even in the 
absence of marked clinical inflammation. CTGF, IL-1β and CC1 were increased in TT 
cases in both epithelial and subepithelial compartments. We suggest that microbial 
stimulation of the epithelium, ongoing sub-clinical inflammation and inflammasome 
activation in the connective tissue and CTGF-driven fibrosis contribute to the pathology 
of trachoma. We also described a potential role for pseudoglands of Henle in trachoma 
that warrants further investigation. CTGF could be responsible for driving inflammation-
induced fibrosis in trachoma, making it a potential therapeutic target [49]. Future 
research should focus on the stimuli that lead to up-regulation of CTGF, S100A7 and 
IL-1β and potential inhibitors that could halt the progression of scarring.  
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Supporting information 
 
Table S10.1. Antibodies and retrieval methods used in this study 
Category Target Dilution Retrieval Supplier Antibody 
Pro-inflammatory 
mediators IL-1β  1:75 H2*(20)‡ ABCAM AB2105 
 
IL-6  1:400 NR§ LEICA NCL-L-IL6 
 
IL-17A  1:350 H1†(30) ABCAM AB136668 
 
CXCL5  1:200 H2(20) ABCAM AB9802 
 
S100A7  1:400 H1(10) ABCAM AB13680 
 
IL-22  1:100 H2(20) ABCAM AB18499 
      Growth Factors PDGF 1:200 H2(20) ABCAM AB178409 
 
TGFβ2  1:100 H1(20) ABCAM AB36495 
 
CTGF  1:300 H1(10) ABCAM AB6992 
      EMT E-cadherin 1:200 H2(20) DAKO NCH-38 
 
Vimentin  1:3000 H2(20) DAKO M0725 
 
αSMA  1:500 NR DAKO M0851 
      Matrix MMP7 1:50 H2(20) ABCAM AB4044 
 
MMP9  1:200 H2(20) LEICA 
NCL-MMP9-
439 
      Inflammasome CC1 1:50  H2(20) ABCAM AB1872 
      
*H2 = Bond (Leica) epitope retrieval solution 2; pH9 EDTA based buffer and surfactant 
at 25°C. 
‡(10) = 10 minutes; (20) = 20 minutes; (30) = 30 minutes. 
§NR = no retrieval.  
†H1 = Bond (Leica) epitope retrieval solution 1; pH6 citrate based buffer and surfactant 
at 25°C.  
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Figure S10.1. Cross-polarized light images of haemotoxylin and eosin stained tissue 
sections. Example images representative of “block” (A), “wavy” (B) and “fine” (C) 
patterns of fibrosis are shown. Images were taken at 200X original magnification. 
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11.1 Overall conclusions 
 
Data from transcriptomic studies in active and scarring trachoma have shown that 
many thousands of genes were differentially regulated [1,2]. In order to reduce some of 
this complexity and to find key pathways that were dysregulated in different stages of 
trachomatous disease, miR expression was investigated (chapter 3; chaper 6 [3,4]). 
miR were not differentially regulated in response to Ct infection in epithelial cells in 
vitro. In vivo, miR-155 and miR-184 were dysregulated in TF and were strongly 
associated with TI. Dysregulation of miR-155 and miR-184 in TF and TI likely reflects 
the activation and increased presence of immune cells in the epithelium, regulation of 
inflammation and epithelial wound healing, possibly including prolonged activation of 
cell proliferation and pro-fibrotic pathways [5–8]. miR-1285 and miR-147b were 
upregulated in individuals with TSI but not in individuals with TS alone. Upregulation of 
miR-147b and miR-1285 in TSI alludes to the regulation of cell proliferation pathways 
and inflammation [9–11]. Regulation of the immune cell inflammatory response 
appears to be a key process in both stages of disease, which perhaps explains why no 
differences were seen in miR expression in Ct infected epithelial cells in vitro. These 
data suggest that miR expression in TF, TI and TSI is indicative of the host’s attempts 
to control clinical inflammation, which is a major risk factor for scarring progression 
[12]. 
 
Ct infected epithelial cells in vitro upregulated expression a number of pro-inflammatory 
cytokines and the growth factor CTGF and expression was slightly greater in response 
to plasmid-competent Ct (Chapter 8). This supports the data of others [13] and could 
explain why pathology is more severe in some animal models in response to plasmid-
competent Ct [14–16]. Ct infection is rarely found in adults with established scarring 
disease however, yet inflammation and fibrosis continues [12]. The factors driving this 
pathological inflammation in the absence of Ct infection remain unclear. Non-
chlamydial bacteria are thought to have a role in driving inflammation and disease in 
the absence of Ct (reviewed in [17]) however mechanistic links have not yet been 
identified and it is unclear whether the differential species diversity detected in 
trachoma is causal or an effect of the altered physiological environment. It seems 
reasonable to speculate that repeated bouts of Ct-induced inflammation and the 
associated wound healing response throughout childhood alters or damages the 
architecture of the conjunctiva, such that it is more susceptible to inflammation 
throughout adulthood in response to stimuli (e.g. dust, commensal bacteria) that might 
be innocuous in an individual with an uncompromised conjunctiva. It is also possible 
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that individuals who resolve inflammation quickly are at lower risk of these changes 
and later scarring complications. Squamous metaplasia, loss of goblet cells and 
epithelial atrophy have previously been observed in histology samples from individuals 
with TS and TT, supporting this hypothesis [18,19]. No differences in epithelial atrophy 
were detected however between TT cases and controls in more recent studies with 
larger sample sizes (Chapter 10; Victor Hu, manuscript in preparation), perhaps 
indicating that this dogma should be readdressed.  
 
Conjunctival tissue from individuals with TT had increased expression of CTGF, IL-1β 
and S100A7 and expression of IL-1β and S100A7 was often located around 
Pseudoglands of Henle (Chapter 10). Epithelial hyperplasia has been observed in 
individuals with TF/TI [20], which could be driven by upregulation of the Wnt pathway, 
mediated by downregulation of miR-184 (chapter 6), and by the upregulation of CTGF 
(Chapters 8 and 10). In some TT cases CTGF expression was highest in the basal 
epithelium, which has previously been reported in the context of gingival fibrosis 
(associated with epithelial hyperplasia) and in corneal scarring following injury [21,22]. 
This could lead to epithelial invagination and the development of pseudoglands that 
become blocked with debris, bacteria and mucus. An increased presence of 
psuedoglands containing entrapped secretions, as has been previously noted in 
individuals with TT [19,18], might promote localized inflammatory responses that 
further drive fibrosis and hyperplasia. This could also be supported by the upregulation 
of miR-1285 in TSI (related to cell proliferation). These results and hypotheses are 
outlined in a graphical summary (Figure 11.1). In vivo confocal microscopy (IVCM) 
could be investigated as a non-invasive method to detect conjunctival psuedoglands in 
trachoma in order to investigate this hypothesis further. EMT was not detected in 
response to Ct infection of epithelial cells in vitro (Chapter 8) or in trichiasis tissue 
(Chapter 10). EMT might be a rare and transient event therefore it is possible that the 
experiments performed were not optimally designed or well powered enough to detect 
the transition. Further experiments to address this are described in section 11.3 below. 
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Figure 11.1. Graphical summary of the results of this thesis, in the form of a cross-
sectional diagram of the conjunctival epithelium in TF/TI (left) and in TS and TT (right). 
“T” and “B” are infiltrating T and B lymphocytes and “PMN” are neutrophils. Factors 
highlighted in red font are direct findings of this thesis. Processes in black font are 
hypothesized contributors to, or results of, the factors in red.  
 
11.2 Wider relevance  
 
It is not clear whether the immunology and pathology of ocular and urogenital 
chlamydial disease share exactly the same mechanisms. There is a paucity of studies 
of human urogenital chlamydial histopathology, largely due to the inherent difficulties of 
obtaining biopsy samples from this anatomical site and of knowing a persons 
chlamydial exposure. For ocular disease one can estimate chlamydial exposure using 
the population prevalence of clinical signs, disease progression can be simply 
assessed by observation of the up-turned conjunctiva, and biopsy material can be 
collected during tarsal rotation surgery for trichiasis. Early urogenital histology studies 
in Ct culture-positive individuals found intense neutrophil infiltration in the epithelium 
and stroma and stromal infiltration of lymphocytes [23,24]. There was focal loss of 
surface columnar epithelial cells however stromal architecture remained intact. 
Neutrophils were not distinguished in the IHC study described in Chapter 10, however 
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the results are in agreement regarding the stromal lymphocyte infiltration, although it 
should be noted that these studies are not directly comparable due to the different 
stages of disease investigated (active infection versus long-term sequelae). Epithelial 
hyperplasia was not reported, however the focal degradation of the epithelium supports 
the damaged or altered ocular epithelium hypothesis. Faults in the integrity of the 
epithelium can also lead to chronic pathological inflammation in other diseases. A 
breakdown of epithelial barrier function during Inflammatory Bowel Disease 
perpetuates the cycle of chronic inflammation as the stroma is exposed to foreign 
antigens (reviewed in [25]), and it thus becomes increasingly difficult to repair the 
epithelial barrier and restore tissue homeostasis.  
 
IL-1β, CTGF and S100A7 expression have repeatedly been shown to be associated 
with active trachoma and scarring trachoma at the expression level [1,12,26–30]. IL-1β 
and S100A7 were in fact the only transcripts associated with scarring progression in a 
longitudinal trachoma cohort [12]. The results described in Chapter 10 corroborate 
these data at the protein level and suggest that these factors may be key components 
in the mechanism of scarring progression. Cervical epithelial cells from women with 
fertility disorders secreted higher levels of IL-1β in response to Chlamydial antigens 
relative to women thought to have had equal exposure (deduced through anti-Ct 
antibody levels) but without fertility problems [31]. Associations between S100A7 and 
CTGF and human urogenital sequelae of chlamydial infection have not been reported, 
however as described above there are a limited number of studies and they are often 
targeted to investigate more classical immune response factors [31–34]. S100A7 was 
upregulated in progesterone-primed endometrial cells in response to Ct in vitro [35]. 
CTGF has been reported to be associated with C. pneumoniae (Cp) infection; at 1 day 
post infection in a HeLa cell in vitro persistence model [36] and in atheromatous 
plaques from Cp HSP60 antibody positive individuals with coronary artery disease 
relative to Cp HSP60 antibody negative individuals [37]. It is unclear if and how 
S100A7, IL-1β and CTGF may interact to induce fibrosis. Research on transgenic 
animals has shown that CTGF is not necessarily pro-fibrotic in isolation and might 
require co-stimulation from factors induced by development or injury and wound 
healing [38,39]. Following corneal injury of mice and rabbits CTGF was expressed 
immediately prior to scarring and staining was strongest in the basal epithelium [22]. 
These data support the hypothesis that CTGF, driven by inflammatory signals such as 
IL-1β and S100A7, is upregulated in the basal epithelium and directly or indirectly 
stimulates the activation of myofibroblasts in the stroma, leading to fibrosis. Knock-out 
of CTGF in the corneal injury model led to a 40% reduction in wound re-
 232 
epithelialization [22]. Whilst inhibition of CTGF would be detrimental in the context of 
an open and healing wound, it may have therapeutic value during trichiasis. CTGF 
might be a key factor driving inflammation-induced fibrosis in scarring trachoma and as 
such warrants further research.   
 
Despite many similarities between ocular and urogenital chlamydial infections, it is 
possible that some aspects of the immunology and pathology are distinct to each 
anatomical site. miR-184 is highly enriched in ocular tissues [8] and was 
downregulated in children with TF (Chapter 6). Its downregulation is associated with 
activation of the WNT pathway and cell proliferation and a genetic deletion in the 
coding sequence of miR-184 can lead to keratoconus [7,40]. miR-184 is not reported to 
be highly abundant in the urogenital epithelium, therefore it is unclear whether miR-184 
could have a parallel role in urogenital pathology. Human miR expression during 
urogenital Ct infection has not yet been reported and it would be of interest to compare 
miR expression profiles during urogenital infection with those described in Chapter 6. 
miRNA expression has been investigated upon urogenital chlamydia infection of mice 
however (discussed in Chapter 1) and some miR exhibit similar expression profiles. 
miR-155 was upregulated upon infection with avirulent but not virulent Cm [41], and 
miR-146 was upregulated 6 days post Cm infection [42]. miR-146b was upregulated 
during active trachoma and Ct infection in the sequencing results, however this was not 
significant upon qPCR validation. These results show that regulation of inflammation is 
an important component of the host miR response to chlamydial infection.   
 
A few studies have investigated miRNA expression in other ocular infectious and 
scarring diseases. Downregulation of miR-215 in Pterygium (an ocular surface disorder 
of excessive fibroblast proliferation and matrix deposition) is associated with fibroblast 
proliferation and addition of exogenous miR-215 decreased this proliferation [43]. miR-
215 was expressed at an average of 2 reads per sample in the small RNA sequencing 
analysis described in Chapter 6 therefore the read depth was too low to ascertain 
whether miR-215 was differentially expressed, however there was no difference in 
expression in scarring trachoma. Small RNA sequencing was recently used to 
investigate the miR expression profile of the cornea during fungal keratitis caused by 
Aspergillus flavus [44]. Many of the differentially expressed miR were also differentially 
expressed in active trachoma with Ct infection: miR-142-5p, miR-155-5p and miR-146b 
were upregulated and miR-184 was downregulated in the sequencing results of both 
studies. This suggests that common inflammatory pathways occur in the cornea and 
the conjunctiva in response to bacterial and fungal infection, as miR-155, -142 and -
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146b regulate immune response pathways. These data also substantiate the 
downregulation of miR-184 upon epithelial damage and its possible role in the wound 
healing response. Resolution of microbial keratitis often results in corneal scarring and 
poor visual acuity [45]. In both microbial keratitis and active trachoma an appropriate 
inflammatory response is required to fight infection; too much inflammation can cause 
pathology however too little inflammation can lead to chronic infection. Broad-spectrum 
anti-inflammatory drugs such as steroids are therefore not used. A specific miR-184 
targeted therapy could have the potential to inhibit excessive cell proliferation and 
fibrosis whilst allowing the host’s immune response to appropriately fight infection. miR 
therapy has been successfully used in human clinical trials to prevent Hepatitis C virus 
infection [46]. An antisense oligonucleotide was injected subcutaneously to bind to and 
sequester mature miR-122, which the virus requires for survival. Exogenous miR-184, 
given as an eye drop for example, could have therapeutic value in trachoma and 
microbial keratitis and potentially other ocular fibrotic diseases, and research on its 
function should be pursued.  
 
11.3 Limitations and future studies  
 
The failure to establish productive chlamydial growth in HCjE cells was a major 
limitation for the in vitro section of this thesis work. Despite the possession of 
appropriate pathogen recognition receptors (Chapter 4), HEp-2 cells are likely to have 
an aberrant genetic background [47] (derived through their isolation from a carcinoma) 
and are not a relevant cell line from which to extrapolate in vitro results to a clinical 
situation. The differences between results derived in commonly used cell lines and 
more clinically relevant cell models have been highlighted several times and relate to 
many aspects of chlamydial biology, not just the inflammatory responses induced [48–
51]. The up-regulation of growth factors and inflammatory cytokines upon Ct infection 
should therefore be validated in a more appropriate in vitro model. The lack of 
differential miRNA expression in infected epithelial cells could also be reassessed, as 
HEp-2 cells had a very different background miRNA expression profile to HCjE cells 
(Chapter 6) and the HCjE cells examined were not productively infected with Ct. It is 
therefore possible that significant changes in miRNA expression might be observed 
upon productive infection of conjunctival epithelial cells with Ct. The differential 
regulation of epithelial-derived miR such as miR-184 in TF also suggests that external 
stimuli from other cell types may be required to generate epithelial miR responses in 
vivo. In order to examine the functions of miR that were differentially regulated in 
trachoma (miR-155, miR-184, miR-147b, miR-1285), co-culture systems could be 
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developed with epithelial, fibroblast and immune cells. A synthetic conjunctiva could be 
engineered in vitro by culturing fibroblasts in a collagen gel scaffold and seeding 
epithelial cells on the surface. Following infection of the epithelial layer by Ct or 
exposure to inflammatory cell factors, cell behavior could be assessed by gene/protein 
expression, immunocytochemistry or by measuring the tensile properties of the 
fibroblast layer using a previously established contraction model [52]. This could 
potentially reveal the relative contribution of each cell type to the response in question. 
Different methods of infection could be investigated in HCjE cells, such as the rocking 
method that was previously used successfully [53], or, an alternative source of 
conjunctival epithelial cells could be used such as the IOBA-NHC cell line or primary 
conjunctival epithelial cells.  
  
The clinical studies in this project had relatively limited sample sizes. Although larger 
sample sizes would have had more power to detect differences, there existed a trade 
off between how many samples it was feasible to collect and the costs associated with 
processing them. Small RNA sequencing was only performed on 10 samples (5 TF 
cases with current Ct infection, 5 controls). The top differentially regulated miR mainly 
reflected the increased activity and presence of adaptive immune cells in TF, therefore 
subtler changes associated with disease pathogenesis may have been obscured. For 
example several miR associated with EMT were differentially regulated (discussed in 
Chapter 8), however the adjusted P values were below the cut-off chosen for 
validation. Increased depth of sequencing and higher total RNA input concentrations 
might have increased the statistical power to detect differences, which could have been 
confirmed by validation of a wider range of miR in all 163 samples. Future experiments, 
beyond the scope of this PhD project, could include fluorescence-activated cell sorting 
directly from clinical conjunctival swab samples. This could allow identification of the 
expression levels of miR at the single cell level using fluorescent intracellular probes. 
This, in combination with extracellular dyes for cell phenotyping would enable us to 
identify the cellular sources of miRNA of interest. Additionally, cells could be sorted 
based on epithelial or lymphocytic cell markers (such as E-cadherin (epithelial cells), 
CD3 (T cells), CD19 (B cells), CD16 and CD56 (NK cells) for example) and then 
subjected to small RNA sequencing to ascertain the full miR expression profiles of 
distinct cell lineages in the conjunctival epithelium.  
 
The evidence suggests that EMT is not induced by Ct infection of epithelial cells in vitro 
(Chapter 8), however it is possible that EMT occurs in vivo in response to inflammation 
and stimuli from a variety of cell types. A role for EMT was not detected in tissue from 
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TT cases by IHC, although Vimentin was slightly increased in the epithelium of TT 
cases (Chapter 10). It was difficult to differentiate cells expressing Vimentin from 
lymphocytes infiltrating the epithelium however, particularly as lymphocytes infiltrating 
the epithelium can change their morphology. Double staining could be used to address 
this and to detect rare or subtle changes associated with EMT. Alternatively more 
complex multiplex staining could be used, such as mass cytometry coupled to laser 
ablation of tissue sections [54]. This technique radiolabels up to 35 targets of interest 
using heavy metal isotopes, uses the laser to ablate the tissue and then performs mass 
spectrometry. The heavy-metal tagged targets can then be mapped to the previously 
intact tissue section. This technique is still in development, however the ability to stain 
for 35 targets in one tissue section would offer considerable advantages for 
investigating marker expression in conjunctival biopsies. Currently however, the data 
suggest that EMT does not have a major role in the fibrotic pathology associated with 
trachoma.  
 
miR-147b and miR-1285 were upregulated in TSI however they had a poor ability to 
classify TS. miR-155 and miR-184 were strong biomarkers for TI, however the real 
value of a miR classifier would be one that could predict scarring progression. In order 
to determine the ability of miR-155, miR-184, miR-147b and miR-1285 to predict 
scarring progression, their expression will be quantified by qPCR in a longitudinal 
cohort of 506 Tanzanians. These individuals were aged between 6-10 at enrollment 
and will be followed for four years, with sub-clinical progressive scarring measured 
using IVCM. This cohort will provide a unique opportunity to investigate whether these 
miR are associated with or predictive of progressive scarring in trachoma and these 
data will further our knowledge of miR biology in trachoma. 
 
11.3 Summary 
 
These data suggest that EMT is not a prominent mechanism in the scarring process, 
however, it may have a more transient or subtle role that the studies performed in this 
PhD project were not able to detect. Epithelial cells did not differentially express miR in 
vitro in response to chlamydial infection and there was no effect of the chlamydial 
plasmid on miR expression. However, the establishment of productive Ct infection in a 
conjunctival epithelial cell line is required to confirm these results. This thesis has 
described human miR expression in various stages of ocular chlamydial disease and 
has revealed key factors involved in the scarring process. Future research on these 
targets will further our knowledge of the mechanisms leading to scarring trachoma, 
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reveal opportunities for therapeutic intervention and might aid vaccine design and 
assessment of efficacy. 
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ANEXO	4:	Pesquisa	de	miRNA	da	conjuntiva	no	Arquipélago	dos	Bijagós	
Formulário	de	Registo	
Examinador/a	_____________	Assistente	de	Laboratório	____________	Fotógrafo/a_______________	
Número	UID	
	
	
Formulário	de	consentimento	preenchido?		 	 	 	 Sim	 	 Não	
	
A	criança	tem	menos	de	10	anos	de	idade?	 	 	 	 Sim	 	 Não	
	
A	criança	tem	tracoma	activo?	 	 	 	 																	 Sim	 	 Não	
Se	Não,	DESISTA!	Preencha	o	formulário	de	consentimento.	
	
Nome		_________________________________		 Apelido____	________________________	
	Exame		Clínico	e	Amostragem	
	
OLHO	ESQUERDA	 TF	 	 TI	 	 N	 	
	 	 	 F					 	 P	 	 C	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 Números	dos	fotos	
	
	
	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
	
Etiqueta	Adesiva	
de	AMOSTRA	1	
1	
2	
3	
	
	
___		___		/	___		___		___		/		___		___		___		___	
Etiqueta	Adesiva	
de	AMOSTRA	2	
AMOSTRA	‘AIR’		
	
Etiqueta	Adesiva	
amostra	de	saliva	
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ANEXO 2 
Informações adicionais e Formulário de Consentimento para Participantes 
Triagem e identificação dos padrões de expressão do microRNA da conjuntiva associados com 
tracoma activo  
Estudo: Mapeamento do Tracoma no Arquipélago dos Bijagós na Guiné Bissau 
Responsável: Dra Anna Last 
Escola de Higiene e Medicina Tropical de Londres no Reino Unido com o Programa Nacional da Saúde da 
Visão (PNSV) da Guiné Bissau 
 
A respeito do que é este estudo? 
Sabemos que o tracoma é um grande problema nas ilhas Bijagós. Nós não sabemos porque   o problema é 
tão grande. A fim de compreender porque é que há um problema tão grande, queremos observar as defezas 
oculares (imunidade) contra a infecção.  
 
Quem está fazendo este estudo? 
Escola de Higiene e Medicina Tropical de Londres no Reino Unido juntamente com o Programa Nacional da 
Saúde da Visão (PNSV) da Guiné Bissau. 
 
Da ajuda de quem precisamos? 
Precisamos da ajuda de cerca de 200 crianças com menos de 10 anos de idade que vivam em comunidades 
nas ilhas. 
 
O que vamos pedir-lhe para fazer? 
Precisamos examinar seus olhos e tomar 2 amostras (com um cotonete) do seu olho esquerdo para fazer 
testes para investigar as defezas oculares (imunidade) contra a infecção e testes de infecção no laboratório. 
Vamos tomar uma foto de cada olho que examinarmos. Pedimos-lhe para cuspir em um tubo para que 
possamos coletar sua saliva. De sua saliva podemos aprender sobre sua genética.  
 
Quais são os benefícios de participar deste estudo? 
O tracoma é um grande problema nas ilhas Bijagós. O tracoma pode ser tratado eficazmente com o antibiótico 
azitromicina, um comprimido. Este tratamento pode curar a infecção e prevenir a cegueira por tracoma. Nós, 
juntamente com o PNSV, vamos a tratar as comunidades com tracoma (com comprimidos) e fazer a cirurgia 
de triquíase para prevenir a cegueira. No futuro este trabalho pode ajudar-nos a desenvover colírios ou 
pomadas para serem usadas como tratamento para inflamação e infecção para prevenir a cegueira e as 
consequências do tracoma.  
 
Existem riscos causados por participar neste estudo? 
O exame e a lavagem são apenas um pouco desconfortáveis mas não vão danificar o olho de maneira 
nenhuma. Vai demorar apenas poucos minutos. Não há riscos no processo de colheita de amostras. Já foi 
feita sem problemas em muitos países.  
 
Que testes serão feitos com as amostras? 
Vamos testar as amostras no laboratório no Reino Unido para aumentar a nossa compreensão do tracoma. 
 
O que vamos fazer com os registos e as fotos que fizermos dos seus olhos? 
Todas as informações que colhermos serão confidenciais. Somente os organizadores do estudo terão acesso 
a elas. 
 
Sou obrigado a participar deste estudo? 
Não, a participação é completamente voluntária. É sua decisão participar deste estudo. Você pode negar-se a 
participar do estudo quando quiser sem dar explicação. E em caso de nao querer participar, isso nao afectará 
o seu relacionamento com o hospital ou o seu tratamento de tracoma ou outras doenças de maneira nenhuma. 
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